6	BREO.xml:S1:4:1	O
ADVERSE	BREO.xml:S1:6:7	O
REACTIONS	BREO.xml:S1:14:9	O

LABA	BREO.xml:S1:29:4	O
,	BREO.xml:S1:33:1	O
such	BREO.xml:S1:35:4	O
as	BREO.xml:S1:40:2	O
vilanterol	BREO.xml:S1:43:10	O
,	BREO.xml:S1:53:1	O
one	BREO.xml:S1:55:3	O
of	BREO.xml:S1:59:2	O
the	BREO.xml:S1:62:3	O
active	BREO.xml:S1:66:6	O
ingredients	BREO.xml:S1:73:11	O
in	BREO.xml:S1:85:2	O
BREO	BREO.xml:S1:88:4	O
ELLIPTA	BREO.xml:S1:93:7	O
,	BREO.xml:S1:100:1	O
increase	BREO.xml:S1:102:8	O
the	BREO.xml:S1:111:3	O
risk	BREO.xml:S1:115:4	B-Factor
of	BREO.xml:S1:120:2	O
asthma	BREO.xml:S1:123:6	O
-	BREO.xml:S1:129:1	O
related	BREO.xml:S1:130:7	O
death	BREO.xml:S1:138:5	B-AdverseReaction
.	BREO.xml:S1:143:1	O

Currently	BREO.xml:S1:145:9	O
available	BREO.xml:S1:155:9	O
data	BREO.xml:S1:165:4	O
are	BREO.xml:S1:170:3	O
inadequate	BREO.xml:S1:174:10	O
to	BREO.xml:S1:185:2	O
determine	BREO.xml:S1:188:9	O
whether	BREO.xml:S1:198:7	O
concurrent	BREO.xml:S1:206:10	O
use	BREO.xml:S1:217:3	O
of	BREO.xml:S1:221:2	O
inhaled	BREO.xml:S1:224:7	O
corticosteroids	BREO.xml:S1:232:15	O
or	BREO.xml:S1:248:2	O
other	BREO.xml:S1:251:5	O
long	BREO.xml:S1:257:4	O
-	BREO.xml:S1:261:1	O
term	BREO.xml:S1:262:4	O
asthma	BREO.xml:S1:267:6	O
control	BREO.xml:S1:274:7	O
drugs	BREO.xml:S1:282:5	O
mitigates	BREO.xml:S1:288:9	O
the	BREO.xml:S1:298:3	O
increased	BREO.xml:S1:302:9	O
risk	BREO.xml:S1:312:4	O
of	BREO.xml:S1:317:2	O
asthma	BREO.xml:S1:320:6	O
-	BREO.xml:S1:326:1	O
related	BREO.xml:S1:327:7	O
death	BREO.xml:S1:335:5	B-AdverseReaction
from	BREO.xml:S1:341:4	O
LABA	BREO.xml:S1:346:4	B-DrugClass
.	BREO.xml:S1:350:1	O

Available	BREO.xml:S1:352:9	O
data	BREO.xml:S1:362:4	O
from	BREO.xml:S1:367:4	O
controlled	BREO.xml:S1:372:10	O
clinical	BREO.xml:S1:383:8	O
trials	BREO.xml:S1:392:6	O
suggest	BREO.xml:S1:399:7	O
that	BREO.xml:S1:407:4	O
LABA	BREO.xml:S1:412:4	O
increase	BREO.xml:S1:417:8	O
the	BREO.xml:S1:426:3	O
risk	BREO.xml:S1:430:4	O
of	BREO.xml:S1:435:2	O
asthma	BREO.xml:S1:438:6	O
-	BREO.xml:S1:444:1	O
related	BREO.xml:S1:445:7	O
hospitalization	BREO.xml:S1:453:15	O
in	BREO.xml:S1:469:2	O
pediatric	BREO.xml:S1:472:9	O
and	BREO.xml:S1:482:3	O
adolescent	BREO.xml:S1:486:10	O
patients	BREO.xml:S1:497:8	O
.	BREO.xml:S1:505:1	O

Data	BREO.xml:S1:507:4	O
from	BREO.xml:S1:512:4	O
a	BREO.xml:S1:517:1	O
large	BREO.xml:S1:519:5	O
placebo	BREO.xml:S1:525:7	O
-	BREO.xml:S1:532:1	O
controlled	BREO.xml:S1:533:10	O
US	BREO.xml:S1:544:2	O
trial	BREO.xml:S1:547:5	O
that	BREO.xml:S1:553:4	O
compared	BREO.xml:S1:558:8	O
the	BREO.xml:S1:567:3	O
safety	BREO.xml:S1:571:6	O
of	BREO.xml:S1:578:2	O
another	BREO.xml:S1:581:7	O
LABA	BREO.xml:S1:589:4	B-DrugClass
(	BREO.xml:S1:594:1	O
salmeterol	BREO.xml:S1:595:10	O
)	BREO.xml:S1:605:1	O
or	BREO.xml:S1:607:2	O
placebo	BREO.xml:S1:610:7	O
added	BREO.xml:S1:618:5	O
to	BREO.xml:S1:624:2	O
usual	BREO.xml:S1:627:5	O
asthma	BREO.xml:S1:633:6	O
therapy	BREO.xml:S1:640:7	O
showed	BREO.xml:S1:648:6	O
an	BREO.xml:S1:655:2	O
increase	BREO.xml:S1:658:8	O
in	BREO.xml:S1:667:2	O
asthma	BREO.xml:S1:670:6	O
-	BREO.xml:S1:676:1	O
related	BREO.xml:S1:677:7	O
deaths	BREO.xml:S1:685:6	B-AdverseReaction
in	BREO.xml:S1:692:2	O
subjects	BREO.xml:S1:695:8	O
receiving	BREO.xml:S1:704:9	O
salmeterol	BREO.xml:S1:714:10	O
.	BREO.xml:S1:724:1	O

[	BREO.xml:S1:727:1	O
See	BREO.xml:S1:728:3	O
Warnings	BREO.xml:S1:732:8	O
and	BREO.xml:S1:741:3	O
Precautions	BREO.xml:S1:745:11	O
(	BREO.xml:S1:757:1	O
5.1	BREO.xml:S1:758:3	O
)	BREO.xml:S1:761:1	O
.	BREO.xml:S1:762:1	O
]	BREO.xml:S1:763:1	O

Systemic	BREO.xml:S1:773:8	O
and	BREO.xml:S1:782:3	O
local	BREO.xml:S1:786:5	O
corticosteroid	BREO.xml:S1:792:14	O
use	BREO.xml:S1:807:3	O
may	BREO.xml:S1:811:3	O
result	BREO.xml:S1:815:6	O
in	BREO.xml:S1:822:2	O
the	BREO.xml:S1:825:3	O
following	BREO.xml:S1:829:9	O
:	BREO.xml:S1:838:1	O

Candida	BREO.xml:S1:850:7	B-AdverseReaction
albicans	BREO.xml:S1:858:8	I-AdverseReaction
infection	BREO.xml:S1:867:9	I-AdverseReaction
[	BREO.xml:S1:877:1	O
see	BREO.xml:S1:878:3	O
Warnings	BREO.xml:S1:882:8	O
and	BREO.xml:S1:891:3	O
Precautions	BREO.xml:S1:895:11	O
(	BREO.xml:S1:907:1	O
5.4	BREO.xml:S1:908:3	O
)]	BREO.xml:S1:911:2	O

Increased	BREO.xml:S1:922:9	O
risk	BREO.xml:S1:932:4	B-Factor
of	BREO.xml:S1:937:2	O
pneumonia	BREO.xml:S1:940:9	B-AdverseReaction
in	BREO.xml:S1:950:2	O
COPD	BREO.xml:S1:953:4	O
[	BREO.xml:S1:958:1	O
see	BREO.xml:S1:959:3	O
Warnings	BREO.xml:S1:963:8	O
and	BREO.xml:S1:972:3	O
Precautions	BREO.xml:S1:976:11	O
(	BREO.xml:S1:988:1	O
5.5	BREO.xml:S1:989:3	O
)]	BREO.xml:S1:992:2	O

Immunosuppression	BREO.xml:S1:1003:17	B-AdverseReaction
[	BREO.xml:S1:1021:1	O
see	BREO.xml:S1:1022:3	O
Warnings	BREO.xml:S1:1026:8	O
and	BREO.xml:S1:1035:3	O
Precautions	BREO.xml:S1:1039:11	O
(	BREO.xml:S1:1051:1	O
5.6	BREO.xml:S1:1052:3	O
)]	BREO.xml:S1:1055:2	O

Hypercorticism	BREO.xml:S1:1066:14	B-AdverseReaction
and	BREO.xml:S1:1081:3	O
adrenal	BREO.xml:S1:1085:7	B-AdverseReaction
suppression	BREO.xml:S1:1093:11	I-AdverseReaction
[	BREO.xml:S1:1105:1	O
see	BREO.xml:S1:1106:3	O
Warnings	BREO.xml:S1:1110:8	O
and	BREO.xml:S1:1119:3	O
Precautions	BREO.xml:S1:1123:11	O
(	BREO.xml:S1:1135:1	O
5.8	BREO.xml:S1:1136:3	O
)]	BREO.xml:S1:1139:2	O

Reduction	BREO.xml:S1:1150:9	B-AdverseReaction
in	BREO.xml:S1:1160:2	I-AdverseReaction
bone	BREO.xml:S1:1163:4	I-AdverseReaction
mineral	BREO.xml:S1:1168:7	I-AdverseReaction
density	BREO.xml:S1:1176:7	I-AdverseReaction
[	BREO.xml:S1:1184:1	O
see	BREO.xml:S1:1185:3	O
Warnings	BREO.xml:S1:1189:8	O
and	BREO.xml:S1:1198:3	O
Precautions	BREO.xml:S1:1202:11	O
(	BREO.xml:S1:1214:1	O
5.13	BREO.xml:S1:1215:4	O
)]	BREO.xml:S1:1219:2	O

Because	BREO.xml:S1:1228:7	O
clinical	BREO.xml:S1:1236:8	O
trials	BREO.xml:S1:1245:6	O
are	BREO.xml:S1:1252:3	O
conducted	BREO.xml:S1:1256:9	O
under	BREO.xml:S1:1266:5	O
widely	BREO.xml:S1:1272:6	O
varying	BREO.xml:S1:1279:7	O
conditions	BREO.xml:S1:1287:10	O
,	BREO.xml:S1:1297:1	O
adverse	BREO.xml:S1:1299:7	O
reaction	BREO.xml:S1:1307:8	O
rates	BREO.xml:S1:1316:5	O
observed	BREO.xml:S1:1322:8	O
in	BREO.xml:S1:1331:2	O
the	BREO.xml:S1:1334:3	O
clinical	BREO.xml:S1:1338:8	O
trials	BREO.xml:S1:1347:6	O
of	BREO.xml:S1:1354:2	O
a	BREO.xml:S1:1357:1	O
drug	BREO.xml:S1:1359:4	O
cannot	BREO.xml:S1:1364:6	O
be	BREO.xml:S1:1371:2	O
directly	BREO.xml:S1:1374:8	O
compared	BREO.xml:S1:1383:8	O
with	BREO.xml:S1:1392:4	O
rates	BREO.xml:S1:1397:5	O
in	BREO.xml:S1:1403:2	O
the	BREO.xml:S1:1406:3	O
clinical	BREO.xml:S1:1410:8	O
trials	BREO.xml:S1:1419:6	O
of	BREO.xml:S1:1426:2	O
another	BREO.xml:S1:1429:7	O
drug	BREO.xml:S1:1437:4	O
and	BREO.xml:S1:1442:3	O
may	BREO.xml:S1:1446:3	O
not	BREO.xml:S1:1450:3	O
reflect	BREO.xml:S1:1454:7	O
the	BREO.xml:S1:1462:3	O
rates	BREO.xml:S1:1466:5	O
observed	BREO.xml:S1:1472:8	O
in	BREO.xml:S1:1481:2	O
practice	BREO.xml:S1:1484:8	O
.	BREO.xml:S1:1492:1	O

EXCERPT	BREO.xml:S1:1501:7	O

:	BREO.xml:S1:1508:1	O
COPD	BREO.xml:S1:1518:4	O
:	BREO.xml:S1:1522:1	O
Most	BREO.xml:S1:1524:4	O
common	BREO.xml:S1:1529:6	O
adverse	BREO.xml:S1:1536:7	O
reactions	BREO.xml:S1:1544:9	O
(	BREO.xml:S1:1554:1	O
incidence	BREO.xml:S1:1555:9	O
greater	BREO.xml:S1:1565:7	O
than	BREO.xml:S1:1573:4	O
or	BREO.xml:S1:1578:2	O
equal	BREO.xml:S1:1581:5	O
to	BREO.xml:S1:1587:2	O
3%	BREO.xml:S1:1590:2	O
)	BREO.xml:S1:1592:1	O
are	BREO.xml:S1:1594:3	O
nasopharyngitis	BREO.xml:S1:1598:15	B-AdverseReaction
,	BREO.xml:S1:1613:1	O
upper	BREO.xml:S1:1615:5	B-AdverseReaction
respiratory	BREO.xml:S1:1621:11	I-AdverseReaction
tract	BREO.xml:S1:1633:5	I-AdverseReaction
infection	BREO.xml:S1:1639:9	I-AdverseReaction
,	BREO.xml:S1:1648:1	O
headache	BREO.xml:S1:1650:8	B-AdverseReaction
,	BREO.xml:S1:1658:1	O
and	BREO.xml:S1:1660:3	O
oral	BREO.xml:S1:1664:4	B-AdverseReaction
candidiasis	BREO.xml:S1:1669:11	I-AdverseReaction
.	BREO.xml:S1:1680:1	O

(	BREO.xml:S1:1682:1	O
6.1	BREO.xml:S1:1685:3	O
)	BREO.xml:S1:1690:1	O

Asthma	BREO.xml:S1:1699:6	O
:	BREO.xml:S1:1705:1	O
Most	BREO.xml:S1:1707:4	O
common	BREO.xml:S1:1712:6	O
adverse	BREO.xml:S1:1719:7	O
reactions	BREO.xml:S1:1727:9	O
(	BREO.xml:S1:1737:1	O
incidence	BREO.xml:S1:1738:9	O
greater	BREO.xml:S1:1748:7	O
than	BREO.xml:S1:1756:4	O
or	BREO.xml:S1:1761:2	O
equal	BREO.xml:S1:1764:5	O
to	BREO.xml:S1:1770:2	O
2%	BREO.xml:S1:1773:2	O
)	BREO.xml:S1:1775:1	O
are	BREO.xml:S1:1777:3	O
nasopharyngitis	BREO.xml:S1:1781:15	B-AdverseReaction
,	BREO.xml:S1:1796:1	O
oral	BREO.xml:S1:1798:4	B-AdverseReaction
candidiasis	BREO.xml:S1:1803:11	I-AdverseReaction
,	BREO.xml:S1:1814:1	O
headache	BREO.xml:S1:1816:8	B-AdverseReaction
,	BREO.xml:S1:1824:1	O
influenza	BREO.xml:S1:1826:9	B-AdverseReaction
,	BREO.xml:S1:1835:1	O
upper	BREO.xml:S1:1837:5	B-AdverseReaction
respiratory	BREO.xml:S1:1843:11	I-AdverseReaction
tract	BREO.xml:S1:1855:5	I-AdverseReaction
infection	BREO.xml:S1:1861:9	I-AdverseReaction
,	BREO.xml:S1:1870:1	O
bronchitis	BREO.xml:S1:1872:10	B-AdverseReaction
,	BREO.xml:S1:1882:1	O
sinusitis	BREO.xml:S1:1884:9	B-AdverseReaction
,	BREO.xml:S1:1893:1	O
oropharyngeal	BREO.xml:S1:1895:13	B-AdverseReaction
pain	BREO.xml:S1:1909:4	I-AdverseReaction
,	BREO.xml:S1:1913:1	O
dysphonia	BREO.xml:S1:1915:9	B-AdverseReaction
,	BREO.xml:S1:1924:1	O
and	BREO.xml:S1:1926:3	O
cough	BREO.xml:S1:1930:5	B-AdverseReaction
.	BREO.xml:S1:1935:1	O

(	BREO.xml:S1:1937:1	O
6.2	BREO.xml:S1:1940:3	O
)	BREO.xml:S1:1945:1	O

To	BREO.xml:S1:1954:2	O
report	BREO.xml:S1:1957:6	O
SUSPECTED	BREO.xml:S1:1964:9	O
ADVERSE	BREO.xml:S1:1974:7	O
REACTIONS	BREO.xml:S1:1982:9	O
,	BREO.xml:S1:1991:1	O
contact	BREO.xml:S1:1993:7	O
GlaxoSmithKline	BREO.xml:S1:2001:15	O
at	BREO.xml:S1:2017:2	O
1	BREO.xml:S1:2020:1	O
-	BREO.xml:S1:2021:1	O
888	BREO.xml:S1:2022:3	O
-	BREO.xml:S1:2025:1	O
825	BREO.xml:S1:2026:3	O
-	BREO.xml:S1:2029:1	O
5249	BREO.xml:S1:2030:4	O
or	BREO.xml:S1:2035:2	O
FDA	BREO.xml:S1:2038:3	O
at	BREO.xml:S1:2042:2	O
1	BREO.xml:S1:2045:1	O
-	BREO.xml:S1:2046:1	O
800	BREO.xml:S1:2047:3	O
-	BREO.xml:S1:2050:1	O
FDA	BREO.xml:S1:2051:3	O
-	BREO.xml:S1:2054:1	O
1088	BREO.xml:S1:2055:4	O
or	BREO.xml:S1:2060:2	O
www	BREO.xml:S1:2063:3	O
.	BREO.xml:S1:2066:1	O
fda	BREO.xml:S1:2067:3	O
.	BREO.xml:S1:2070:1	O
gov	BREO.xml:S1:2071:3	O
medwatch	BREO.xml:S1:2075:8	O
.	BREO.xml:S1:2083:1	O

6.1	BREO.xml:S1:2095:3	O

Clinical	BREO.xml:S1:2099:8	O

Trials	BREO.xml:S1:2108:6	O
Experience	BREO.xml:S1:2115:10	O
in	BREO.xml:S1:2126:2	O
Chronic	BREO.xml:S1:2129:7	O
Obstructive	BREO.xml:S1:2137:11	O
Pulmonary	BREO.xml:S1:2149:9	O
Disease	BREO.xml:S1:2159:7	O

The	BREO.xml:S1:2170:3	O
clinical	BREO.xml:S1:2174:8	O
program	BREO.xml:S1:2183:7	O
for	BREO.xml:S1:2191:3	O
BREO	BREO.xml:S1:2195:4	O
ELLIPTA	BREO.xml:S1:2200:7	O
included	BREO.xml:S1:2208:8	O
7	BREO.xml:S1:2217:1	O
,	BREO.xml:S1:2218:1	O
700	BREO.xml:S1:2219:3	O
subjects	BREO.xml:S1:2223:8	O
with	BREO.xml:S1:2232:4	O
COPD	BREO.xml:S1:2237:4	O
in	BREO.xml:S1:2242:2	O
two	BREO.xml:S1:2245:3	O
6	BREO.xml:S1:2249:1	O
-	BREO.xml:S1:2250:1	O
month	BREO.xml:S1:2251:5	O
lung	BREO.xml:S1:2257:4	O
function	BREO.xml:S1:2262:8	O
trials	BREO.xml:S1:2271:6	O
,	BREO.xml:S1:2277:1	O
two	BREO.xml:S1:2279:3	O
12	BREO.xml:S1:2283:2	O
-	BREO.xml:S1:2285:1	O
month	BREO.xml:S1:2286:5	O
exacerbation	BREO.xml:S1:2292:12	O
trials	BREO.xml:S1:2305:6	O
,	BREO.xml:S1:2311:1	O
and	BREO.xml:S1:2313:3	O
6	BREO.xml:S1:2317:1	O
other	BREO.xml:S1:2319:5	O
trials	BREO.xml:S1:2325:6	O
of	BREO.xml:S1:2332:2	O
shorter	BREO.xml:S1:2335:7	O
duration	BREO.xml:S1:2343:8	O
.	BREO.xml:S1:2351:1	O

A	BREO.xml:S1:2353:1	O
total	BREO.xml:S1:2355:5	O
of	BREO.xml:S1:2361:2	O
2	BREO.xml:S1:2364:1	O
,	BREO.xml:S1:2365:1	O
034	BREO.xml:S1:2366:3	O
subjects	BREO.xml:S1:2370:8	O
with	BREO.xml:S1:2379:4	O
COPD	BREO.xml:S1:2384:4	O
received	BREO.xml:S1:2389:8	O
at	BREO.xml:S1:2398:2	O
least	BREO.xml:S1:2401:5	O
1	BREO.xml:S1:2407:1	O
dose	BREO.xml:S1:2409:4	O
of	BREO.xml:S1:2414:2	O
BREO	BREO.xml:S1:2417:4	O
ELLIPTA	BREO.xml:S1:2422:7	O
100	BREO.xml:S1:2430:3	O
25	BREO.xml:S1:2434:2	O
,	BREO.xml:S1:2436:1	O
and	BREO.xml:S1:2438:3	O
1	BREO.xml:S1:2442:1	O
,	BREO.xml:S1:2443:1	O
087	BREO.xml:S1:2444:3	O
subjects	BREO.xml:S1:2448:8	O
received	BREO.xml:S1:2457:8	O
a	BREO.xml:S1:2466:1	O
higher	BREO.xml:S1:2468:6	O
strength	BREO.xml:S1:2475:8	O
of	BREO.xml:S1:2484:2	O
fluticasone	BREO.xml:S1:2487:11	O
furoate	BREO.xml:S1:2499:7	O
vilanterol	BREO.xml:S1:2507:10	O
.	BREO.xml:S1:2517:1	O

The	BREO.xml:S1:2519:3	O
safety	BREO.xml:S1:2523:6	O
data	BREO.xml:S1:2530:4	O
described	BREO.xml:S1:2535:9	O
below	BREO.xml:S1:2545:5	O
are	BREO.xml:S1:2551:3	O
based	BREO.xml:S1:2555:5	O
on	BREO.xml:S1:2561:2	O
the	BREO.xml:S1:2564:3	O
confirmatory	BREO.xml:S1:2568:12	O
6	BREO.xml:S1:2581:1	O
-	BREO.xml:S1:2582:1	O
and	BREO.xml:S1:2584:3	O
12	BREO.xml:S1:2588:2	O
-	BREO.xml:S1:2590:1	O
month	BREO.xml:S1:2591:5	O
trials	BREO.xml:S1:2597:6	O
.	BREO.xml:S1:2603:1	O

Adverse	BREO.xml:S1:2605:7	O
reactions	BREO.xml:S1:2613:9	O
observed	BREO.xml:S1:2623:8	O
in	BREO.xml:S1:2632:2	O
the	BREO.xml:S1:2635:3	O
other	BREO.xml:S1:2639:5	O
trials	BREO.xml:S1:2645:6	O
were	BREO.xml:S1:2652:4	O
similar	BREO.xml:S1:2657:7	O
to	BREO.xml:S1:2665:2	O
those	BREO.xml:S1:2668:5	O
observed	BREO.xml:S1:2674:8	O
in	BREO.xml:S1:2683:2	O
the	BREO.xml:S1:2686:3	O
confirmatory	BREO.xml:S1:2690:12	O
trials	BREO.xml:S1:2703:6	O
.	BREO.xml:S1:2709:1	O

6	BREO.xml:S1:2717:1	O
-	BREO.xml:S1:2718:1	O
Month	BREO.xml:S1:2719:5	O
Trials	BREO.xml:S1:2725:6	O

The	BREO.xml:S1:2738:3	O
incidence	BREO.xml:S1:2742:9	O
of	BREO.xml:S1:2752:2	O
adverse	BREO.xml:S1:2755:7	O
reactions	BREO.xml:S1:2763:9	O
associated	BREO.xml:S1:2773:10	O
with	BREO.xml:S1:2784:4	O
BREO	BREO.xml:S1:2789:4	O
ELLIPTA	BREO.xml:S1:2794:7	O
100	BREO.xml:S1:2802:3	O
25	BREO.xml:S1:2806:2	O
in	BREO.xml:S1:2809:2	O
Table	BREO.xml:S1:2812:5	O
1	BREO.xml:S1:2818:1	O
is	BREO.xml:S1:2820:2	O
based	BREO.xml:S1:2823:5	O
on	BREO.xml:S1:2829:2	O
2	BREO.xml:S1:2832:1	O
placebo	BREO.xml:S1:2834:7	O
-	BREO.xml:S1:2841:1	O
controlled	BREO.xml:S1:2842:10	O
,	BREO.xml:S1:2852:1	O
6	BREO.xml:S1:2854:1	O
-	BREO.xml:S1:2855:1	O
month	BREO.xml:S1:2856:5	O
clinical	BREO.xml:S1:2862:8	O
trials	BREO.xml:S1:2871:6	O
(	BREO.xml:S1:2878:1	O
Trials	BREO.xml:S1:2879:6	O
1	BREO.xml:S1:2886:1	O
and	BREO.xml:S1:2888:3	O
2	BREO.xml:S1:2892:1	O
;	BREO.xml:S1:2893:1	O
n	BREO.xml:S1:2895:1	O
1	BREO.xml:S1:2899:1	O
,	BREO.xml:S1:2900:1	O
224	BREO.xml:S1:2901:3	O
and	BREO.xml:S1:2905:3	O
n	BREO.xml:S1:2909:1	O
1	BREO.xml:S1:2913:1	O
,	BREO.xml:S1:2914:1	O
030	BREO.xml:S1:2915:3	O
,	BREO.xml:S1:2918:1	O
respectively	BREO.xml:S1:2920:12	O
)	BREO.xml:S1:2932:1	O
.	BREO.xml:S1:2933:1	O

Of	BREO.xml:S1:2935:2	O
the	BREO.xml:S1:2938:3	O
2	BREO.xml:S1:2942:1	O
,	BREO.xml:S1:2943:1	O
254	BREO.xml:S1:2944:3	O
subjects	BREO.xml:S1:2948:8	O
,	BREO.xml:S1:2956:1	O
70%	BREO.xml:S1:2958:3	O
were	BREO.xml:S1:2962:4	O
male	BREO.xml:S1:2967:4	O
and	BREO.xml:S1:2972:3	O
84%	BREO.xml:S1:2976:3	O
were	BREO.xml:S1:2980:4	O
white	BREO.xml:S1:2985:5	O
.	BREO.xml:S1:2990:1	O

They	BREO.xml:S1:2992:4	O
had	BREO.xml:S1:2997:3	O
a	BREO.xml:S1:3001:1	O
mean	BREO.xml:S1:3003:4	O
age	BREO.xml:S1:3008:3	O
of	BREO.xml:S1:3012:2	O
62	BREO.xml:S1:3015:2	O
years	BREO.xml:S1:3018:5	O
and	BREO.xml:S1:3024:3	O
an	BREO.xml:S1:3028:2	O
average	BREO.xml:S1:3031:7	O
smoking	BREO.xml:S1:3039:7	O
history	BREO.xml:S1:3047:7	O
of	BREO.xml:S1:3055:2	O
44	BREO.xml:S1:3058:2	O
pack	BREO.xml:S1:3061:4	O
-	BREO.xml:S1:3065:1	O
years	BREO.xml:S1:3066:5	O
,	BREO.xml:S1:3071:1	O
with	BREO.xml:S1:3073:4	O
54%	BREO.xml:S1:3078:3	O
identified	BREO.xml:S1:3082:10	O
as	BREO.xml:S1:3093:2	O
current	BREO.xml:S1:3096:7	O
smokers	BREO.xml:S1:3104:7	O
.	BREO.xml:S1:3111:1	O

At	BREO.xml:S1:3113:2	O
screening	BREO.xml:S1:3116:9	O
,	BREO.xml:S1:3125:1	O
the	BREO.xml:S1:3127:3	O
mean	BREO.xml:S1:3131:4	O
postbronchodilator	BREO.xml:S1:3136:18	O
percent	BREO.xml:S1:3155:7	O
predicted	BREO.xml:S1:3163:9	O
FEV1was	BREO.xml:S1:3173:7	O
48%	BREO.xml:S1:3181:3	O
(	BREO.xml:S1:3185:1	O
range	BREO.xml:S1:3186:5	O
:	BREO.xml:S1:3191:1	O
14%	BREO.xml:S1:3193:3	O
to	BREO.xml:S1:3197:2	O
87%	BREO.xml:S1:3200:3	O
)	BREO.xml:S1:3203:1	O
,	BREO.xml:S1:3204:1	O
the	BREO.xml:S1:3206:3	O
mean	BREO.xml:S1:3210:4	O
postbronchodilator	BREO.xml:S1:3215:18	O
FEV1	BREO.xml:S1:3234:4	O
forced	BREO.xml:S1:3239:6	O
vital	BREO.xml:S1:3246:5	O
capacity	BREO.xml:S1:3252:8	O
(	BREO.xml:S1:3261:1	O
FVC	BREO.xml:S1:3262:3	O
)	BREO.xml:S1:3265:1	O
ratio	BREO.xml:S1:3267:5	O
was	BREO.xml:S1:3273:3	O
47%	BREO.xml:S1:3277:3	O
(	BREO.xml:S1:3281:1	O
range	BREO.xml:S1:3282:5	O
:	BREO.xml:S1:3287:1	O
17%	BREO.xml:S1:3289:3	O
to	BREO.xml:S1:3293:2	O
88%	BREO.xml:S1:3296:3	O
)	BREO.xml:S1:3299:1	O
,	BREO.xml:S1:3300:1	O
and	BREO.xml:S1:3302:3	O
the	BREO.xml:S1:3306:3	O
mean	BREO.xml:S1:3310:4	O
percent	BREO.xml:S1:3315:7	O
reversibility	BREO.xml:S1:3323:13	O
was	BREO.xml:S1:3337:3	O
14%	BREO.xml:S1:3341:3	O
(	BREO.xml:S1:3345:1	O
range	BREO.xml:S1:3346:5	O
:	BREO.xml:S1:3351:1	O
-	BREO.xml:S1:3353:1	O
41%	BREO.xml:S1:3354:3	O
to	BREO.xml:S1:3358:2	O
152%	BREO.xml:S1:3361:4	O
)	BREO.xml:S1:3365:1	O
.	BREO.xml:S1:3366:1	O

Subjects	BREO.xml:S1:3372:8	O
received	BREO.xml:S1:3381:8	O
1	BREO.xml:S1:3390:1	O
inhalation	BREO.xml:S1:3392:10	O
once	BREO.xml:S1:3403:4	O
daily	BREO.xml:S1:3408:5	O
of	BREO.xml:S1:3414:2	O
the	BREO.xml:S1:3417:3	O
following	BREO.xml:S1:3421:9	O
:	BREO.xml:S1:3430:1	O
BREO	BREO.xml:S1:3432:4	O
ELLIPTA	BREO.xml:S1:3437:7	O
100	BREO.xml:S1:3445:3	O
25	BREO.xml:S1:3449:2	O
,	BREO.xml:S1:3451:1	O
BREO	BREO.xml:S1:3453:4	O
ELLIPTA	BREO.xml:S1:3458:7	O
200	BREO.xml:S1:3466:3	O
25	BREO.xml:S1:3470:2	O
,	BREO.xml:S1:3472:1	O
fluticasone	BREO.xml:S1:3474:11	O
furoate	BREO.xml:S1:3486:7	O
vilanterol	BREO.xml:S1:3494:10	O
50	BREO.xml:S1:3505:2	O
mcg	BREO.xml:S1:3508:3	O
25	BREO.xml:S1:3512:2	O
mcg	BREO.xml:S1:3515:3	O
,	BREO.xml:S1:3518:1	O
fluticasone	BREO.xml:S1:3520:11	O
furoate	BREO.xml:S1:3532:7	O
100	BREO.xml:S1:3540:3	O
mcg	BREO.xml:S1:3544:3	O
,	BREO.xml:S1:3547:1	O
fluticasone	BREO.xml:S1:3549:11	O
furoate	BREO.xml:S1:3561:7	O
200	BREO.xml:S1:3569:3	O
mcg	BREO.xml:S1:3573:3	O
,	BREO.xml:S1:3576:1	O
vilanterol	BREO.xml:S1:3578:10	O
25	BREO.xml:S1:3589:2	O
mcg	BREO.xml:S1:3592:3	O
,	BREO.xml:S1:3595:1	O
or	BREO.xml:S1:3597:2	O
placebo	BREO.xml:S1:3600:7	O
.	BREO.xml:S1:3607:1	O

Table	BREO.xml:S1:3615:5	O
1	BREO.xml:S1:3621:1	O
.	BREO.xml:S1:3622:1	O

Adverse	BREO.xml:S1:3624:7	O
Reactions	BREO.xml:S1:3632:9	O
with	BREO.xml:S1:3642:4	O
BREO	BREO.xml:S1:3647:4	O
ELLIPTA	BREO.xml:S1:3652:7	O
100	BREO.xml:S1:3660:3	O
25	BREO.xml:S1:3664:2	O
with	BREO.xml:S1:3667:4	O
3%	BREO.xml:S1:3674:2	O
Incidence	BREO.xml:S1:3677:9	O
and	BREO.xml:S1:3687:3	O
More	BREO.xml:S1:3691:4	O
Common	BREO.xml:S1:3696:6	O
than	BREO.xml:S1:3703:4	O
Placebo	BREO.xml:S1:3708:7	O
in	BREO.xml:S1:3716:2	O
Subjects	BREO.xml:S1:3719:8	O
with	BREO.xml:S1:3728:4	O
Chronic	BREO.xml:S1:3733:7	O
Obstructive	BREO.xml:S1:3741:11	O
Pulmonary	BREO.xml:S1:3753:9	O
Disease	BREO.xml:S1:3763:7	O

Adverse	BREO.xml:S1:3779:7	O
Reaction	BREO.xml:S1:3787:8	O
BREO	BREO.xml:S1:3820:4	O
ELLIPTA	BREO.xml:S1:3825:7	O
100	BREO.xml:S1:3834:3	O
25	BREO.xml:S1:3838:2	O
(	BREO.xml:S1:3842:1	O
n	BREO.xml:S1:3843:1	O
410	BREO.xml:S1:3847:3	O
)	BREO.xml:S1:3850:1	O
Vilanterol	BREO.xml:S1:3858:10	O
25	BREO.xml:S1:3870:2	O
mcg	BREO.xml:S1:3873:3	O
(	BREO.xml:S1:3878:1	O
n	BREO.xml:S1:3879:1	O
408	BREO.xml:S1:3883:3	O
)	BREO.xml:S1:3886:1	O
Fluticasone	BREO.xml:S1:3894:11	O
Furoate	BREO.xml:S1:3906:7	O
100	BREO.xml:S1:3915:3	O
mcg	BREO.xml:S1:3919:3	O
(	BREO.xml:S1:3924:1	O
n	BREO.xml:S1:3925:1	O
410	BREO.xml:S1:3929:3	O
)	BREO.xml:S1:3932:1	O
Placebo	BREO.xml:S1:3940:7	O
(	BREO.xml:S1:3949:1	O
n	BREO.xml:S1:3950:1	O
412	BREO.xml:S1:3954:3	O
)	BREO.xml:S1:3957:1	O

Infections	BREO.xml:S1:3968:10	O
and	BREO.xml:S1:3979:3	O
infestations	BREO.xml:S1:3983:12	O

Nasopharyngitis	BREO.xml:S1:4122:15	B-AdverseReaction

9	BREO.xml:S1:4247:1	O
10	BREO.xml:S1:4268:2	O
8	BREO.xml:S1:4282:1	O
8	BREO.xml:S1:4305:1	O

Upper	BREO.xml:S1:4360:5	B-AdverseReaction
respiratory	BREO.xml:S1:4366:11	I-AdverseReaction
tract	BREO.xml:S1:4378:5	I-AdverseReaction
infection	BREO.xml:S1:4384:9	I-AdverseReaction

7	BREO.xml:S1:4485:1	O
5	BREO.xml:S1:4506:1	O
4	BREO.xml:S1:4520:1	O
3	BREO.xml:S1:4543:1	O

Oropharyngeal	BREO.xml:S1:4598:13	B-AdverseReaction
candidiasis	BREO.xml:S1:4612:11	I-AdverseReaction
a	BREO.xml:S1:4625:1	O

5	BREO.xml:S1:4723:1	O
2	BREO.xml:S1:4744:1	O
3	BREO.xml:S1:4758:1	O
2	BREO.xml:S1:4781:1	O

Nervous	BREO.xml:S1:4796:7	O
system	BREO.xml:S1:4804:6	O
disorders	BREO.xml:S1:4811:9	O

Headache	BREO.xml:S1:4950:8	B-AdverseReaction

7	BREO.xml:S1:5075:1	O
9	BREO.xml:S1:5096:1	O
7	BREO.xml:S1:5110:1	O
5	BREO.xml:S1:5133:1	O

a	BREO.xml:S1:5159:1	O
Includes	BREO.xml:S1:5162:8	O
oral	BREO.xml:S1:5171:4	B-AdverseReaction
candidiasis	BREO.xml:S1:5176:11	I-AdverseReaction
,	BREO.xml:S1:5187:1	O
oropharyngeal	BREO.xml:S1:5189:13	B-AdverseReaction
candidiasis	BREO.xml:S1:5203:11	I-AdverseReaction
,	BREO.xml:S1:5214:1	O
candidiasis	BREO.xml:S1:5216:11	B-AdverseReaction
,	BREO.xml:S1:5227:1	O
and	BREO.xml:S1:5229:3	O
fungal	BREO.xml:S1:5233:6	B-AdverseReaction
oropharyngitis	BREO.xml:S1:5240:14	I-AdverseReaction
.	BREO.xml:S1:5254:1	O

12	BREO.xml:S1:5262:2	O

-	BREO.xml:S1:5264:1	O
Month	BREO.xml:S1:5265:5	O
Trials	BREO.xml:S1:5271:6	O

Long	BREO.xml:S1:5284:4	O
-	BREO.xml:S1:5288:1	O
term	BREO.xml:S1:5289:4	O
safety	BREO.xml:S1:5294:6	O
data	BREO.xml:S1:5301:4	O
is	BREO.xml:S1:5306:2	O
based	BREO.xml:S1:5309:5	O
on	BREO.xml:S1:5315:2	O
two	BREO.xml:S1:5318:3	O
12	BREO.xml:S1:5322:2	O
-	BREO.xml:S1:5324:1	O
month	BREO.xml:S1:5325:5	O
trials	BREO.xml:S1:5331:6	O
(	BREO.xml:S1:5338:1	O
Trials	BREO.xml:S1:5339:6	O
3	BREO.xml:S1:5346:1	O
and	BREO.xml:S1:5348:3	O
4	BREO.xml:S1:5352:1	O
;	BREO.xml:S1:5353:1	O
n	BREO.xml:S1:5355:1	O
1	BREO.xml:S1:5359:1	O
,	BREO.xml:S1:5360:1	O
633	BREO.xml:S1:5361:3	O
and	BREO.xml:S1:5365:3	O
n	BREO.xml:S1:5369:1	O
1	BREO.xml:S1:5373:1	O
,	BREO.xml:S1:5374:1	O
622	BREO.xml:S1:5375:3	O
,	BREO.xml:S1:5378:1	O
respectively	BREO.xml:S1:5380:12	O
)	BREO.xml:S1:5392:1	O
.	BREO.xml:S1:5393:1	O

Trials	BREO.xml:S1:5395:6	O
3	BREO.xml:S1:5402:1	O
and	BREO.xml:S1:5404:3	O
4	BREO.xml:S1:5408:1	O
included	BREO.xml:S1:5410:8	O
3	BREO.xml:S1:5419:1	O
,	BREO.xml:S1:5420:1	O
255	BREO.xml:S1:5421:3	O
subjects	BREO.xml:S1:5425:8	O
,	BREO.xml:S1:5433:1	O
of	BREO.xml:S1:5435:2	O
which	BREO.xml:S1:5438:5	O
57%	BREO.xml:S1:5444:3	O
were	BREO.xml:S1:5448:4	O
male	BREO.xml:S1:5453:4	O
and	BREO.xml:S1:5458:3	O
85%	BREO.xml:S1:5462:3	O
were	BREO.xml:S1:5466:4	O
white	BREO.xml:S1:5471:5	O
.	BREO.xml:S1:5476:1	O

They	BREO.xml:S1:5478:4	O
had	BREO.xml:S1:5483:3	O
a	BREO.xml:S1:5487:1	O
mean	BREO.xml:S1:5489:4	O
age	BREO.xml:S1:5494:3	O
of	BREO.xml:S1:5498:2	O
64	BREO.xml:S1:5501:2	O
years	BREO.xml:S1:5504:5	O
and	BREO.xml:S1:5510:3	O
an	BREO.xml:S1:5514:2	O
average	BREO.xml:S1:5517:7	O
smoking	BREO.xml:S1:5525:7	O
history	BREO.xml:S1:5533:7	O
of	BREO.xml:S1:5541:2	O
46	BREO.xml:S1:5544:2	O
pack	BREO.xml:S1:5547:4	O
-	BREO.xml:S1:5551:1	O
years	BREO.xml:S1:5552:5	O
,	BREO.xml:S1:5557:1	O
with	BREO.xml:S1:5559:4	O
44%	BREO.xml:S1:5564:3	O
identified	BREO.xml:S1:5568:10	O
as	BREO.xml:S1:5579:2	O
current	BREO.xml:S1:5582:7	O
smokers	BREO.xml:S1:5590:7	O
.	BREO.xml:S1:5597:1	O

At	BREO.xml:S1:5599:2	O
screening	BREO.xml:S1:5602:9	O
,	BREO.xml:S1:5611:1	O
the	BREO.xml:S1:5613:3	O
mean	BREO.xml:S1:5617:4	O
postbronchodilator	BREO.xml:S1:5622:18	O
percent	BREO.xml:S1:5641:7	O
predicted	BREO.xml:S1:5649:9	O
FEV1was	BREO.xml:S1:5659:7	O
45%	BREO.xml:S1:5667:3	O
(	BREO.xml:S1:5671:1	O
range	BREO.xml:S1:5672:5	O
:	BREO.xml:S1:5677:1	O
12%	BREO.xml:S1:5679:3	O
to	BREO.xml:S1:5683:2	O
91%	BREO.xml:S1:5686:3	O
)	BREO.xml:S1:5689:1	O
,	BREO.xml:S1:5690:1	O
and	BREO.xml:S1:5692:3	O
the	BREO.xml:S1:5696:3	O
mean	BREO.xml:S1:5700:4	O
postbronchodilator	BREO.xml:S1:5705:18	O
FEV1	BREO.xml:S1:5724:4	O
FVC	BREO.xml:S1:5729:3	O
ratio	BREO.xml:S1:5733:5	O
was	BREO.xml:S1:5739:3	O
46%	BREO.xml:S1:5743:3	O
(	BREO.xml:S1:5747:1	O
range	BREO.xml:S1:5748:5	O
:	BREO.xml:S1:5753:1	O
17%	BREO.xml:S1:5755:3	O
to	BREO.xml:S1:5759:2	O
81%	BREO.xml:S1:5762:3	O
)	BREO.xml:S1:5765:1	O
,	BREO.xml:S1:5766:1	O
indicating	BREO.xml:S1:5768:10	O
that	BREO.xml:S1:5779:4	O
the	BREO.xml:S1:5784:3	O
subject	BREO.xml:S1:5788:7	O
population	BREO.xml:S1:5796:10	O
had	BREO.xml:S1:5807:3	O
moderate	BREO.xml:S1:5811:8	O
to	BREO.xml:S1:5820:2	O
very	BREO.xml:S1:5823:4	O
severely	BREO.xml:S1:5828:8	O
impaired	BREO.xml:S1:5837:8	O
airflow	BREO.xml:S1:5846:7	O
obstruction	BREO.xml:S1:5854:11	O
.	BREO.xml:S1:5865:1	O

Subjects	BREO.xml:S1:5867:8	O
received	BREO.xml:S1:5876:8	O
1	BREO.xml:S1:5885:1	O
inhalation	BREO.xml:S1:5887:10	O
once	BREO.xml:S1:5898:4	O
daily	BREO.xml:S1:5903:5	O
of	BREO.xml:S1:5909:2	O
the	BREO.xml:S1:5912:3	O
following	BREO.xml:S1:5916:9	O
:	BREO.xml:S1:5925:1	O
BREO	BREO.xml:S1:5927:4	O
ELLIPTA	BREO.xml:S1:5932:7	O
100	BREO.xml:S1:5940:3	O
25	BREO.xml:S1:5944:2	O
,	BREO.xml:S1:5946:1	O
BREO	BREO.xml:S1:5948:4	O
ELLIPTA	BREO.xml:S1:5953:7	O
200	BREO.xml:S1:5961:3	O
25	BREO.xml:S1:5965:2	O
,	BREO.xml:S1:5967:1	O
fluticasone	BREO.xml:S1:5969:11	O
furoate	BREO.xml:S1:5981:7	O
vilanterol	BREO.xml:S1:5989:10	O
50	BREO.xml:S1:6000:2	O
mcg	BREO.xml:S1:6003:3	O
25	BREO.xml:S1:6007:2	O
mcg	BREO.xml:S1:6010:3	O
,	BREO.xml:S1:6013:1	O
or	BREO.xml:S1:6015:2	O
vilanterol	BREO.xml:S1:6018:10	O
25	BREO.xml:S1:6029:2	O
mcg	BREO.xml:S1:6032:3	O
.	BREO.xml:S1:6035:1	O

In	BREO.xml:S1:6037:2	O
addition	BREO.xml:S1:6040:8	O
to	BREO.xml:S1:6049:2	O
the	BREO.xml:S1:6052:3	O
reactions	BREO.xml:S1:6056:9	O
shown	BREO.xml:S1:6066:5	O
in	BREO.xml:S1:6072:2	O
Table	BREO.xml:S1:6075:5	O
1	BREO.xml:S1:6081:1	O
,	BREO.xml:S1:6082:1	O
adverse	BREO.xml:S1:6084:7	O
reactions	BREO.xml:S1:6092:9	O
occurring	BREO.xml:S1:6102:9	O
in	BREO.xml:S1:6112:2	O
greater	BREO.xml:S1:6115:7	O
than	BREO.xml:S1:6123:4	O
or	BREO.xml:S1:6128:2	O
equal	BREO.xml:S1:6131:5	O
to	BREO.xml:S1:6137:2	O
3%	BREO.xml:S1:6140:2	O
of	BREO.xml:S1:6143:2	O
the	BREO.xml:S1:6146:3	O
subjects	BREO.xml:S1:6150:8	O
treated	BREO.xml:S1:6159:7	O
with	BREO.xml:S1:6167:4	O
BREO	BREO.xml:S1:6172:4	O
ELLIPTA	BREO.xml:S1:6177:7	O
100	BREO.xml:S1:6185:3	O
25	BREO.xml:S1:6189:2	O
(	BREO.xml:S1:6192:1	O
n	BREO.xml:S1:6193:1	O
806	BREO.xml:S1:6197:3	O
)	BREO.xml:S1:6200:1	O
for	BREO.xml:S1:6202:3	O
12	BREO.xml:S1:6206:2	O
months	BREO.xml:S1:6209:6	O
included	BREO.xml:S1:6216:8	O
back	BREO.xml:S1:6225:4	B-AdverseReaction
pain	BREO.xml:S1:6230:4	I-AdverseReaction
,	BREO.xml:S1:6234:1	O
pneumonia	BREO.xml:S1:6236:9	B-AdverseReaction
[	BREO.xml:S1:6247:1	O
see	BREO.xml:S1:6248:3	O
Warnings	BREO.xml:S1:6252:8	O
and	BREO.xml:S1:6261:3	O
Precautions	BREO.xml:S1:6265:11	O
(	BREO.xml:S1:6277:1	O
5.5	BREO.xml:S1:6278:3	O
)]	BREO.xml:S1:6281:2	O
,	BREO.xml:S1:6285:1	O
bronchitis	BREO.xml:S1:6287:10	B-AdverseReaction
,	BREO.xml:S1:6297:1	O
sinusitis	BREO.xml:S1:6299:9	B-AdverseReaction
,	BREO.xml:S1:6308:1	O
cough	BREO.xml:S1:6310:5	B-AdverseReaction
,	BREO.xml:S1:6315:1	O
oropharyngeal	BREO.xml:S1:6317:13	B-AdverseReaction
pain	BREO.xml:S1:6331:4	I-AdverseReaction
,	BREO.xml:S1:6335:1	O
arthralgia	BREO.xml:S1:6337:10	B-AdverseReaction
,	BREO.xml:S1:6347:1	O
influenza	BREO.xml:S1:6349:9	B-AdverseReaction
,	BREO.xml:S1:6358:1	O
pharyngitis	BREO.xml:S1:6360:11	B-AdverseReaction
,	BREO.xml:S1:6371:1	O
and	BREO.xml:S1:6373:3	O
pyrexia	BREO.xml:S1:6377:7	B-AdverseReaction
.	BREO.xml:S1:6384:1	O

6.2	BREO.xml:S1:6392:3	O
Clinical	BREO.xml:S1:6396:8	O
Trials	BREO.xml:S1:6405:6	O
Experience	BREO.xml:S1:6412:10	O
in	BREO.xml:S1:6423:2	O
Asthma	BREO.xml:S1:6426:6	O

BREO	BREO.xml:S1:6436:4	O
ELLIPTA	BREO.xml:S1:6441:7	O
for	BREO.xml:S1:6449:3	O
the	BREO.xml:S1:6453:3	O
treatment	BREO.xml:S1:6457:9	O
of	BREO.xml:S1:6467:2	O
asthma	BREO.xml:S1:6470:6	O
was	BREO.xml:S1:6477:3	O
studied	BREO.xml:S1:6481:7	O
in	BREO.xml:S1:6489:2	O
18	BREO.xml:S1:6492:2	O
double	BREO.xml:S1:6495:6	O
-	BREO.xml:S1:6501:1	O
blind	BREO.xml:S1:6502:5	O
,	BREO.xml:S1:6507:1	O
parallel	BREO.xml:S1:6509:8	O
-	BREO.xml:S1:6517:1	O
group	BREO.xml:S1:6518:5	O
,	BREO.xml:S1:6523:1	O
controlled	BREO.xml:S1:6525:10	O
trials	BREO.xml:S1:6536:6	O
(	BREO.xml:S1:6543:1	O
11	BREO.xml:S1:6544:2	O
with	BREO.xml:S1:6547:4	O
placebo	BREO.xml:S1:6552:7	O
)	BREO.xml:S1:6559:1	O
of	BREO.xml:S1:6561:2	O
4	BREO.xml:S1:6564:1	O
to	BREO.xml:S1:6566:2	O
76	BREO.xml:S1:6569:2	O
weeks	BREO.xml:S1:6572:5	O
duration	BREO.xml:S1:6579:8	O
,	BREO.xml:S1:6587:1	O
which	BREO.xml:S1:6589:5	O
enrolled	BREO.xml:S1:6595:8	O
9	BREO.xml:S1:6604:1	O
,	BREO.xml:S1:6605:1	O
969	BREO.xml:S1:6606:3	O
subjects	BREO.xml:S1:6610:8	O
with	BREO.xml:S1:6619:4	O
asthma	BREO.xml:S1:6624:6	O
.	BREO.xml:S1:6630:1	O

BREO	BREO.xml:S1:6632:4	O
ELLIPTA	BREO.xml:S1:6637:7	O
100	BREO.xml:S1:6645:3	O
25	BREO.xml:S1:6649:2	O
was	BREO.xml:S1:6652:3	O
studied	BREO.xml:S1:6656:7	O
in	BREO.xml:S1:6664:2	O
2	BREO.xml:S1:6667:1	O
,	BREO.xml:S1:6668:1	O
369	BREO.xml:S1:6669:3	O
subjects	BREO.xml:S1:6673:8	O
and	BREO.xml:S1:6682:3	O
BREO	BREO.xml:S1:6686:4	O
ELLIPTA	BREO.xml:S1:6691:7	O
200	BREO.xml:S1:6699:3	O
25	BREO.xml:S1:6703:2	O
was	BREO.xml:S1:6706:3	O
studied	BREO.xml:S1:6710:7	O
in	BREO.xml:S1:6718:2	O
956	BREO.xml:S1:6721:3	O
subjects	BREO.xml:S1:6725:8	O
.	BREO.xml:S1:6733:1	O

While	BREO.xml:S1:6735:5	O
subjects	BREO.xml:S1:6741:8	O
aged	BREO.xml:S1:6750:4	O
12	BREO.xml:S1:6755:2	O
to	BREO.xml:S1:6758:2	O
17	BREO.xml:S1:6761:2	O
years	BREO.xml:S1:6764:5	O
were	BREO.xml:S1:6770:4	O
included	BREO.xml:S1:6775:8	O
in	BREO.xml:S1:6784:2	O
these	BREO.xml:S1:6787:5	O
trials	BREO.xml:S1:6793:6	O
,	BREO.xml:S1:6799:1	O
BREO	BREO.xml:S1:6801:4	O
ELLIPTA	BREO.xml:S1:6806:7	O
is	BREO.xml:S1:6814:2	O
not	BREO.xml:S1:6817:3	O
approved	BREO.xml:S1:6821:8	O
for	BREO.xml:S1:6830:3	O
use	BREO.xml:S1:6834:3	O
in	BREO.xml:S1:6838:2	O
this	BREO.xml:S1:6841:4	O
age	BREO.xml:S1:6846:3	O
-	BREO.xml:S1:6849:1	O
group	BREO.xml:S1:6850:5	O
[	BREO.xml:S1:6857:1	O
see	BREO.xml:S1:6858:3	O
Use	BREO.xml:S1:6862:3	O
in	BREO.xml:S1:6866:2	O
Specific	BREO.xml:S1:6869:8	O
Populations	BREO.xml:S1:6878:11	O
(	BREO.xml:S1:6890:1	O
8.4	BREO.xml:S1:6891:3	O
)]	BREO.xml:S1:6894:2	O
.	BREO.xml:S1:6898:1	O

The	BREO.xml:S1:6900:3	O
safety	BREO.xml:S1:6904:6	O
data	BREO.xml:S1:6911:4	O
described	BREO.xml:S1:6916:9	O
below	BREO.xml:S1:6926:5	O
are	BREO.xml:S1:6932:3	O
based	BREO.xml:S1:6936:5	O
on	BREO.xml:S1:6942:2	O
two	BREO.xml:S1:6945:3	O
12	BREO.xml:S1:6949:2	O
-	BREO.xml:S1:6951:1	O
week	BREO.xml:S1:6952:4	O
efficacy	BREO.xml:S1:6957:8	O
trials	BREO.xml:S1:6966:6	O
,	BREO.xml:S1:6972:1	O
one	BREO.xml:S1:6974:3	O
24	BREO.xml:S1:6978:2	O
-	BREO.xml:S1:6980:1	O
week	BREO.xml:S1:6981:4	O
efficacy	BREO.xml:S1:6986:8	O
trial	BREO.xml:S1:6995:5	O
,	BREO.xml:S1:7000:1	O
and	BREO.xml:S1:7002:3	O
two	BREO.xml:S1:7006:3	O
long	BREO.xml:S1:7010:4	O
-	BREO.xml:S1:7014:1	O
term	BREO.xml:S1:7015:4	O
trials	BREO.xml:S1:7020:6	O
.	BREO.xml:S1:7026:1	O

12	BREO.xml:S1:7034:2	O
-	BREO.xml:S1:7036:1	O
Week	BREO.xml:S1:7037:4	O
Trials	BREO.xml:S1:7042:6	O

Trial	BREO.xml:S1:7055:5	O
1	BREO.xml:S1:7061:1	O
was	BREO.xml:S1:7063:3	O
a	BREO.xml:S1:7067:1	O
12	BREO.xml:S1:7069:2	O
-	BREO.xml:S1:7071:1	O
week	BREO.xml:S1:7072:4	O
trial	BREO.xml:S1:7077:5	O
that	BREO.xml:S1:7083:4	O
evaluated	BREO.xml:S1:7088:9	O
the	BREO.xml:S1:7098:3	O
efficacy	BREO.xml:S1:7102:8	O
of	BREO.xml:S1:7111:2	O
BREO	BREO.xml:S1:7114:4	O
ELLIPTA	BREO.xml:S1:7119:7	O
100	BREO.xml:S1:7127:3	O
25	BREO.xml:S1:7131:2	O
in	BREO.xml:S1:7134:2	O
adolescent	BREO.xml:S1:7137:10	O
and	BREO.xml:S1:7148:3	O
adult	BREO.xml:S1:7152:5	O
subjects	BREO.xml:S1:7158:8	O
with	BREO.xml:S1:7167:4	O
asthma	BREO.xml:S1:7172:6	O
compared	BREO.xml:S1:7179:8	O
with	BREO.xml:S1:7188:4	O
fluticasone	BREO.xml:S1:7193:11	O
furoate	BREO.xml:S1:7205:7	O
100	BREO.xml:S1:7213:3	O
mcg	BREO.xml:S1:7217:3	O
and	BREO.xml:S1:7221:3	O
placebo	BREO.xml:S1:7225:7	O
.	BREO.xml:S1:7232:1	O

Of	BREO.xml:S1:7234:2	O
the	BREO.xml:S1:7237:3	O
609	BREO.xml:S1:7241:3	O
subjects	BREO.xml:S1:7245:8	O
,	BREO.xml:S1:7253:1	O
58%	BREO.xml:S1:7255:3	O
were	BREO.xml:S1:7259:4	O
female	BREO.xml:S1:7264:6	O
and	BREO.xml:S1:7271:3	O
84%	BREO.xml:S1:7275:3	O
were	BREO.xml:S1:7279:4	O
white	BREO.xml:S1:7284:5	O
;	BREO.xml:S1:7289:1	O
the	BREO.xml:S1:7291:3	O
mean	BREO.xml:S1:7295:4	O
age	BREO.xml:S1:7300:3	O
was	BREO.xml:S1:7304:3	O
40	BREO.xml:S1:7308:2	O
years	BREO.xml:S1:7311:5	O
.	BREO.xml:S1:7316:1	O

The	BREO.xml:S1:7318:3	O
incidence	BREO.xml:S1:7322:9	O
of	BREO.xml:S1:7332:2	O
adverse	BREO.xml:S1:7335:7	O
reactions	BREO.xml:S1:7343:9	O
associated	BREO.xml:S1:7353:10	O
with	BREO.xml:S1:7364:4	O
BREO	BREO.xml:S1:7369:4	O
ELLIPTA	BREO.xml:S1:7374:7	O
100	BREO.xml:S1:7382:3	O
25	BREO.xml:S1:7386:2	O
is	BREO.xml:S1:7389:2	O
shown	BREO.xml:S1:7392:5	O
in	BREO.xml:S1:7398:2	O
Table	BREO.xml:S1:7401:5	O
2	BREO.xml:S1:7407:1	O
.	BREO.xml:S1:7408:1	O

Table	BREO.xml:S1:7416:5	O
2	BREO.xml:S1:7422:1	O
.	BREO.xml:S1:7423:1	O

Adverse	BREO.xml:S1:7425:7	O
Reactions	BREO.xml:S1:7433:9	O
with	BREO.xml:S1:7443:4	O
BREO	BREO.xml:S1:7448:4	O
ELLIPTA	BREO.xml:S1:7453:7	O
100	BREO.xml:S1:7461:3	O
25	BREO.xml:S1:7465:2	O
with	BREO.xml:S1:7468:4	O
2%	BREO.xml:S1:7475:2	O
Incidence	BREO.xml:S1:7478:9	O
and	BREO.xml:S1:7488:3	O
More	BREO.xml:S1:7492:4	O
Common	BREO.xml:S1:7497:6	O
than	BREO.xml:S1:7504:4	O
Placebo	BREO.xml:S1:7509:7	O
in	BREO.xml:S1:7517:2	O
Subjects	BREO.xml:S1:7520:8	O
with	BREO.xml:S1:7529:4	O
Asthma	BREO.xml:S1:7534:6	O
(	BREO.xml:S1:7541:1	O
Trial	BREO.xml:S1:7542:5	O
1	BREO.xml:S1:7548:1	O
)	BREO.xml:S1:7549:1	O

Adverse	BREO.xml:S1:7559:7	O
Reaction	BREO.xml:S1:7567:8	O
BREO	BREO.xml:S1:7608:4	O
ELLIPTA	BREO.xml:S1:7613:7	O
100	BREO.xml:S1:7622:3	O
25	BREO.xml:S1:7626:2	O
(	BREO.xml:S1:7630:1	O
n	BREO.xml:S1:7631:1	O
201	BREO.xml:S1:7635:3	O
)	BREO.xml:S1:7638:1	O
Fluticasone	BREO.xml:S1:7646:11	O
Furoate	BREO.xml:S1:7658:7	O
100	BREO.xml:S1:7667:3	O
mcg	BREO.xml:S1:7671:3	O
(	BREO.xml:S1:7676:1	O
n	BREO.xml:S1:7677:1	O
205	BREO.xml:S1:7681:3	O
)	BREO.xml:S1:7684:1	O
Placebo	BREO.xml:S1:7692:7	O
(	BREO.xml:S1:7701:1	O
n	BREO.xml:S1:7702:1	O
203	BREO.xml:S1:7706:3	O
)	BREO.xml:S1:7709:1	O

Infections	BREO.xml:S1:7720:10	O
and	BREO.xml:S1:7731:3	O
infestations	BREO.xml:S1:7735:12	O

Nasopharyngitis	BREO.xml:S1:7879:15	B-AdverseReaction

10	BREO.xml:S1:8028:2	O
7	BREO.xml:S1:8050:1	O
7	BREO.xml:S1:8074:1	O

Oral	BREO.xml:S1:8138:4	B-AdverseReaction
candidiasis	BREO.xml:S1:8143:11	I-AdverseReaction
a	BREO.xml:S1:8156:1	O

2	BREO.xml:S1:8287:1	O
2	BREO.xml:S1:8309:1	O
0	BREO.xml:S1:8333:1	O

Nervous	BREO.xml:S1:8349:7	O
system	BREO.xml:S1:8357:6	O
disorders	BREO.xml:S1:8364:9	O

Headache	BREO.xml:S1:8508:8	B-AdverseReaction

5	BREO.xml:S1:8657:1	O
4	BREO.xml:S1:8679:1	O
4	BREO.xml:S1:8703:1	O

Respiratory	BREO.xml:S1:8719:11	O
,	BREO.xml:S1:8730:1	O
thoracic	BREO.xml:S1:8732:8	O
,	BREO.xml:S1:8740:1	O
and	BREO.xml:S1:8742:3	O
mediastinal	BREO.xml:S1:8746:11	O
disorders	BREO.xml:S1:8758:9	O

Oropharyngeal	BREO.xml:S1:8881:13	B-AdverseReaction
pain	BREO.xml:S1:8895:4	I-AdverseReaction

2	BREO.xml:S1:9030:1	O
2	BREO.xml:S1:9052:1	O
1	BREO.xml:S1:9076:1	O

Dysphonia	BREO.xml:S1:9140:9	B-AdverseReaction

2	BREO.xml:S1:9289:1	O
1	BREO.xml:S1:9311:1	O
0	BREO.xml:S1:9335:1	O

a	BREO.xml:S1:9361:1	O
Includes	BREO.xml:S1:9364:8	O
oral	BREO.xml:S1:9373:4	B-AdverseReaction
candidiasis	BREO.xml:S1:9378:11	I-AdverseReaction
and	BREO.xml:S1:9390:3	O
oropharyngeal	BREO.xml:S1:9394:13	B-AdverseReaction
candidiasis	BREO.xml:S1:9408:11	I-AdverseReaction
.	BREO.xml:S1:9419:1	O

Trial	BREO.xml:S1:9425:5	O

2	BREO.xml:S1:9431:1	O
was	BREO.xml:S1:9433:3	O
a	BREO.xml:S1:9437:1	O
12	BREO.xml:S1:9439:2	O
-	BREO.xml:S1:9441:1	O
week	BREO.xml:S1:9442:4	O
trial	BREO.xml:S1:9447:5	O
that	BREO.xml:S1:9453:4	O
evaluated	BREO.xml:S1:9458:9	O
the	BREO.xml:S1:9468:3	O
efficacy	BREO.xml:S1:9472:8	O
of	BREO.xml:S1:9481:2	O
BREO	BREO.xml:S1:9484:4	O
ELLIPTA	BREO.xml:S1:9489:7	O
100	BREO.xml:S1:9497:3	O
25	BREO.xml:S1:9501:2	O
,	BREO.xml:S1:9503:1	O
BREO	BREO.xml:S1:9505:4	O
ELLIPTA	BREO.xml:S1:9510:7	O
200	BREO.xml:S1:9518:3	O
25	BREO.xml:S1:9522:2	O
,	BREO.xml:S1:9524:1	O
and	BREO.xml:S1:9526:3	O
fluticasone	BREO.xml:S1:9530:11	O
furoate	BREO.xml:S1:9542:7	O
100	BREO.xml:S1:9550:3	O
mcg	BREO.xml:S1:9554:3	O
in	BREO.xml:S1:9558:2	O
adolescent	BREO.xml:S1:9561:10	O
and	BREO.xml:S1:9572:3	O
adult	BREO.xml:S1:9576:5	O
subjects	BREO.xml:S1:9582:8	O
with	BREO.xml:S1:9591:4	O
asthma	BREO.xml:S1:9596:6	O
.	BREO.xml:S1:9602:1	O

This	BREO.xml:S1:9604:4	O
trial	BREO.xml:S1:9609:5	O
did	BREO.xml:S1:9615:3	O
not	BREO.xml:S1:9619:3	O
have	BREO.xml:S1:9623:4	O
a	BREO.xml:S1:9628:1	O
placebo	BREO.xml:S1:9630:7	O
arm	BREO.xml:S1:9638:3	O
.	BREO.xml:S1:9641:1	O

Of	BREO.xml:S1:9643:2	O
the	BREO.xml:S1:9646:3	O
1	BREO.xml:S1:9650:1	O
,	BREO.xml:S1:9651:1	O
039	BREO.xml:S1:9652:3	O
subjects	BREO.xml:S1:9656:8	O
,	BREO.xml:S1:9664:1	O
60%	BREO.xml:S1:9666:3	O
were	BREO.xml:S1:9670:4	O
female	BREO.xml:S1:9675:6	O
and	BREO.xml:S1:9682:3	O
88%	BREO.xml:S1:9686:3	O
were	BREO.xml:S1:9690:4	O
white	BREO.xml:S1:9695:5	O
;	BREO.xml:S1:9700:1	O
the	BREO.xml:S1:9702:3	O
mean	BREO.xml:S1:9706:4	O
age	BREO.xml:S1:9711:3	O
was	BREO.xml:S1:9715:3	O
46	BREO.xml:S1:9719:2	O
years	BREO.xml:S1:9722:5	O
.	BREO.xml:S1:9727:1	O

The	BREO.xml:S1:9729:3	O
incidence	BREO.xml:S1:9733:9	O
of	BREO.xml:S1:9743:2	O
adverse	BREO.xml:S1:9746:7	O
reactions	BREO.xml:S1:9754:9	O
associated	BREO.xml:S1:9764:10	O
with	BREO.xml:S1:9775:4	O
BREO	BREO.xml:S1:9780:4	O
ELLIPTA	BREO.xml:S1:9785:7	O
100	BREO.xml:S1:9793:3	O
25	BREO.xml:S1:9797:2	O
and	BREO.xml:S1:9800:3	O
BREO	BREO.xml:S1:9804:4	O
ELLIPTA	BREO.xml:S1:9809:7	O
200	BREO.xml:S1:9817:3	O
25	BREO.xml:S1:9821:2	O
is	BREO.xml:S1:9824:2	O
shown	BREO.xml:S1:9827:5	O
in	BREO.xml:S1:9833:2	O
Table	BREO.xml:S1:9836:5	O
3	BREO.xml:S1:9842:1	O
.	BREO.xml:S1:9843:1	O

Table	BREO.xml:S1:9851:5	O
3	BREO.xml:S1:9857:1	O
.	BREO.xml:S1:9858:1	O

Adverse	BREO.xml:S1:9860:7	O
Reactions	BREO.xml:S1:9868:9	O
with	BREO.xml:S1:9878:4	O
BREO	BREO.xml:S1:9883:4	O
ELLIPTA	BREO.xml:S1:9888:7	O
100	BREO.xml:S1:9896:3	O
25	BREO.xml:S1:9900:2	O
and	BREO.xml:S1:9903:3	O
BREO	BREO.xml:S1:9907:4	O
ELLIPTA	BREO.xml:S1:9912:7	O
200	BREO.xml:S1:9920:3	O
25	BREO.xml:S1:9924:2	O
with	BREO.xml:S1:9927:4	O
2%	BREO.xml:S1:9934:2	O
Incidence	BREO.xml:S1:9937:9	O
in	BREO.xml:S1:9947:2	O
Subjects	BREO.xml:S1:9950:8	O
with	BREO.xml:S1:9959:4	O
Asthma	BREO.xml:S1:9964:6	O
(	BREO.xml:S1:9971:1	O
Trial	BREO.xml:S1:9972:5	O
2	BREO.xml:S1:9978:1	O
)	BREO.xml:S1:9979:1	O

Adverse	BREO.xml:S1:9989:7	O
Reaction	BREO.xml:S1:9997:8	O
BREO	BREO.xml:S1:10034:4	O
ELLIPTA	BREO.xml:S1:10039:7	O
200	BREO.xml:S1:10048:3	O
25	BREO.xml:S1:10052:2	O
(	BREO.xml:S1:10056:1	O
n	BREO.xml:S1:10057:1	O
346	BREO.xml:S1:10061:3	O
)	BREO.xml:S1:10064:1	O
BREO	BREO.xml:S1:10072:4	O
ELLIPTA	BREO.xml:S1:10077:7	O
100	BREO.xml:S1:10086:3	O
25	BREO.xml:S1:10090:2	O
(	BREO.xml:S1:10094:1	O
n	BREO.xml:S1:10095:1	O
346	BREO.xml:S1:10099:3	O
)	BREO.xml:S1:10102:1	O
Fluticasone	BREO.xml:S1:10110:11	O
Furoate	BREO.xml:S1:10122:7	O
100	BREO.xml:S1:10131:3	O
mcg	BREO.xml:S1:10135:3	O
(	BREO.xml:S1:10140:1	O
n	BREO.xml:S1:10141:1	O
347	BREO.xml:S1:10145:3	O
)	BREO.xml:S1:10148:1	O

Nervous	BREO.xml:S1:10159:7	O
system	BREO.xml:S1:10167:6	O
disorders	BREO.xml:S1:10174:9	O

Headache	BREO.xml:S1:10314:8	B-AdverseReaction

8	BREO.xml:S1:10451:1	O
8	BREO.xml:S1:10471:1	O
9	BREO.xml:S1:10491:1	O

Infections	BREO.xml:S1:10517:10	O
and	BREO.xml:S1:10528:3	O
infestations	BREO.xml:S1:10532:12	O

Nasopharyngitis	BREO.xml:S1:10672:15	B-AdverseReaction

7	BREO.xml:S1:10809:1	O
6	BREO.xml:S1:10829:1	O
7	BREO.xml:S1:10849:1	O

Influenza	BREO.xml:S1:10919:9	B-AdverseReaction

3	BREO.xml:S1:11056:1	O
3	BREO.xml:S1:11076:1	O
1	BREO.xml:S1:11096:1	O

Upper	BREO.xml:S1:11166:5	B-AdverseReaction
respiratory	BREO.xml:S1:11172:11	I-AdverseReaction
tract	BREO.xml:S1:11184:5	I-AdverseReaction
infection	BREO.xml:S1:11190:9	I-AdverseReaction

2	BREO.xml:S1:11303:1	O
2	BREO.xml:S1:11323:1	O
3	BREO.xml:S1:11343:1	O

Sinusitis	BREO.xml:S1:11413:9	B-AdverseReaction

2	BREO.xml:S1:11550:1	O
1	BREO.xml:S1:11570:1	O
1	BREO.xml:S1:11591:1	O

Bronchitis	BREO.xml:S1:11660:10	B-AdverseReaction

2	BREO.xml:S1:11797:1	O
1	BREO.xml:S1:11818:1	O
2	BREO.xml:S1:11837:1	O

Respiratory	BREO.xml:S1:11863:11	O
,	BREO.xml:S1:11874:1	O
thoracic	BREO.xml:S1:11876:8	O
and	BREO.xml:S1:11885:3	O
mediastinal	BREO.xml:S1:11889:11	O
disorders	BREO.xml:S1:11901:9	O

Oropharyngeal	BREO.xml:S1:12024:13	B-AdverseReaction
pain	BREO.xml:S1:12038:4	I-AdverseReaction

2	BREO.xml:S1:12161:1	O
2	BREO.xml:S1:12181:1	O
1	BREO.xml:S1:12201:1	O

Cough	BREO.xml:S1:12271:5	B-AdverseReaction

1	BREO.xml:S1:12408:1	O
2	BREO.xml:S1:12428:1	O
1	BREO.xml:S1:12448:1	O

24	BREO.xml:S1:12484:2	O
-	BREO.xml:S1:12486:1	O
Week	BREO.xml:S1:12487:4	O
Trial	BREO.xml:S1:12492:5	O

Trial	BREO.xml:S1:12504:5	O

3	BREO.xml:S1:12510:1	O
was	BREO.xml:S1:12512:3	O
a	BREO.xml:S1:12516:1	O
24	BREO.xml:S1:12518:2	O
-	BREO.xml:S1:12520:1	O
week	BREO.xml:S1:12521:4	O
trial	BREO.xml:S1:12526:5	O
that	BREO.xml:S1:12532:4	O
evaluated	BREO.xml:S1:12537:9	O
the	BREO.xml:S1:12547:3	O
efficacy	BREO.xml:S1:12551:8	O
of	BREO.xml:S1:12560:2	O
BREO	BREO.xml:S1:12563:4	O
ELLIPTA	BREO.xml:S1:12568:7	O
200	BREO.xml:S1:12576:3	O
25	BREO.xml:S1:12580:2	O
once	BREO.xml:S1:12583:4	O
daily	BREO.xml:S1:12588:5	O
,	BREO.xml:S1:12593:1	O
fluticasone	BREO.xml:S1:12595:11	O
furoate	BREO.xml:S1:12607:7	O
200	BREO.xml:S1:12615:3	O
mcg	BREO.xml:S1:12619:3	O
once	BREO.xml:S1:12623:4	O
daily	BREO.xml:S1:12628:5	O
,	BREO.xml:S1:12633:1	O
and	BREO.xml:S1:12635:3	O
fluticasone	BREO.xml:S1:12639:11	O
propionate	BREO.xml:S1:12651:10	O
500	BREO.xml:S1:12662:3	O
mcg	BREO.xml:S1:12666:3	O
twice	BREO.xml:S1:12670:5	O
daily	BREO.xml:S1:12676:5	O
in	BREO.xml:S1:12682:2	O
adolescent	BREO.xml:S1:12685:10	O
and	BREO.xml:S1:12696:3	O
adult	BREO.xml:S1:12700:5	O
subjects	BREO.xml:S1:12706:8	O
with	BREO.xml:S1:12715:4	O
asthma	BREO.xml:S1:12720:6	O
.	BREO.xml:S1:12726:1	O

Of	BREO.xml:S1:12728:2	O
the	BREO.xml:S1:12731:3	O
586	BREO.xml:S1:12735:3	O
subjects	BREO.xml:S1:12739:8	O
,	BREO.xml:S1:12747:1	O
59%	BREO.xml:S1:12749:3	O
were	BREO.xml:S1:12753:4	O
female	BREO.xml:S1:12758:6	O
and	BREO.xml:S1:12765:3	O
84%	BREO.xml:S1:12769:3	O
were	BREO.xml:S1:12773:4	O
white	BREO.xml:S1:12778:5	O
;	BREO.xml:S1:12783:1	O
the	BREO.xml:S1:12785:3	O
mean	BREO.xml:S1:12789:4	O
age	BREO.xml:S1:12794:3	O
was	BREO.xml:S1:12798:3	O
46	BREO.xml:S1:12802:2	O
years	BREO.xml:S1:12805:5	O
.	BREO.xml:S1:12810:1	O

This	BREO.xml:S1:12812:4	O
trial	BREO.xml:S1:12817:5	O
did	BREO.xml:S1:12823:3	O
not	BREO.xml:S1:12827:3	O
have	BREO.xml:S1:12831:4	O
a	BREO.xml:S1:12836:1	O
placebo	BREO.xml:S1:12838:7	O
arm	BREO.xml:S1:12846:3	O
.	BREO.xml:S1:12849:1	O

In	BREO.xml:S1:12851:2	O
addition	BREO.xml:S1:12854:8	O
to	BREO.xml:S1:12863:2	O
the	BREO.xml:S1:12866:3	O
reactions	BREO.xml:S1:12870:9	O
shown	BREO.xml:S1:12880:5	O
in	BREO.xml:S1:12886:2	O
Tables	BREO.xml:S1:12889:6	O
2	BREO.xml:S1:12896:1	O
and	BREO.xml:S1:12898:3	O
3	BREO.xml:S1:12902:1	O
,	BREO.xml:S1:12903:1	O
adverse	BREO.xml:S1:12905:7	O
reactions	BREO.xml:S1:12913:9	O
occurring	BREO.xml:S1:12923:9	O
in	BREO.xml:S1:12933:2	O
greater	BREO.xml:S1:12936:7	O
than	BREO.xml:S1:12944:4	O
or	BREO.xml:S1:12949:2	O
equal	BREO.xml:S1:12952:5	O
to	BREO.xml:S1:12958:2	O
2%	BREO.xml:S1:12961:2	O
of	BREO.xml:S1:12964:2	O
subjects	BREO.xml:S1:12967:8	O
treated	BREO.xml:S1:12976:7	O
with	BREO.xml:S1:12984:4	O
BREO	BREO.xml:S1:12989:4	O
ELLIPTA	BREO.xml:S1:12994:7	O
200	BREO.xml:S1:13002:3	O
25	BREO.xml:S1:13006:2	O
included	BREO.xml:S1:13009:8	O
viral	BREO.xml:S1:13018:5	B-AdverseReaction
respiratory	BREO.xml:S1:13024:11	I-AdverseReaction
tract	BREO.xml:S1:13036:5	I-AdverseReaction
infection	BREO.xml:S1:13042:9	I-AdverseReaction
,	BREO.xml:S1:13051:1	O
pharyngitis	BREO.xml:S1:13053:11	B-AdverseReaction
,	BREO.xml:S1:13064:1	O
pyrexia	BREO.xml:S1:13066:7	B-AdverseReaction
,	BREO.xml:S1:13073:1	O
and	BREO.xml:S1:13075:3	O
arthralgia	BREO.xml:S1:13079:10	B-AdverseReaction
.	BREO.xml:S1:13089:1	O

12	BREO.xml:S1:13097:2	O
-	BREO.xml:S1:13099:1	O
Month	BREO.xml:S1:13100:5	O
Trial	BREO.xml:S1:13106:5	O

Long	BREO.xml:S1:13118:4	O
-	BREO.xml:S1:13122:1	O
term	BREO.xml:S1:13123:4	O
safety	BREO.xml:S1:13128:6	O
data	BREO.xml:S1:13135:4	O
is	BREO.xml:S1:13140:2	O
based	BREO.xml:S1:13143:5	O
on	BREO.xml:S1:13149:2	O
a	BREO.xml:S1:13152:1	O
12	BREO.xml:S1:13154:2	O
-	BREO.xml:S1:13156:1	O
month	BREO.xml:S1:13157:5	O
trial	BREO.xml:S1:13163:5	O
that	BREO.xml:S1:13169:4	O
evaluated	BREO.xml:S1:13174:9	O
the	BREO.xml:S1:13184:3	O
safety	BREO.xml:S1:13188:6	O
of	BREO.xml:S1:13195:2	O
BREO	BREO.xml:S1:13198:4	O
ELLIPTA	BREO.xml:S1:13203:7	O
100	BREO.xml:S1:13211:3	O
25	BREO.xml:S1:13215:2	O
once	BREO.xml:S1:13218:4	O
daily	BREO.xml:S1:13223:5	O
(	BREO.xml:S1:13229:1	O
n	BREO.xml:S1:13230:1	O
201	BREO.xml:S1:13234:3	O
)	BREO.xml:S1:13237:1	O
,	BREO.xml:S1:13238:1	O
BREO	BREO.xml:S1:13240:4	O
ELLIPTA	BREO.xml:S1:13245:7	O
200	BREO.xml:S1:13253:3	O
25	BREO.xml:S1:13257:2	O
once	BREO.xml:S1:13260:4	O
daily	BREO.xml:S1:13265:5	O
(	BREO.xml:S1:13271:1	O
n	BREO.xml:S1:13272:1	O
202	BREO.xml:S1:13276:3	O
)	BREO.xml:S1:13279:1	O
,	BREO.xml:S1:13280:1	O
and	BREO.xml:S1:13282:3	O
fluticasone	BREO.xml:S1:13286:11	O
propionate	BREO.xml:S1:13298:10	O
500	BREO.xml:S1:13309:3	O
mcg	BREO.xml:S1:13313:3	O
twice	BREO.xml:S1:13317:5	O
daily	BREO.xml:S1:13323:5	O
(	BREO.xml:S1:13329:1	O
n	BREO.xml:S1:13330:1	O
100	BREO.xml:S1:13334:3	O
)	BREO.xml:S1:13337:1	O
in	BREO.xml:S1:13339:2	O
adolescent	BREO.xml:S1:13342:10	O
and	BREO.xml:S1:13353:3	O
adult	BREO.xml:S1:13357:5	O
subjects	BREO.xml:S1:13363:8	O
with	BREO.xml:S1:13372:4	O
asthma	BREO.xml:S1:13377:6	O
(	BREO.xml:S1:13384:1	O
Trial	BREO.xml:S1:13385:5	O
4	BREO.xml:S1:13391:1	O
)	BREO.xml:S1:13392:1	O
.	BREO.xml:S1:13393:1	O

Overall	BREO.xml:S1:13395:7	O
,	BREO.xml:S1:13402:1	O
63%	BREO.xml:S1:13404:3	O
were	BREO.xml:S1:13408:4	O
female	BREO.xml:S1:13413:6	O
and	BREO.xml:S1:13420:3	O
67%	BREO.xml:S1:13424:3	O
were	BREO.xml:S1:13428:4	O
white	BREO.xml:S1:13433:5	O
.	BREO.xml:S1:13438:1	O

The	BREO.xml:S1:13440:3	O
mean	BREO.xml:S1:13444:4	O
age	BREO.xml:S1:13449:3	O
was	BREO.xml:S1:13453:3	O
39	BREO.xml:S1:13457:2	O
years	BREO.xml:S1:13460:5	O
;	BREO.xml:S1:13465:1	O
adolescents	BREO.xml:S1:13467:11	O
(	BREO.xml:S1:13479:1	O
aged	BREO.xml:S1:13480:4	O
12	BREO.xml:S1:13485:2	O
to	BREO.xml:S1:13488:2	O
17	BREO.xml:S1:13491:2	O
years	BREO.xml:S1:13494:5	O
)	BREO.xml:S1:13499:1	O
made	BREO.xml:S1:13501:4	O
up	BREO.xml:S1:13506:2	O
16%	BREO.xml:S1:13509:3	O
of	BREO.xml:S1:13513:2	O
the	BREO.xml:S1:13516:3	O
population	BREO.xml:S1:13520:10	O
.	BREO.xml:S1:13530:1	O

In	BREO.xml:S1:13532:2	O
addition	BREO.xml:S1:13535:8	O
to	BREO.xml:S1:13544:2	O
the	BREO.xml:S1:13547:3	O
reactions	BREO.xml:S1:13551:9	O
shown	BREO.xml:S1:13561:5	O
in	BREO.xml:S1:13567:2	O
Tables	BREO.xml:S1:13570:6	O
2	BREO.xml:S1:13577:1	O
and	BREO.xml:S1:13579:3	O
3	BREO.xml:S1:13583:1	O
,	BREO.xml:S1:13584:1	O
adverse	BREO.xml:S1:13586:7	O
reactions	BREO.xml:S1:13594:9	O
occurring	BREO.xml:S1:13604:9	O
in	BREO.xml:S1:13614:2	O
greater	BREO.xml:S1:13617:7	O
than	BREO.xml:S1:13625:4	O
or	BREO.xml:S1:13630:2	O
equal	BREO.xml:S1:13633:5	O
to	BREO.xml:S1:13639:2	O
2%	BREO.xml:S1:13642:2	O
of	BREO.xml:S1:13645:2	O
the	BREO.xml:S1:13648:3	O
subjects	BREO.xml:S1:13652:8	O
treated	BREO.xml:S1:13661:7	O
with	BREO.xml:S1:13669:4	O
BREO	BREO.xml:S1:13674:4	O
ELLIPTA	BREO.xml:S1:13679:7	O
100	BREO.xml:S1:13687:3	O
25	BREO.xml:S1:13691:2	O
or	BREO.xml:S1:13694:2	O
BREO	BREO.xml:S1:13697:4	O
ELLIPTA	BREO.xml:S1:13702:7	O
200	BREO.xml:S1:13710:3	O
25	BREO.xml:S1:13714:2	O
for	BREO.xml:S1:13717:3	O
12	BREO.xml:S1:13721:2	O
months	BREO.xml:S1:13724:6	O
included	BREO.xml:S1:13731:8	O
pyrexia	BREO.xml:S1:13740:7	B-AdverseReaction
,	BREO.xml:S1:13747:1	O
back	BREO.xml:S1:13749:4	B-AdverseReaction
pain	BREO.xml:S1:13754:4	I-AdverseReaction
,	BREO.xml:S1:13758:1	O
extrasystoles	BREO.xml:S1:13760:13	B-AdverseReaction
,	BREO.xml:S1:13773:1	O
upper	BREO.xml:S1:13775:5	B-AdverseReaction
abdominal	BREO.xml:S1:13781:9	I-AdverseReaction
pain	BREO.xml:S1:13791:4	I-AdverseReaction
,	BREO.xml:S1:13795:1	O
respiratory	BREO.xml:S1:13797:11	B-AdverseReaction
tract	BREO.xml:S1:13809:5	I-AdverseReaction
infection	BREO.xml:S1:13815:9	I-AdverseReaction
,	BREO.xml:S1:13824:1	O
allergic	BREO.xml:S1:13826:8	B-AdverseReaction
rhinitis	BREO.xml:S1:13835:8	I-AdverseReaction
,	BREO.xml:S1:13843:1	O
pharyngitis	BREO.xml:S1:13845:11	B-AdverseReaction
,	BREO.xml:S1:13856:1	O
rhinitis	BREO.xml:S1:13858:8	B-AdverseReaction
,	BREO.xml:S1:13866:1	O
arthralgia	BREO.xml:S1:13868:10	B-AdverseReaction
,	BREO.xml:S1:13878:1	O
supraventricular	BREO.xml:S1:13880:16	B-AdverseReaction
extrasystoles	BREO.xml:S1:13897:13	I-AdverseReaction
,	BREO.xml:S1:13910:1	O
ventricular	BREO.xml:S1:13912:11	B-AdverseReaction
extrasystoles	BREO.xml:S1:13924:13	I-AdverseReaction
,	BREO.xml:S1:13937:1	O
acute	BREO.xml:S1:13939:5	B-AdverseReaction
sinusitis	BREO.xml:S1:13945:9	I-AdverseReaction
,	BREO.xml:S1:13954:1	O
and	BREO.xml:S1:13956:3	O
pneumonia	BREO.xml:S1:13960:9	B-AdverseReaction
.	BREO.xml:S1:13969:1	O

Exacerbation	BREO.xml:S1:13977:12	O
Trial	BREO.xml:S1:13990:5	O

In	BREO.xml:S1:14002:2	O
a	BREO.xml:S1:14005:1	O
24	BREO.xml:S1:14007:2	O
-	BREO.xml:S1:14009:1	O
to	BREO.xml:S1:14011:2	O
76	BREO.xml:S1:14014:2	O
-	BREO.xml:S1:14016:1	O
week	BREO.xml:S1:14017:4	O
trial	BREO.xml:S1:14022:5	O
,	BREO.xml:S1:14027:1	O
subjects	BREO.xml:S1:14029:8	O
received	BREO.xml:S1:14038:8	O
BREO	BREO.xml:S1:14047:4	O
ELLIPTA	BREO.xml:S1:14052:7	O
100	BREO.xml:S1:14060:3	O
25	BREO.xml:S1:14064:2	O
(	BREO.xml:S1:14067:1	O
n	BREO.xml:S1:14068:1	O
1	BREO.xml:S1:14072:1	O
,	BREO.xml:S1:14073:1	O
009	BREO.xml:S1:14074:3	O
)	BREO.xml:S1:14077:1	O
or	BREO.xml:S1:14079:2	O
fluticasone	BREO.xml:S1:14082:11	O
furoate	BREO.xml:S1:14094:7	O
100	BREO.xml:S1:14102:3	O
mcg	BREO.xml:S1:14106:3	O
(	BREO.xml:S1:14110:1	O
n	BREO.xml:S1:14111:1	O
1	BREO.xml:S1:14115:1	O
,	BREO.xml:S1:14116:1	O
010	BREO.xml:S1:14117:3	O
)	BREO.xml:S1:14120:1	O
(	BREO.xml:S1:14122:1	O
Trial	BREO.xml:S1:14123:5	O
5	BREO.xml:S1:14129:1	O
)	BREO.xml:S1:14130:1	O
.	BREO.xml:S1:14131:1	O

Subjects	BREO.xml:S1:14133:8	O
participating	BREO.xml:S1:14142:13	O
in	BREO.xml:S1:14156:2	O
this	BREO.xml:S1:14159:4	O
trial	BREO.xml:S1:14164:5	O
had	BREO.xml:S1:14170:3	O
a	BREO.xml:S1:14174:1	O
history	BREO.xml:S1:14176:7	O
of	BREO.xml:S1:14184:2	O
one	BREO.xml:S1:14187:3	O
or	BREO.xml:S1:14191:2	O
more	BREO.xml:S1:14194:4	O
asthma	BREO.xml:S1:14199:6	O
exacerbations	BREO.xml:S1:14206:13	O
that	BREO.xml:S1:14220:4	O
required	BREO.xml:S1:14225:8	O
treatment	BREO.xml:S1:14234:9	O
with	BREO.xml:S1:14244:4	O
oral	BREO.xml:S1:14249:4	O
systemic	BREO.xml:S1:14254:8	O
corticosteroids	BREO.xml:S1:14263:15	O
or	BREO.xml:S1:14279:2	O
emergency	BREO.xml:S1:14282:9	O
department	BREO.xml:S1:14292:10	O
visit	BREO.xml:S1:14303:5	O
or	BREO.xml:S1:14309:2	O
in	BREO.xml:S1:14312:2	O
-	BREO.xml:S1:14314:1	O
patient	BREO.xml:S1:14315:7	O
hospitalization	BREO.xml:S1:14323:15	O
for	BREO.xml:S1:14339:3	O
the	BREO.xml:S1:14343:3	O
treatment	BREO.xml:S1:14347:9	O
of	BREO.xml:S1:14357:2	O
asthma	BREO.xml:S1:14360:6	O
in	BREO.xml:S1:14367:2	O
the	BREO.xml:S1:14370:3	O
year	BREO.xml:S1:14374:4	O
prior	BREO.xml:S1:14379:5	O
to	BREO.xml:S1:14385:2	O
trial	BREO.xml:S1:14388:5	O
entry	BREO.xml:S1:14394:5	O
.	BREO.xml:S1:14399:1	O

Overall	BREO.xml:S1:14401:7	O
,	BREO.xml:S1:14408:1	O
67%	BREO.xml:S1:14410:3	O
were	BREO.xml:S1:14414:4	O
female	BREO.xml:S1:14419:6	O
and	BREO.xml:S1:14426:3	O
73%	BREO.xml:S1:14430:3	O
were	BREO.xml:S1:14434:4	O
white	BREO.xml:S1:14439:5	O
;	BREO.xml:S1:14444:1	O
the	BREO.xml:S1:14446:3	O
mean	BREO.xml:S1:14450:4	O
age	BREO.xml:S1:14455:3	O
was	BREO.xml:S1:14459:3	O
42	BREO.xml:S1:14463:2	O
years	BREO.xml:S1:14466:5	O
(	BREO.xml:S1:14472:1	O
adolescents	BREO.xml:S1:14473:11	O
aged	BREO.xml:S1:14485:4	O
12	BREO.xml:S1:14490:2	O
to	BREO.xml:S1:14493:2	O
17	BREO.xml:S1:14496:2	O
years	BREO.xml:S1:14499:5	O
made	BREO.xml:S1:14505:4	O
up	BREO.xml:S1:14510:2	O
14%	BREO.xml:S1:14513:3	O
of	BREO.xml:S1:14517:2	O
the	BREO.xml:S1:14520:3	O
population	BREO.xml:S1:14524:10	O
)	BREO.xml:S1:14534:1	O
.	BREO.xml:S1:14535:1	O

While	BREO.xml:S1:14537:5	O
subjects	BREO.xml:S1:14543:8	O
aged	BREO.xml:S1:14552:4	O
12	BREO.xml:S1:14557:2	O
to	BREO.xml:S1:14560:2	O
17	BREO.xml:S1:14563:2	O
years	BREO.xml:S1:14566:5	O
were	BREO.xml:S1:14572:4	O
included	BREO.xml:S1:14577:8	O
in	BREO.xml:S1:14586:2	O
this	BREO.xml:S1:14589:4	O
trial	BREO.xml:S1:14594:5	O
,	BREO.xml:S1:14599:1	O
BREO	BREO.xml:S1:14601:4	O
ELLIPTA	BREO.xml:S1:14606:7	O
is	BREO.xml:S1:14614:2	O
not	BREO.xml:S1:14617:3	O
approved	BREO.xml:S1:14621:8	O
for	BREO.xml:S1:14630:3	O
use	BREO.xml:S1:14634:3	O
in	BREO.xml:S1:14638:2	O
this	BREO.xml:S1:14641:4	O
age	BREO.xml:S1:14646:3	O
-	BREO.xml:S1:14649:1	O
group	BREO.xml:S1:14650:5	O
[	BREO.xml:S1:14657:1	O
see	BREO.xml:S1:14658:3	O
Use	BREO.xml:S1:14662:3	O
in	BREO.xml:S1:14666:2	O
Specific	BREO.xml:S1:14669:8	O
Populations	BREO.xml:S1:14678:11	O
(	BREO.xml:S1:14690:1	O
8.4	BREO.xml:S1:14691:3	O
)]	BREO.xml:S1:14694:2	O
.	BREO.xml:S1:14698:1	O

Asthma	BREO.xml:S1:14700:6	O
-	BREO.xml:S1:14706:1	O
related	BREO.xml:S1:14707:7	O
hospitalizations	BREO.xml:S1:14715:16	O
occurred	BREO.xml:S1:14732:8	O
in	BREO.xml:S1:14741:2	O
10	BREO.xml:S1:14744:2	O
subjects	BREO.xml:S1:14747:8	O
(	BREO.xml:S1:14756:1	O
1%	BREO.xml:S1:14757:2	O
)	BREO.xml:S1:14759:1	O
treated	BREO.xml:S1:14761:7	O
with	BREO.xml:S1:14769:4	O
BREO	BREO.xml:S1:14774:4	O
ELLIPTA	BREO.xml:S1:14779:7	O
100	BREO.xml:S1:14787:3	O
25	BREO.xml:S1:14791:2	O
compared	BREO.xml:S1:14794:8	O
with	BREO.xml:S1:14803:4	O
7	BREO.xml:S1:14808:1	O
subjects	BREO.xml:S1:14810:8	O
(	BREO.xml:S1:14819:1	O
0.7%	BREO.xml:S1:14820:4	O
)	BREO.xml:S1:14824:1	O
treated	BREO.xml:S1:14826:7	O
with	BREO.xml:S1:14834:4	O
fluticasone	BREO.xml:S1:14839:11	O
furoate	BREO.xml:S1:14851:7	O
100	BREO.xml:S1:14859:3	O
mcg	BREO.xml:S1:14863:3	O
.	BREO.xml:S1:14866:1	O

Among	BREO.xml:S1:14868:5	O
subjects	BREO.xml:S1:14874:8	O
aged	BREO.xml:S1:14883:4	O
12	BREO.xml:S1:14888:2	O
to	BREO.xml:S1:14891:2	O
17	BREO.xml:S1:14894:2	O
years	BREO.xml:S1:14897:5	O
,	BREO.xml:S1:14902:1	O
asthma	BREO.xml:S1:14904:6	O
-	BREO.xml:S1:14910:1	O
related	BREO.xml:S1:14911:7	O
hospitalizations	BREO.xml:S1:14919:16	O
occurred	BREO.xml:S1:14936:8	O
in	BREO.xml:S1:14945:2	O
4	BREO.xml:S1:14948:1	O
subjects	BREO.xml:S1:14950:8	O
(	BREO.xml:S1:14959:1	O
2.6%	BREO.xml:S1:14960:4	O
)	BREO.xml:S1:14964:1	O
treated	BREO.xml:S1:14966:7	O
with	BREO.xml:S1:14974:4	O
BREO	BREO.xml:S1:14979:4	O
ELLIPTA	BREO.xml:S1:14984:7	O
100	BREO.xml:S1:14992:3	O
25	BREO.xml:S1:14996:2	O
(	BREO.xml:S1:14999:1	O
n	BREO.xml:S1:15000:1	O
151	BREO.xml:S1:15004:3	O
)	BREO.xml:S1:15007:1	O
compared	BREO.xml:S1:15009:8	O
with	BREO.xml:S1:15018:4	O
0	BREO.xml:S1:15023:1	O
subjects	BREO.xml:S1:15025:8	O
treated	BREO.xml:S1:15034:7	O
with	BREO.xml:S1:15042:4	O
fluticasone	BREO.xml:S1:15047:11	O
furoate	BREO.xml:S1:15059:7	O
100	BREO.xml:S1:15067:3	O
mcg	BREO.xml:S1:15071:3	O
(	BREO.xml:S1:15075:1	O
n	BREO.xml:S1:15076:1	O
130	BREO.xml:S1:15080:3	O
)	BREO.xml:S1:15083:1	O
.	BREO.xml:S1:15084:1	O

There	BREO.xml:S1:15086:5	O
were	BREO.xml:S1:15092:4	O
no	BREO.xml:S1:15097:2	B-Negation
asthma	BREO.xml:S1:15100:6	O
-	BREO.xml:S1:15106:1	O
related	BREO.xml:S1:15107:7	O
deaths	BREO.xml:S1:15115:6	B-AdverseReaction
or	BREO.xml:S1:15122:2	O
asthma	BREO.xml:S1:15125:6	O
-	BREO.xml:S1:15131:1	O
related	BREO.xml:S1:15132:7	O
intubations	BREO.xml:S1:15140:11	O
observed	BREO.xml:S1:15152:8	O
in	BREO.xml:S1:15161:2	O
this	BREO.xml:S1:15164:4	O
trial	BREO.xml:S1:15169:5	O
.	BREO.xml:S1:15174:1	O

6.3	BREO.xml:S1:15182:3	O
Postmarketing	BREO.xml:S1:15186:13	O
Experience	BREO.xml:S1:15200:10	O

In	BREO.xml:S1:15214:2	O
addition	BREO.xml:S1:15217:8	O
to	BREO.xml:S1:15226:2	O
adverse	BREO.xml:S1:15229:7	O
reactions	BREO.xml:S1:15237:9	O
reported	BREO.xml:S1:15247:8	O
from	BREO.xml:S1:15256:4	O
clinical	BREO.xml:S1:15261:8	O
trials	BREO.xml:S1:15270:6	O
,	BREO.xml:S1:15276:1	O
the	BREO.xml:S1:15278:3	O
following	BREO.xml:S1:15282:9	O
adverse	BREO.xml:S1:15292:7	O
reactions	BREO.xml:S1:15300:9	O
have	BREO.xml:S1:15310:4	O
been	BREO.xml:S1:15315:4	O
identified	BREO.xml:S1:15320:10	O
during	BREO.xml:S1:15331:6	O
postapproval	BREO.xml:S1:15338:12	O
use	BREO.xml:S1:15351:3	O
of	BREO.xml:S1:15355:2	O
BREO	BREO.xml:S1:15358:4	O
ELLIPTA	BREO.xml:S1:15363:7	O
.	BREO.xml:S1:15370:1	O

Because	BREO.xml:S1:15372:7	O
these	BREO.xml:S1:15380:5	O
reactions	BREO.xml:S1:15386:9	O
are	BREO.xml:S1:15396:3	O
reported	BREO.xml:S1:15400:8	O
voluntarily	BREO.xml:S1:15409:11	O
from	BREO.xml:S1:15421:4	O
a	BREO.xml:S1:15426:1	O
population	BREO.xml:S1:15428:10	O
of	BREO.xml:S1:15439:2	O
uncertain	BREO.xml:S1:15442:9	O
size	BREO.xml:S1:15452:4	O
,	BREO.xml:S1:15456:1	O
it	BREO.xml:S1:15458:2	O
is	BREO.xml:S1:15461:2	O
not	BREO.xml:S1:15464:3	O
always	BREO.xml:S1:15468:6	O
possible	BREO.xml:S1:15475:8	O
to	BREO.xml:S1:15484:2	O
reliably	BREO.xml:S1:15487:8	O
estimate	BREO.xml:S1:15496:8	O
their	BREO.xml:S1:15505:5	O
frequency	BREO.xml:S1:15511:9	O
or	BREO.xml:S1:15521:2	O
establish	BREO.xml:S1:15524:9	O
a	BREO.xml:S1:15534:1	O
causal	BREO.xml:S1:15536:6	O
relationship	BREO.xml:S1:15543:12	O
to	BREO.xml:S1:15556:2	O
drug	BREO.xml:S1:15559:4	O
exposure	BREO.xml:S1:15564:8	O
.	BREO.xml:S1:15572:1	O

These	BREO.xml:S1:15574:5	O
events	BREO.xml:S1:15580:6	O
have	BREO.xml:S1:15587:4	O
been	BREO.xml:S1:15592:4	O
chosen	BREO.xml:S1:15597:6	O
for	BREO.xml:S1:15604:3	O
inclusion	BREO.xml:S1:15608:9	O
due	BREO.xml:S1:15618:3	O
to	BREO.xml:S1:15622:2	O
either	BREO.xml:S1:15625:6	O
their	BREO.xml:S1:15632:5	O
seriousness	BREO.xml:S1:15638:11	O
,	BREO.xml:S1:15649:1	O
frequency	BREO.xml:S1:15651:9	O
of	BREO.xml:S1:15661:2	O
reporting	BREO.xml:S1:15664:9	O
,	BREO.xml:S1:15673:1	O
or	BREO.xml:S1:15675:2	O
causal	BREO.xml:S1:15678:6	O
connection	BREO.xml:S1:15685:10	O
to	BREO.xml:S1:15696:2	O
BREO	BREO.xml:S1:15699:4	O
ELLIPTA	BREO.xml:S1:15704:7	O
or	BREO.xml:S1:15712:2	O
a	BREO.xml:S1:15715:1	O
combination	BREO.xml:S1:15717:11	O
of	BREO.xml:S1:15729:2	O
these	BREO.xml:S1:15732:5	O
factors	BREO.xml:S1:15738:7	O
.	BREO.xml:S1:15745:1	O

Cardiac	BREO.xml:S1:15753:7	O
Disorders	BREO.xml:S1:15761:9	O

Palpitations	BREO.xml:S1:15777:12	B-AdverseReaction
,	BREO.xml:S1:15789:1	O
tachycardia	BREO.xml:S1:15791:11	B-AdverseReaction
.	BREO.xml:S1:15802:1	O

Immune	BREO.xml:S1:15810:6	O
System	BREO.xml:S1:15817:6	O
Disorders	BREO.xml:S1:15824:9	O

Hypersensitivity	BREO.xml:S1:15840:16	B-AdverseReaction
reactions	BREO.xml:S1:15857:9	I-AdverseReaction
,	BREO.xml:S1:15866:1	O
including	BREO.xml:S1:15868:9	O
anaphylaxis	BREO.xml:S1:15878:11	B-AdverseReaction
,	BREO.xml:S1:15889:1	O
angioedema	BREO.xml:S1:15891:10	B-AdverseReaction
,	BREO.xml:S1:15901:1	O
rash	BREO.xml:S1:15903:4	B-AdverseReaction
,	BREO.xml:S1:15907:1	O
and	BREO.xml:S1:15909:3	O
urticaria	BREO.xml:S1:15913:9	B-AdverseReaction
.	BREO.xml:S1:15922:1	O

Musculoskeletal	BREO.xml:S1:15930:15	O
and	BREO.xml:S1:15946:3	O
Connective	BREO.xml:S1:15950:10	O
Tissue	BREO.xml:S1:15961:6	O
Disorders	BREO.xml:S1:15968:9	O

Muscle	BREO.xml:S1:15984:6	B-AdverseReaction
spasms	BREO.xml:S1:15991:6	I-AdverseReaction
.	BREO.xml:S1:15997:1	O

Nervous	BREO.xml:S1:16005:7	O
System	BREO.xml:S1:16013:6	O
Disorders	BREO.xml:S1:16020:9	O

Tremor	BREO.xml:S1:16036:6	B-AdverseReaction
.	BREO.xml:S1:16042:1	O

Psychiatric	BREO.xml:S1:16050:11	O
Disorders	BREO.xml:S1:16062:9	O

Nervousness	BREO.xml:S1:16078:11	B-AdverseReaction
.	BREO.xml:S1:16089:1	O
\n\n	BREO.xml:S2:0:2	O
BOXED	BREO.xml:S2:6:5	O
WARNING	BREO.xml:S2:12:7	O
:	BREO.xml:S2:19:1	O
WARNING	BREO.xml:S2:21:7	O
:	BREO.xml:S2:28:1	O
ASTHMA	BREO.xml:S2:30:6	O
-	BREO.xml:S2:36:1	O
RELATED	BREO.xml:S2:37:7	O
DEATH	BREO.xml:S2:45:5	B-AdverseReaction
\n\n	BREO.xml:S2:50:2	O
WARNING	BREO.xml:S2:54:7	O
:	BREO.xml:S2:61:1	O
ASTHMA	BREO.xml:S2:63:6	O
-	BREO.xml:S2:69:1	O
RELATED	BREO.xml:S2:70:7	O
DEATH	BREO.xml:S2:78:5	B-AdverseReaction
\n\n	BREO.xml:S2:83:2	O
Long	BREO.xml:S2:89:4	O
-	BREO.xml:S2:93:1	O
acting	BREO.xml:S2:94:6	O
beta2	BREO.xml:S2:101:5	O
-	BREO.xml:S2:106:1	O
adrenergic	BREO.xml:S2:107:10	O
agonists	BREO.xml:S2:118:8	O
(	BREO.xml:S2:127:1	O
LABA	BREO.xml:S2:128:4	B-DrugClass
)	BREO.xml:S2:132:1	O
,	BREO.xml:S2:133:1	O
such	BREO.xml:S2:135:4	O
as	BREO.xml:S2:140:2	O
vilanterol	BREO.xml:S2:143:10	O
,	BREO.xml:S2:153:1	O
one	BREO.xml:S2:155:3	O
of	BREO.xml:S2:159:2	O
the	BREO.xml:S2:162:3	O
active	BREO.xml:S2:166:6	O
ingredients	BREO.xml:S2:173:11	O
in	BREO.xml:S2:185:2	O
BREO	BREO.xml:S2:188:4	O
ELLIPTA	BREO.xml:S2:193:7	O
,	BREO.xml:S2:200:1	O
increase	BREO.xml:S2:202:8	O
the	BREO.xml:S2:211:3	O
risk	BREO.xml:S2:215:4	O
of	BREO.xml:S2:220:2	O
asthma	BREO.xml:S2:223:6	O
-	BREO.xml:S2:229:1	O
related	BREO.xml:S2:230:7	O
death	BREO.xml:S2:238:5	B-AdverseReaction
.	BREO.xml:S2:243:1	O

Data	BREO.xml:S2:245:4	O
from	BREO.xml:S2:250:4	O
a	BREO.xml:S2:255:1	O
large	BREO.xml:S2:257:5	O
placebo	BREO.xml:S2:263:7	O
-	BREO.xml:S2:270:1	O
controlled	BREO.xml:S2:271:10	O
US	BREO.xml:S2:282:2	O
trial	BREO.xml:S2:285:5	O
that	BREO.xml:S2:291:4	O
compared	BREO.xml:S2:296:8	O
the	BREO.xml:S2:305:3	O
safety	BREO.xml:S2:309:6	O
of	BREO.xml:S2:316:2	O
another	BREO.xml:S2:319:7	O
LABA	BREO.xml:S2:327:4	B-DrugClass
(	BREO.xml:S2:332:1	O
salmeterol	BREO.xml:S2:333:10	O
)	BREO.xml:S2:343:1	O
with	BREO.xml:S2:345:4	O
placebo	BREO.xml:S2:350:7	O
added	BREO.xml:S2:358:5	O
to	BREO.xml:S2:364:2	O
usual	BREO.xml:S2:367:5	O
asthma	BREO.xml:S2:373:6	O
therapy	BREO.xml:S2:380:7	O
showed	BREO.xml:S2:388:6	O
an	BREO.xml:S2:395:2	O
increase	BREO.xml:S2:398:8	O
in	BREO.xml:S2:407:2	O
asthma	BREO.xml:S2:410:6	O
-	BREO.xml:S2:416:1	O
related	BREO.xml:S2:417:7	O
deaths	BREO.xml:S2:425:6	B-AdverseReaction
in	BREO.xml:S2:432:2	O
subjects	BREO.xml:S2:435:8	O
receiving	BREO.xml:S2:444:9	O
salmeterol	BREO.xml:S2:454:10	O
.	BREO.xml:S2:464:1	O

This	BREO.xml:S2:466:4	O
finding	BREO.xml:S2:471:7	O
with	BREO.xml:S2:479:4	O
salmeterol	BREO.xml:S2:484:10	O
is	BREO.xml:S2:495:2	O
considered	BREO.xml:S2:498:10	O
a	BREO.xml:S2:509:1	O
class	BREO.xml:S2:511:5	O
effect	BREO.xml:S2:517:6	O
of	BREO.xml:S2:524:2	O
LABA	BREO.xml:S2:527:4	O
.	BREO.xml:S2:531:1	O

Currently	BREO.xml:S2:533:9	O
available	BREO.xml:S2:543:9	O
data	BREO.xml:S2:553:4	O
are	BREO.xml:S2:558:3	O
inadequate	BREO.xml:S2:562:10	O
to	BREO.xml:S2:573:2	O
determine	BREO.xml:S2:576:9	O
whether	BREO.xml:S2:586:7	O
concurrent	BREO.xml:S2:594:10	O
use	BREO.xml:S2:605:3	O
of	BREO.xml:S2:609:2	O
inhaled	BREO.xml:S2:612:7	O
corticosteroids	BREO.xml:S2:620:15	O
(	BREO.xml:S2:636:1	O
ICS	BREO.xml:S2:637:3	O
)	BREO.xml:S2:640:1	O
or	BREO.xml:S2:642:2	O
other	BREO.xml:S2:645:5	O
long	BREO.xml:S2:651:4	O
-	BREO.xml:S2:655:1	O
term	BREO.xml:S2:656:4	O
asthma	BREO.xml:S2:661:6	O
control	BREO.xml:S2:668:7	O
drugs	BREO.xml:S2:676:5	O
mitigates	BREO.xml:S2:682:9	O
the	BREO.xml:S2:692:3	O
increased	BREO.xml:S2:696:9	O
risk	BREO.xml:S2:706:4	O
of	BREO.xml:S2:711:2	O
asthma	BREO.xml:S2:714:6	O
-	BREO.xml:S2:720:1	O
related	BREO.xml:S2:721:7	O
death	BREO.xml:S2:729:5	B-AdverseReaction
from	BREO.xml:S2:735:4	O
LABA	BREO.xml:S2:740:4	B-DrugClass
.	BREO.xml:S2:744:1	O

Available	BREO.xml:S2:746:9	O
data	BREO.xml:S2:756:4	O
from	BREO.xml:S2:761:4	O
controlled	BREO.xml:S2:766:10	O
clinical	BREO.xml:S2:777:8	O
trials	BREO.xml:S2:786:6	O
suggest	BREO.xml:S2:793:7	O
that	BREO.xml:S2:801:4	O
LABA	BREO.xml:S2:806:4	O
increase	BREO.xml:S2:811:8	O
the	BREO.xml:S2:820:3	O
risk	BREO.xml:S2:824:4	O
of	BREO.xml:S2:829:2	O
asthma	BREO.xml:S2:832:6	O
-	BREO.xml:S2:838:1	O
related	BREO.xml:S2:839:7	O
hospitalization	BREO.xml:S2:847:15	O
in	BREO.xml:S2:863:2	O
pediatric	BREO.xml:S2:866:9	O
and	BREO.xml:S2:876:3	O
adolescent	BREO.xml:S2:880:10	O
patients	BREO.xml:S2:891:8	O
.	BREO.xml:S2:899:1	O

Therefore	BREO.xml:S2:909:9	O
,	BREO.xml:S2:918:1	O
when	BREO.xml:S2:920:4	O
treating	BREO.xml:S2:925:8	O
patients	BREO.xml:S2:934:8	O
with	BREO.xml:S2:943:4	O
asthma	BREO.xml:S2:948:6	O
,	BREO.xml:S2:954:1	O
physicians	BREO.xml:S2:956:10	O
should	BREO.xml:S2:967:6	O
only	BREO.xml:S2:974:4	O
prescribe	BREO.xml:S2:979:9	O
BREO	BREO.xml:S2:989:4	O
ELLIPTA	BREO.xml:S2:994:7	O
for	BREO.xml:S2:1002:3	O
patients	BREO.xml:S2:1006:8	O
not	BREO.xml:S2:1015:3	O
adequately	BREO.xml:S2:1019:10	O
controlled	BREO.xml:S2:1030:10	O
on	BREO.xml:S2:1041:2	O
a	BREO.xml:S2:1044:1	O
long	BREO.xml:S2:1046:4	O
-	BREO.xml:S2:1050:1	O
term	BREO.xml:S2:1051:4	O
asthma	BREO.xml:S2:1056:6	O
control	BREO.xml:S2:1063:7	O
medication	BREO.xml:S2:1071:10	O
,	BREO.xml:S2:1081:1	O
such	BREO.xml:S2:1083:4	O
as	BREO.xml:S2:1088:2	O
an	BREO.xml:S2:1091:2	O
inhaled	BREO.xml:S2:1094:7	O
corticosteroid	BREO.xml:S2:1102:14	O
,	BREO.xml:S2:1116:1	O
or	BREO.xml:S2:1118:2	O
whose	BREO.xml:S2:1121:5	O
disease	BREO.xml:S2:1127:7	O
severity	BREO.xml:S2:1135:8	O
clearly	BREO.xml:S2:1144:7	O
warrants	BREO.xml:S2:1152:8	O
initiation	BREO.xml:S2:1161:10	O
of	BREO.xml:S2:1172:2	O
treatment	BREO.xml:S2:1175:9	O
with	BREO.xml:S2:1185:4	O
both	BREO.xml:S2:1190:4	O
an	BREO.xml:S2:1195:2	O
inhaled	BREO.xml:S2:1198:7	O
corticosteroid	BREO.xml:S2:1206:14	O
and	BREO.xml:S2:1221:3	O
a	BREO.xml:S2:1225:1	O
LABA	BREO.xml:S2:1227:4	O
.	BREO.xml:S2:1231:1	O

Once	BREO.xml:S2:1233:4	O
asthma	BREO.xml:S2:1238:6	O
control	BREO.xml:S2:1245:7	O
is	BREO.xml:S2:1253:2	O
achieved	BREO.xml:S2:1256:8	O
and	BREO.xml:S2:1265:3	O
maintained	BREO.xml:S2:1269:10	O
,	BREO.xml:S2:1279:1	O
assess	BREO.xml:S2:1281:6	O
the	BREO.xml:S2:1288:3	O
patient	BREO.xml:S2:1292:7	O
at	BREO.xml:S2:1300:2	O
regular	BREO.xml:S2:1303:7	O
intervals	BREO.xml:S2:1311:9	O
and	BREO.xml:S2:1321:3	O
step	BREO.xml:S2:1325:4	O
down	BREO.xml:S2:1330:4	O
therapy	BREO.xml:S2:1335:7	O
(	BREO.xml:S2:1343:1	O
e	BREO.xml:S2:1344:1	O
.	BREO.xml:S2:1345:1	O
g	BREO.xml:S2:1346:1	O
.	BREO.xml:S2:1347:1	O
,	BREO.xml:S2:1348:1	O
discontinue	BREO.xml:S2:1350:11	O
BREO	BREO.xml:S2:1362:4	O
ELLIPTA	BREO.xml:S2:1367:7	O
)	BREO.xml:S2:1374:1	O
if	BREO.xml:S2:1376:2	O
possible	BREO.xml:S2:1379:8	O
without	BREO.xml:S2:1388:7	O
loss	BREO.xml:S2:1396:4	O
of	BREO.xml:S2:1401:2	O
asthma	BREO.xml:S2:1404:6	O
control	BREO.xml:S2:1411:7	O
and	BREO.xml:S2:1419:3	O
maintain	BREO.xml:S2:1423:8	O
the	BREO.xml:S2:1432:3	O
patient	BREO.xml:S2:1436:7	O
on	BREO.xml:S2:1444:2	O
a	BREO.xml:S2:1447:1	O
long	BREO.xml:S2:1449:4	O
-	BREO.xml:S2:1453:1	O
term	BREO.xml:S2:1454:4	O
asthma	BREO.xml:S2:1459:6	O
control	BREO.xml:S2:1466:7	O
medication	BREO.xml:S2:1474:10	O
,	BREO.xml:S2:1484:1	O
such	BREO.xml:S2:1486:4	O
as	BREO.xml:S2:1491:2	O
an	BREO.xml:S2:1494:2	O
inhaled	BREO.xml:S2:1497:7	O
corticosteroid	BREO.xml:S2:1505:14	O
.	BREO.xml:S2:1519:1	O

Do	BREO.xml:S2:1521:2	O
not	BREO.xml:S2:1524:3	O
use	BREO.xml:S2:1528:3	O
BREO	BREO.xml:S2:1532:4	O
ELLIPTA	BREO.xml:S2:1537:7	O
for	BREO.xml:S2:1545:3	O
patients	BREO.xml:S2:1549:8	O
whose	BREO.xml:S2:1558:5	O
asthma	BREO.xml:S2:1564:6	O
is	BREO.xml:S2:1571:2	O
adequately	BREO.xml:S2:1574:10	O
controlled	BREO.xml:S2:1585:10	O
on	BREO.xml:S2:1596:2	O
low	BREO.xml:S2:1599:3	O
-	BREO.xml:S2:1602:1	O
or	BREO.xml:S2:1604:2	O
medium	BREO.xml:S2:1607:6	O
-	BREO.xml:S2:1613:1	O
dose	BREO.xml:S2:1614:4	O
inhaled	BREO.xml:S2:1619:7	O
corticosteroids	BREO.xml:S2:1627:15	O
[	BREO.xml:S2:1645:1	O
see	BREO.xml:S2:1646:3	O
Warnings	BREO.xml:S2:1650:8	O
and	BREO.xml:S2:1659:3	O
Precautions	BREO.xml:S2:1663:11	O
(	BREO.xml:S2:1675:1	O
5.1	BREO.xml:S2:1676:3	O
)]	BREO.xml:S2:1679:2	O
.	BREO.xml:S2:1683:1	O

EXCERPT	BREO.xml:S2:1693:7	O
:	BREO.xml:S2:1700:1	O
WARNING	BREO.xml:S2:1704:7	O
:	BREO.xml:S2:1711:1	O
ASTHMA	BREO.xml:S2:1713:6	O
-	BREO.xml:S2:1719:1	O
RELATED	BREO.xml:S2:1720:7	O
DEATH	BREO.xml:S2:1728:5	B-AdverseReaction
\n\n\n\n	BREO.xml:S2:1733:4	O
See	BREO.xml:S2:1740:3	O
full	BREO.xml:S2:1744:4	O
prescribing	BREO.xml:S2:1749:11	O
information	BREO.xml:S2:1761:11	O
for	BREO.xml:S2:1773:3	O
complete	BREO.xml:S2:1777:8	O
boxed	BREO.xml:S2:1786:5	O
warning	BREO.xml:S2:1792:7	O
.	BREO.xml:S2:1799:1	O

Long	BREO.xml:S2:1810:4	O
-	BREO.xml:S2:1814:1	O
acting	BREO.xml:S2:1815:6	O
beta2	BREO.xml:S2:1822:5	O
-	BREO.xml:S2:1827:1	O
adrenergic	BREO.xml:S2:1828:10	O
agonists	BREO.xml:S2:1839:8	O
(	BREO.xml:S2:1848:1	O
LABA	BREO.xml:S2:1849:4	B-DrugClass
)	BREO.xml:S2:1853:1	O
,	BREO.xml:S2:1854:1	O
such	BREO.xml:S2:1856:4	O
as	BREO.xml:S2:1861:2	O
vilanterol	BREO.xml:S2:1864:10	O
,	BREO.xml:S2:1874:1	O
increase	BREO.xml:S2:1876:8	O
the	BREO.xml:S2:1885:3	O
risk	BREO.xml:S2:1889:4	O
of	BREO.xml:S2:1894:2	O
asthma	BREO.xml:S2:1897:6	O
-	BREO.xml:S2:1903:1	O
related	BREO.xml:S2:1904:7	O
death	BREO.xml:S2:1912:5	B-AdverseReaction
.	BREO.xml:S2:1917:1	O

A	BREO.xml:S2:1919:1	O
placebo	BREO.xml:S2:1921:7	O
-	BREO.xml:S2:1928:1	O
controlled	BREO.xml:S2:1929:10	O
trial	BREO.xml:S2:1940:5	O
with	BREO.xml:S2:1946:4	O
another	BREO.xml:S2:1951:7	O
LABA	BREO.xml:S2:1959:4	B-DrugClass
(	BREO.xml:S2:1964:1	O
salmeterol	BREO.xml:S2:1965:10	O
)	BREO.xml:S2:1975:1	O
showed	BREO.xml:S2:1977:6	O
an	BREO.xml:S2:1984:2	O
increase	BREO.xml:S2:1987:8	O
in	BREO.xml:S2:1996:2	O
asthma	BREO.xml:S2:1999:6	O
-	BREO.xml:S2:2005:1	O
related	BREO.xml:S2:2006:7	O
deaths	BREO.xml:S2:2014:6	B-AdverseReaction
.	BREO.xml:S2:2020:1	O

This	BREO.xml:S2:2022:4	O
finding	BREO.xml:S2:2027:7	O
with	BREO.xml:S2:2035:4	O
salmeterol	BREO.xml:S2:2040:10	O
is	BREO.xml:S2:2051:2	O
considered	BREO.xml:S2:2054:10	O
a	BREO.xml:S2:2065:1	O
class	BREO.xml:S2:2067:5	O
effect	BREO.xml:S2:2073:6	O
of	BREO.xml:S2:2080:2	O
all	BREO.xml:S2:2083:3	O
LABA	BREO.xml:S2:2087:4	O
.	BREO.xml:S2:2091:1	O

Currently	BREO.xml:S2:2093:9	O
available	BREO.xml:S2:2103:9	O
data	BREO.xml:S2:2113:4	O
are	BREO.xml:S2:2118:3	O
inadequate	BREO.xml:S2:2122:10	O
to	BREO.xml:S2:2133:2	O
determine	BREO.xml:S2:2136:9	O
whether	BREO.xml:S2:2146:7	O
concurrent	BREO.xml:S2:2154:10	O
use	BREO.xml:S2:2165:3	O
of	BREO.xml:S2:2169:2	O
inhaled	BREO.xml:S2:2172:7	O
corticosteroids	BREO.xml:S2:2180:15	O
(	BREO.xml:S2:2196:1	O
ICS	BREO.xml:S2:2197:3	O
)	BREO.xml:S2:2200:1	O
or	BREO.xml:S2:2202:2	O
other	BREO.xml:S2:2205:5	O
long	BREO.xml:S2:2211:4	O
-	BREO.xml:S2:2215:1	O
term	BREO.xml:S2:2216:4	O
asthma	BREO.xml:S2:2221:6	O
control	BREO.xml:S2:2228:7	O
drugs	BREO.xml:S2:2236:5	O
mitigates	BREO.xml:S2:2242:9	O
the	BREO.xml:S2:2252:3	O
increased	BREO.xml:S2:2256:9	O
risk	BREO.xml:S2:2266:4	O
of	BREO.xml:S2:2271:2	O
asthma	BREO.xml:S2:2274:6	O
-	BREO.xml:S2:2280:1	O
related	BREO.xml:S2:2281:7	O
death	BREO.xml:S2:2289:5	B-AdverseReaction
from	BREO.xml:S2:2295:4	O
LABA	BREO.xml:S2:2300:4	B-DrugClass
.	BREO.xml:S2:2304:1	O

Available	BREO.xml:S2:2306:9	O
data	BREO.xml:S2:2316:4	O
from	BREO.xml:S2:2321:4	O
controlled	BREO.xml:S2:2326:10	O
clinical	BREO.xml:S2:2337:8	O
trials	BREO.xml:S2:2346:6	O
suggest	BREO.xml:S2:2353:7	O
that	BREO.xml:S2:2361:4	O
LABA	BREO.xml:S2:2366:4	O
increase	BREO.xml:S2:2371:8	O
the	BREO.xml:S2:2380:3	O
risk	BREO.xml:S2:2384:4	O
of	BREO.xml:S2:2389:2	O
asthma	BREO.xml:S2:2392:6	O
-	BREO.xml:S2:2398:1	O
related	BREO.xml:S2:2399:7	O
hospitalization	BREO.xml:S2:2407:15	O
in	BREO.xml:S2:2423:2	O
pediatric	BREO.xml:S2:2426:9	O
and	BREO.xml:S2:2436:3	O
adolescent	BREO.xml:S2:2440:10	O
patients	BREO.xml:S2:2451:8	O
.	BREO.xml:S2:2459:1	O

(	BREO.xml:S2:2461:1	O
5.1	BREO.xml:S2:2462:3	O
)	BREO.xml:S2:2465:1	O
\n	BREO.xml:S2:2467:1	O
When	BREO.xml:S2:2472:4	O
treating	BREO.xml:S2:2477:8	O
patients	BREO.xml:S2:2486:8	O
with	BREO.xml:S2:2495:4	O
asthma	BREO.xml:S2:2500:6	O
,	BREO.xml:S2:2506:1	O
only	BREO.xml:S2:2508:4	O
prescribe	BREO.xml:S2:2513:9	O
BREO	BREO.xml:S2:2523:4	O
ELLIPTA	BREO.xml:S2:2528:7	O
for	BREO.xml:S2:2536:3	O
patients	BREO.xml:S2:2540:8	O
not	BREO.xml:S2:2549:3	O
adequately	BREO.xml:S2:2553:10	O
controlled	BREO.xml:S2:2564:10	O
on	BREO.xml:S2:2575:2	O
a	BREO.xml:S2:2578:1	O
long	BREO.xml:S2:2580:4	O
-	BREO.xml:S2:2584:1	O
term	BREO.xml:S2:2585:4	O
asthma	BREO.xml:S2:2590:6	O
control	BREO.xml:S2:2597:7	O
medication	BREO.xml:S2:2605:10	O
,	BREO.xml:S2:2615:1	O
such	BREO.xml:S2:2617:4	O
as	BREO.xml:S2:2622:2	O
an	BREO.xml:S2:2625:2	O
ICS	BREO.xml:S2:2628:3	O
,	BREO.xml:S2:2631:1	O
or	BREO.xml:S2:2633:2	O
whose	BREO.xml:S2:2636:5	O
disease	BREO.xml:S2:2642:7	O
severity	BREO.xml:S2:2650:8	O
clearly	BREO.xml:S2:2659:7	O
warrants	BREO.xml:S2:2667:8	O
initiation	BREO.xml:S2:2676:10	O
of	BREO.xml:S2:2687:2	O
treatment	BREO.xml:S2:2690:9	O
with	BREO.xml:S2:2700:4	O
both	BREO.xml:S2:2705:4	O
an	BREO.xml:S2:2710:2	O
ICS	BREO.xml:S2:2713:3	O
and	BREO.xml:S2:2717:3	O
a	BREO.xml:S2:2721:1	O
LABA	BREO.xml:S2:2723:4	O
.	BREO.xml:S2:2727:1	O

Once	BREO.xml:S2:2729:4	O
asthma	BREO.xml:S2:2734:6	O
control	BREO.xml:S2:2741:7	O
is	BREO.xml:S2:2749:2	O
achieved	BREO.xml:S2:2752:8	O
and	BREO.xml:S2:2761:3	O
maintained	BREO.xml:S2:2765:10	O
,	BREO.xml:S2:2775:1	O
assess	BREO.xml:S2:2777:6	O
the	BREO.xml:S2:2784:3	O
patient	BREO.xml:S2:2788:7	O
at	BREO.xml:S2:2796:2	O
regular	BREO.xml:S2:2799:7	O
intervals	BREO.xml:S2:2807:9	O
and	BREO.xml:S2:2817:3	O
step	BREO.xml:S2:2821:4	O
down	BREO.xml:S2:2826:4	O
therapy	BREO.xml:S2:2831:7	O
(	BREO.xml:S2:2839:1	O
e	BREO.xml:S2:2840:1	O
.	BREO.xml:S2:2841:1	O
g	BREO.xml:S2:2842:1	O
.	BREO.xml:S2:2843:1	O
,	BREO.xml:S2:2844:1	O
discontinue	BREO.xml:S2:2846:11	O
BREO	BREO.xml:S2:2858:4	O
ELLIPTA	BREO.xml:S2:2863:7	O
)	BREO.xml:S2:2870:1	O
if	BREO.xml:S2:2872:2	O
possible	BREO.xml:S2:2875:8	O
without	BREO.xml:S2:2884:7	O
loss	BREO.xml:S2:2892:4	O
of	BREO.xml:S2:2897:2	O
asthma	BREO.xml:S2:2900:6	O
control	BREO.xml:S2:2907:7	O
and	BREO.xml:S2:2915:3	O
maintain	BREO.xml:S2:2919:8	O
the	BREO.xml:S2:2928:3	O
patient	BREO.xml:S2:2932:7	O
on	BREO.xml:S2:2940:2	O
a	BREO.xml:S2:2943:1	O
long	BREO.xml:S2:2945:4	O
-	BREO.xml:S2:2949:1	O
term	BREO.xml:S2:2950:4	O
asthma	BREO.xml:S2:2955:6	O
control	BREO.xml:S2:2962:7	O
medication	BREO.xml:S2:2970:10	O
,	BREO.xml:S2:2980:1	O
such	BREO.xml:S2:2982:4	O
as	BREO.xml:S2:2987:2	O
an	BREO.xml:S2:2990:2	O
ICS	BREO.xml:S2:2993:3	O
.	BREO.xml:S2:2996:1	O

Do	BREO.xml:S2:2998:2	O
not	BREO.xml:S2:3001:3	O
use	BREO.xml:S2:3005:3	O
BREO	BREO.xml:S2:3009:4	O
ELLIPTA	BREO.xml:S2:3014:7	O
for	BREO.xml:S2:3022:3	O
patients	BREO.xml:S2:3026:8	O
whose	BREO.xml:S2:3035:5	O
asthma	BREO.xml:S2:3041:6	O
is	BREO.xml:S2:3048:2	O
adequately	BREO.xml:S2:3051:10	O
controlled	BREO.xml:S2:3062:10	O
on	BREO.xml:S2:3073:2	O
low	BREO.xml:S2:3076:3	O
-	BREO.xml:S2:3079:1	O
or	BREO.xml:S2:3081:2	O
medium	BREO.xml:S2:3084:6	O
-	BREO.xml:S2:3090:1	O
dose	BREO.xml:S2:3091:4	O
ICS	BREO.xml:S2:3096:3	O
.	BREO.xml:S2:3099:1	O

(	BREO.xml:S2:3100:1	O
1.2	BREO.xml:S2:3101:3	O
,	BREO.xml:S2:3104:1	O
5.1	BREO.xml:S2:3106:3	O
)	BREO.xml:S2:3109:1	O
\n	BREO.xml:S2:3111:1	O
5	BREO.xml:S3:4:1	O
WARNINGS	BREO.xml:S3:6:8	O
AND	BREO.xml:S3:15:3	O
PRECAUTIONS	BREO.xml:S3:19:11	O

EXCERPT	BREO.xml:S3:37:7	O
:	BREO.xml:S3:44:1	O
LABA	BREO.xml:S3:54:4	B-DrugClass
increase	BREO.xml:S3:59:8	O
the	BREO.xml:S3:68:3	O
risk	BREO.xml:S3:72:4	O
of	BREO.xml:S3:77:2	O
asthma	BREO.xml:S3:80:6	O
-	BREO.xml:S3:86:1	O
related	BREO.xml:S3:87:7	O
death	BREO.xml:S3:95:5	B-AdverseReaction
and	BREO.xml:S3:101:3	O
asthma	BREO.xml:S3:105:6	O
-	BREO.xml:S3:111:1	O
related	BREO.xml:S3:112:7	O
hospitalizations	BREO.xml:S3:120:16	O
.	BREO.xml:S3:136:1	O

Prescribe	BREO.xml:S3:138:9	O
only	BREO.xml:S3:148:4	O
for	BREO.xml:S3:153:3	O
recommended	BREO.xml:S3:157:11	O
patient	BREO.xml:S3:169:7	O
populations	BREO.xml:S3:177:11	O
.	BREO.xml:S3:188:1	O

(	BREO.xml:S3:190:1	O
5.1	BREO.xml:S3:193:3	O
)	BREO.xml:S3:198:1	O

Do	BREO.xml:S3:207:2	O
not	BREO.xml:S3:210:3	O
initiate	BREO.xml:S3:214:8	O
in	BREO.xml:S3:223:2	O
acutely	BREO.xml:S3:226:7	O
deteriorating	BREO.xml:S3:234:13	O
COPD	BREO.xml:S3:248:4	O
or	BREO.xml:S3:253:2	O
asthma	BREO.xml:S3:256:6	O
.	BREO.xml:S3:262:1	O

Do	BREO.xml:S3:264:2	O
not	BREO.xml:S3:267:3	O
use	BREO.xml:S3:271:3	O
to	BREO.xml:S3:275:2	O
treat	BREO.xml:S3:278:5	O
acute	BREO.xml:S3:284:5	O
symptoms	BREO.xml:S3:290:8	O
.	BREO.xml:S3:298:1	O

(	BREO.xml:S3:300:1	O
5.2	BREO.xml:S3:303:3	O
)	BREO.xml:S3:308:1	O

Do	BREO.xml:S3:317:2	O
not	BREO.xml:S3:320:3	O
use	BREO.xml:S3:324:3	O
in	BREO.xml:S3:328:2	O
combination	BREO.xml:S3:331:11	O
with	BREO.xml:S3:343:4	O
an	BREO.xml:S3:348:2	O
additional	BREO.xml:S3:351:10	O
medicine	BREO.xml:S3:362:8	O
containing	BREO.xml:S3:371:10	O
a	BREO.xml:S3:382:1	O
LABA	BREO.xml:S3:384:4	O
because	BREO.xml:S3:389:7	O
of	BREO.xml:S3:397:2	O
risk	BREO.xml:S3:400:4	O
of	BREO.xml:S3:405:2	O
overdose	BREO.xml:S3:408:8	O
.	BREO.xml:S3:416:1	O

(	BREO.xml:S3:418:1	O
5.3	BREO.xml:S3:421:3	O
)	BREO.xml:S3:426:1	O

Candida	BREO.xml:S3:436:7	B-AdverseReaction
albicans	BREO.xml:S3:444:8	I-AdverseReaction
infection	BREO.xml:S3:453:9	I-AdverseReaction
of	BREO.xml:S3:463:2	I-AdverseReaction
the	BREO.xml:S3:466:3	I-AdverseReaction
mouth	BREO.xml:S3:470:5	I-AdverseReaction
and	BREO.xml:S3:476:3	O
pharynx	BREO.xml:S3:480:7	I-AdverseReaction
may	BREO.xml:S3:488:3	B-Factor
occur	BREO.xml:S3:492:5	O
.	BREO.xml:S3:497:1	O

Monitor	BREO.xml:S3:499:7	O
patients	BREO.xml:S3:507:8	O
periodically	BREO.xml:S3:516:12	O
.	BREO.xml:S3:528:1	O

Advise	BREO.xml:S3:530:6	O
the	BREO.xml:S3:537:3	O
patient	BREO.xml:S3:541:7	O
to	BREO.xml:S3:549:2	O
rinse	BREO.xml:S3:552:5	O
his	BREO.xml:S3:558:3	O
her	BREO.xml:S3:562:3	O
mouth	BREO.xml:S3:566:5	O
with	BREO.xml:S3:572:4	O
water	BREO.xml:S3:577:5	O
without	BREO.xml:S3:583:7	O
swallowing	BREO.xml:S3:591:10	O
after	BREO.xml:S3:602:5	O
inhalation	BREO.xml:S3:608:10	O
to	BREO.xml:S3:619:2	O
help	BREO.xml:S3:622:4	O
reduce	BREO.xml:S3:627:6	O
the	BREO.xml:S3:634:3	O
risk	BREO.xml:S3:638:4	O
.	BREO.xml:S3:642:1	O

(	BREO.xml:S3:644:1	O
5.4	BREO.xml:S3:647:3	O
)	BREO.xml:S3:652:1	O

Increased	BREO.xml:S3:661:9	O
risk	BREO.xml:S3:671:4	B-Factor
of	BREO.xml:S3:676:2	O
pneumonia	BREO.xml:S3:679:9	B-AdverseReaction
in	BREO.xml:S3:689:2	O
patients	BREO.xml:S3:692:8	O
with	BREO.xml:S3:701:4	O
COPD	BREO.xml:S3:706:4	O
.	BREO.xml:S3:710:1	O

Monitor	BREO.xml:S3:712:7	O
patients	BREO.xml:S3:720:8	O
for	BREO.xml:S3:729:3	O
signs	BREO.xml:S3:733:5	O
and	BREO.xml:S3:739:3	O
symptoms	BREO.xml:S3:743:8	O
of	BREO.xml:S3:752:2	O
pneumonia	BREO.xml:S3:755:9	O
.	BREO.xml:S3:764:1	O

(	BREO.xml:S3:766:1	O
5.5	BREO.xml:S3:769:3	O
)	BREO.xml:S3:774:1	O

Potential	BREO.xml:S3:783:9	B-Factor
worsening	BREO.xml:S3:793:9	B-AdverseReaction
of	BREO.xml:S3:803:2	I-AdverseReaction
infections	BREO.xml:S3:806:10	I-AdverseReaction
(	BREO.xml:S3:817:1	O
e	BREO.xml:S3:818:1	O
.	BREO.xml:S3:819:1	O
g	BREO.xml:S3:820:1	O
.	BREO.xml:S3:821:1	O
,	BREO.xml:S3:822:1	O
existing	BREO.xml:S3:824:8	I-AdverseReaction
tuberculosis	BREO.xml:S3:833:12	I-AdverseReaction
;	BREO.xml:S3:845:1	O
fungal	BREO.xml:S3:847:6	I-AdverseReaction
,	BREO.xml:S3:853:1	O
bacterial	BREO.xml:S3:855:9	I-AdverseReaction
,	BREO.xml:S3:864:1	O
viral	BREO.xml:S3:866:5	I-AdverseReaction
,	BREO.xml:S3:871:1	O
or	BREO.xml:S3:873:2	O
parasitic	BREO.xml:S3:876:9	I-AdverseReaction
infections	BREO.xml:S3:886:10	I-AdverseReaction
;	BREO.xml:S3:896:1	O
ocular	BREO.xml:S3:898:6	I-AdverseReaction
herpes	BREO.xml:S3:905:6	I-AdverseReaction
simplex	BREO.xml:S3:912:7	I-AdverseReaction
)	BREO.xml:S3:919:1	O
.	BREO.xml:S3:920:1	O

Use	BREO.xml:S3:922:3	O
with	BREO.xml:S3:926:4	O
caution	BREO.xml:S3:931:7	O
in	BREO.xml:S3:939:2	O
patients	BREO.xml:S3:942:8	O
with	BREO.xml:S3:951:4	O
these	BREO.xml:S3:956:5	O
infections	BREO.xml:S3:962:10	O
.	BREO.xml:S3:972:1	O

More	BREO.xml:S3:974:4	O
serious	BREO.xml:S3:979:7	B-Severity
or	BREO.xml:S3:987:2	O
even	BREO.xml:S3:990:4	O
fatal	BREO.xml:S3:995:5	B-AdverseReaction
course	BREO.xml:S3:1001:6	O
of	BREO.xml:S3:1008:2	O
chickenpox	BREO.xml:S3:1011:10	B-AdverseReaction
or	BREO.xml:S3:1022:2	O
measles	BREO.xml:S3:1025:7	B-AdverseReaction
can	BREO.xml:S3:1033:3	B-Factor
occur	BREO.xml:S3:1037:5	O
in	BREO.xml:S3:1043:2	O
susceptible	BREO.xml:S3:1046:11	O
patients	BREO.xml:S3:1058:8	O
.	BREO.xml:S3:1066:1	O

(	BREO.xml:S3:1068:1	O
5.6	BREO.xml:S3:1071:3	O
)	BREO.xml:S3:1076:1	O

Risk	BREO.xml:S3:1085:4	B-Factor
of	BREO.xml:S3:1090:2	O
impaired	BREO.xml:S3:1093:8	B-AdverseReaction
adrenal	BREO.xml:S3:1102:7	I-AdverseReaction
function	BREO.xml:S3:1110:8	I-AdverseReaction
when	BREO.xml:S3:1119:4	O
transferring	BREO.xml:S3:1124:12	O
from	BREO.xml:S3:1137:4	O
systemic	BREO.xml:S3:1142:8	O
corticosteroids	BREO.xml:S3:1151:15	O
.	BREO.xml:S3:1166:1	O

Taper	BREO.xml:S3:1168:5	O
patients	BREO.xml:S3:1174:8	O
slowly	BREO.xml:S3:1183:6	O
from	BREO.xml:S3:1190:4	O
systemic	BREO.xml:S3:1195:8	O
corticosteroids	BREO.xml:S3:1204:15	O
if	BREO.xml:S3:1220:2	O
transferring	BREO.xml:S3:1223:12	O
to	BREO.xml:S3:1236:2	O
BREO	BREO.xml:S3:1239:4	O
ELLIPTA	BREO.xml:S3:1244:7	O
.	BREO.xml:S3:1251:1	O

(	BREO.xml:S3:1253:1	O
5.7	BREO.xml:S3:1256:3	O
)	BREO.xml:S3:1261:1	O

Hypercorticism	BREO.xml:S3:1270:14	B-AdverseReaction
and	BREO.xml:S3:1285:3	O
adrenal	BREO.xml:S3:1289:7	B-AdverseReaction
suppression	BREO.xml:S3:1297:11	I-AdverseReaction
may	BREO.xml:S3:1309:3	B-Factor
occur	BREO.xml:S3:1313:5	O
with	BREO.xml:S3:1319:4	O
very	BREO.xml:S3:1324:4	O
high	BREO.xml:S3:1329:4	O
dosages	BREO.xml:S3:1334:7	O
or	BREO.xml:S3:1342:2	O
at	BREO.xml:S3:1345:2	O
the	BREO.xml:S3:1348:3	O
regular	BREO.xml:S3:1352:7	O
dosage	BREO.xml:S3:1360:6	O
in	BREO.xml:S3:1367:2	O
susceptible	BREO.xml:S3:1370:11	O
individuals	BREO.xml:S3:1382:11	O
.	BREO.xml:S3:1393:1	O

If	BREO.xml:S3:1395:2	O
such	BREO.xml:S3:1398:4	O
changes	BREO.xml:S3:1403:7	O
occur	BREO.xml:S3:1411:5	O
,	BREO.xml:S3:1416:1	O
discontinue	BREO.xml:S3:1418:11	O
BREO	BREO.xml:S3:1430:4	O
ELLIPTA	BREO.xml:S3:1435:7	O
slowly	BREO.xml:S3:1443:6	O
.	BREO.xml:S3:1449:1	O

(	BREO.xml:S3:1451:1	O
5.8	BREO.xml:S3:1454:3	O
)	BREO.xml:S3:1459:1	O

If	BREO.xml:S3:1468:2	O
paradoxical	BREO.xml:S3:1471:11	O
bronchospasm	BREO.xml:S3:1483:12	O
occurs	BREO.xml:S3:1496:6	O
,	BREO.xml:S3:1502:1	O
discontinue	BREO.xml:S3:1504:11	O
BREO	BREO.xml:S3:1516:4	O
ELLIPTA	BREO.xml:S3:1521:7	O
and	BREO.xml:S3:1529:3	O
institute	BREO.xml:S3:1533:9	O
alternative	BREO.xml:S3:1543:11	O
therapy	BREO.xml:S3:1555:7	O
.	BREO.xml:S3:1562:1	O

(	BREO.xml:S3:1564:1	O
5.10	BREO.xml:S3:1567:4	O
)	BREO.xml:S3:1573:1	O

Use	BREO.xml:S3:1582:3	O
with	BREO.xml:S3:1586:4	O
caution	BREO.xml:S3:1591:7	O
in	BREO.xml:S3:1599:2	O
patients	BREO.xml:S3:1602:8	O
with	BREO.xml:S3:1611:4	O
cardiovascular	BREO.xml:S3:1616:14	O
disorders	BREO.xml:S3:1631:9	O
because	BREO.xml:S3:1641:7	O
of	BREO.xml:S3:1649:2	O
beta	BREO.xml:S3:1652:4	O
-	BREO.xml:S3:1656:1	O
adrenergic	BREO.xml:S3:1657:10	O
stimulation	BREO.xml:S3:1668:11	O
.	BREO.xml:S3:1679:1	O

(	BREO.xml:S3:1681:1	O
5.12	BREO.xml:S3:1684:4	O
)	BREO.xml:S3:1690:1	O

Assess	BREO.xml:S3:1699:6	O
for	BREO.xml:S3:1706:3	O
decrease	BREO.xml:S3:1710:8	O
in	BREO.xml:S3:1719:2	O
bone	BREO.xml:S3:1722:4	O
mineral	BREO.xml:S3:1727:7	O
density	BREO.xml:S3:1735:7	O
initially	BREO.xml:S3:1743:9	O
and	BREO.xml:S3:1753:3	O
periodically	BREO.xml:S3:1757:12	O
thereafter	BREO.xml:S3:1770:10	O
.	BREO.xml:S3:1780:1	O

(	BREO.xml:S3:1782:1	O
5.13	BREO.xml:S3:1785:4	O
)	BREO.xml:S3:1791:1	O

Close	BREO.xml:S3:1800:5	O
monitoring	BREO.xml:S3:1806:10	O
for	BREO.xml:S3:1817:3	O
glaucoma	BREO.xml:S3:1821:8	O
and	BREO.xml:S3:1830:3	O
cataracts	BREO.xml:S3:1834:9	O
is	BREO.xml:S3:1844:2	O
warranted	BREO.xml:S3:1847:9	O
.	BREO.xml:S3:1856:1	O

(	BREO.xml:S3:1858:1	O
5.14	BREO.xml:S3:1861:4	O
)	BREO.xml:S3:1867:1	O

Use	BREO.xml:S3:1876:3	O
with	BREO.xml:S3:1880:4	O
caution	BREO.xml:S3:1885:7	O
in	BREO.xml:S3:1893:2	O
patients	BREO.xml:S3:1896:8	O
with	BREO.xml:S3:1905:4	O
convulsive	BREO.xml:S3:1910:10	O
disorders	BREO.xml:S3:1921:9	O
,	BREO.xml:S3:1930:1	O
thyrotoxicosis	BREO.xml:S3:1932:14	O
,	BREO.xml:S3:1946:1	O
diabetes	BREO.xml:S3:1948:8	O
mellitus	BREO.xml:S3:1957:8	O
,	BREO.xml:S3:1965:1	O
and	BREO.xml:S3:1967:3	O
ketoacidosis	BREO.xml:S3:1971:12	O
.	BREO.xml:S3:1983:1	O

(	BREO.xml:S3:1985:1	O
5.15	BREO.xml:S3:1988:4	O
)	BREO.xml:S3:1994:1	O

Be	BREO.xml:S3:2003:2	O
alert	BREO.xml:S3:2006:5	O
to	BREO.xml:S3:2012:2	O
hypokalemia	BREO.xml:S3:2015:11	O
and	BREO.xml:S3:2027:3	O
hyperglycemia	BREO.xml:S3:2031:13	O
.	BREO.xml:S3:2044:1	O

(	BREO.xml:S3:2046:1	O
5.16	BREO.xml:S3:2049:4	O
)	BREO.xml:S3:2055:1	O

5.1	BREO.xml:S3:2069:3	O

Asthma	BREO.xml:S3:2073:6	O

-	BREO.xml:S3:2079:1	O
Related	BREO.xml:S3:2080:7	O
Death	BREO.xml:S3:2088:5	O

LABA	BREO.xml:S3:2100:4	B-DrugClass
,	BREO.xml:S3:2104:1	O
such	BREO.xml:S3:2106:4	O
as	BREO.xml:S3:2111:2	O
vilanterol	BREO.xml:S3:2114:10	O
,	BREO.xml:S3:2124:1	O
one	BREO.xml:S3:2126:3	O
of	BREO.xml:S3:2130:2	O
the	BREO.xml:S3:2133:3	O
active	BREO.xml:S3:2137:6	O
ingredients	BREO.xml:S3:2144:11	O
in	BREO.xml:S3:2156:2	O
BREO	BREO.xml:S3:2159:4	O
ELLIPTA	BREO.xml:S3:2164:7	O
,	BREO.xml:S3:2171:1	O
increase	BREO.xml:S3:2173:8	O
the	BREO.xml:S3:2182:3	O
risk	BREO.xml:S3:2186:4	O
of	BREO.xml:S3:2191:2	O
asthma	BREO.xml:S3:2194:6	O
-	BREO.xml:S3:2200:1	O
related	BREO.xml:S3:2201:7	O
death	BREO.xml:S3:2209:5	B-AdverseReaction
.	BREO.xml:S3:2214:1	O

Currently	BREO.xml:S3:2216:9	O
available	BREO.xml:S3:2226:9	O
data	BREO.xml:S3:2236:4	O
are	BREO.xml:S3:2241:3	O
inadequate	BREO.xml:S3:2245:10	O
to	BREO.xml:S3:2256:2	O
determine	BREO.xml:S3:2259:9	O
whether	BREO.xml:S3:2269:7	O
concurrent	BREO.xml:S3:2277:10	O
use	BREO.xml:S3:2288:3	O
of	BREO.xml:S3:2292:2	O
inhaled	BREO.xml:S3:2295:7	O
corticosteroids	BREO.xml:S3:2303:15	O
or	BREO.xml:S3:2319:2	O
other	BREO.xml:S3:2322:5	O
long	BREO.xml:S3:2328:4	O
-	BREO.xml:S3:2332:1	O
term	BREO.xml:S3:2333:4	O
asthma	BREO.xml:S3:2338:6	O
control	BREO.xml:S3:2345:7	O
drugs	BREO.xml:S3:2353:5	O
mitigates	BREO.xml:S3:2359:9	O
the	BREO.xml:S3:2369:3	O
increased	BREO.xml:S3:2373:9	O
risk	BREO.xml:S3:2383:4	O
of	BREO.xml:S3:2388:2	O
asthma	BREO.xml:S3:2391:6	O
-	BREO.xml:S3:2397:1	O
related	BREO.xml:S3:2398:7	O
death	BREO.xml:S3:2406:5	B-AdverseReaction
from	BREO.xml:S3:2412:4	O
LABA	BREO.xml:S3:2417:4	B-DrugClass
.	BREO.xml:S3:2421:1	O

Available	BREO.xml:S3:2423:9	O
data	BREO.xml:S3:2433:4	O
from	BREO.xml:S3:2438:4	O
controlled	BREO.xml:S3:2443:10	O
clinical	BREO.xml:S3:2454:8	O
trials	BREO.xml:S3:2463:6	O
suggest	BREO.xml:S3:2470:7	O
that	BREO.xml:S3:2478:4	O
LABA	BREO.xml:S3:2483:4	O
increase	BREO.xml:S3:2488:8	O
the	BREO.xml:S3:2497:3	O
risk	BREO.xml:S3:2501:4	O
of	BREO.xml:S3:2506:2	O
asthma	BREO.xml:S3:2509:6	O
-	BREO.xml:S3:2515:1	O
related	BREO.xml:S3:2516:7	O
hospitalization	BREO.xml:S3:2524:15	O
in	BREO.xml:S3:2540:2	O
pediatric	BREO.xml:S3:2543:9	O
and	BREO.xml:S3:2553:3	O
adolescent	BREO.xml:S3:2557:10	O
patients	BREO.xml:S3:2568:8	O
.	BREO.xml:S3:2576:1	O

Therefore	BREO.xml:S3:2578:9	O
,	BREO.xml:S3:2587:1	O
when	BREO.xml:S3:2589:4	O
treating	BREO.xml:S3:2594:8	O
patients	BREO.xml:S3:2603:8	O
with	BREO.xml:S3:2612:4	O
asthma	BREO.xml:S3:2617:6	O
,	BREO.xml:S3:2623:1	O
physicians	BREO.xml:S3:2625:10	O
should	BREO.xml:S3:2636:6	O
only	BREO.xml:S3:2643:4	O
prescribe	BREO.xml:S3:2648:9	O
BREO	BREO.xml:S3:2658:4	O
ELLIPTA	BREO.xml:S3:2663:7	O
for	BREO.xml:S3:2671:3	O
patients	BREO.xml:S3:2675:8	O
not	BREO.xml:S3:2684:3	O
adequately	BREO.xml:S3:2688:10	O
controlled	BREO.xml:S3:2699:10	O
on	BREO.xml:S3:2710:2	O
a	BREO.xml:S3:2713:1	O
long	BREO.xml:S3:2715:4	O
-	BREO.xml:S3:2719:1	O
term	BREO.xml:S3:2720:4	O
asthma	BREO.xml:S3:2725:6	O
control	BREO.xml:S3:2732:7	O
medication	BREO.xml:S3:2740:10	O
,	BREO.xml:S3:2750:1	O
such	BREO.xml:S3:2752:4	O
as	BREO.xml:S3:2757:2	O
an	BREO.xml:S3:2760:2	O
inhaled	BREO.xml:S3:2763:7	O
corticosteroid	BREO.xml:S3:2771:14	O
,	BREO.xml:S3:2785:1	O
or	BREO.xml:S3:2787:2	O
whose	BREO.xml:S3:2790:5	O
disease	BREO.xml:S3:2796:7	O
severity	BREO.xml:S3:2804:8	O
clearly	BREO.xml:S3:2813:7	O
warrants	BREO.xml:S3:2821:8	O
initiation	BREO.xml:S3:2830:10	O
of	BREO.xml:S3:2841:2	O
treatment	BREO.xml:S3:2844:9	O
with	BREO.xml:S3:2854:4	O
both	BREO.xml:S3:2859:4	O
an	BREO.xml:S3:2864:2	O
inhaled	BREO.xml:S3:2867:7	O
corticosteroid	BREO.xml:S3:2875:14	O
and	BREO.xml:S3:2890:3	O
a	BREO.xml:S3:2894:1	O
LABA	BREO.xml:S3:2896:4	O
.	BREO.xml:S3:2900:1	O

Once	BREO.xml:S3:2902:4	O
asthma	BREO.xml:S3:2907:6	O
control	BREO.xml:S3:2914:7	O
is	BREO.xml:S3:2922:2	O
achieved	BREO.xml:S3:2925:8	O
and	BREO.xml:S3:2934:3	O
maintained	BREO.xml:S3:2938:10	O
,	BREO.xml:S3:2948:1	O
assess	BREO.xml:S3:2950:6	O
the	BREO.xml:S3:2957:3	O
patient	BREO.xml:S3:2961:7	O
at	BREO.xml:S3:2969:2	O
regular	BREO.xml:S3:2972:7	O
intervals	BREO.xml:S3:2980:9	O
and	BREO.xml:S3:2990:3	O
step	BREO.xml:S3:2994:4	O
down	BREO.xml:S3:2999:4	O
therapy	BREO.xml:S3:3004:7	O
(	BREO.xml:S3:3012:1	O
e	BREO.xml:S3:3013:1	O
.	BREO.xml:S3:3014:1	O
g	BREO.xml:S3:3015:1	O
.	BREO.xml:S3:3016:1	O
,	BREO.xml:S3:3017:1	O
discontinue	BREO.xml:S3:3019:11	O
BREO	BREO.xml:S3:3031:4	O
ELLIPTA	BREO.xml:S3:3036:7	O
)	BREO.xml:S3:3043:1	O
if	BREO.xml:S3:3045:2	O
possible	BREO.xml:S3:3048:8	O
without	BREO.xml:S3:3057:7	O
loss	BREO.xml:S3:3065:4	O
of	BREO.xml:S3:3070:2	O
asthma	BREO.xml:S3:3073:6	O
control	BREO.xml:S3:3080:7	O
and	BREO.xml:S3:3088:3	O
maintain	BREO.xml:S3:3092:8	O
the	BREO.xml:S3:3101:3	O
patient	BREO.xml:S3:3105:7	O
on	BREO.xml:S3:3113:2	O
a	BREO.xml:S3:3116:1	O
long	BREO.xml:S3:3118:4	O
-	BREO.xml:S3:3122:1	O
term	BREO.xml:S3:3123:4	O
asthma	BREO.xml:S3:3128:6	O
control	BREO.xml:S3:3135:7	O
medication	BREO.xml:S3:3143:10	O
,	BREO.xml:S3:3153:1	O
such	BREO.xml:S3:3155:4	O
as	BREO.xml:S3:3160:2	O
an	BREO.xml:S3:3163:2	O
inhaled	BREO.xml:S3:3166:7	O
corticosteroid	BREO.xml:S3:3174:14	O
.	BREO.xml:S3:3188:1	O

Do	BREO.xml:S3:3190:2	O
not	BREO.xml:S3:3193:3	O
use	BREO.xml:S3:3197:3	O
BREO	BREO.xml:S3:3201:4	O
ELLIPTA	BREO.xml:S3:3206:7	O
for	BREO.xml:S3:3214:3	O
patients	BREO.xml:S3:3218:8	O
whose	BREO.xml:S3:3227:5	O
asthma	BREO.xml:S3:3233:6	O
is	BREO.xml:S3:3240:2	O
adequately	BREO.xml:S3:3243:10	O
controlled	BREO.xml:S3:3254:10	O
on	BREO.xml:S3:3265:2	O
low	BREO.xml:S3:3268:3	O
-	BREO.xml:S3:3271:1	O
or	BREO.xml:S3:3273:2	O
medium	BREO.xml:S3:3276:6	O
-	BREO.xml:S3:3282:1	O
dose	BREO.xml:S3:3283:4	O
inhaled	BREO.xml:S3:3288:7	O
corticosteroids	BREO.xml:S3:3296:15	O
.	BREO.xml:S3:3311:1	O

A	BREO.xml:S3:3319:1	O
28	BREO.xml:S3:3321:2	O
-	BREO.xml:S3:3323:1	O
week	BREO.xml:S3:3324:4	O
,	BREO.xml:S3:3328:1	O
placebo	BREO.xml:S3:3330:7	O
-	BREO.xml:S3:3337:1	O
controlled	BREO.xml:S3:3338:10	O
,	BREO.xml:S3:3348:1	O
US	BREO.xml:S3:3350:2	O
trial	BREO.xml:S3:3353:5	O
that	BREO.xml:S3:3359:4	O
compared	BREO.xml:S3:3364:8	O
the	BREO.xml:S3:3373:3	O
safety	BREO.xml:S3:3377:6	O
of	BREO.xml:S3:3384:2	O
another	BREO.xml:S3:3387:7	O
LABA	BREO.xml:S3:3395:4	B-DrugClass
(	BREO.xml:S3:3400:1	O
salmeterol	BREO.xml:S3:3401:10	O
)	BREO.xml:S3:3411:1	O
with	BREO.xml:S3:3413:4	O
placebo	BREO.xml:S3:3418:7	O
,	BREO.xml:S3:3425:1	O
each	BREO.xml:S3:3427:4	O
added	BREO.xml:S3:3432:5	O
to	BREO.xml:S3:3438:2	O
usual	BREO.xml:S3:3441:5	O
asthma	BREO.xml:S3:3447:6	O
therapy	BREO.xml:S3:3454:7	O
,	BREO.xml:S3:3461:1	O
showed	BREO.xml:S3:3463:6	O
an	BREO.xml:S3:3470:2	O
increase	BREO.xml:S3:3473:8	O
in	BREO.xml:S3:3482:2	O
asthma	BREO.xml:S3:3485:6	O
-	BREO.xml:S3:3491:1	O
related	BREO.xml:S3:3492:7	O
deaths	BREO.xml:S3:3500:6	B-AdverseReaction
in	BREO.xml:S3:3507:2	O
subjects	BREO.xml:S3:3510:8	O
receiving	BREO.xml:S3:3519:9	O
salmeterol	BREO.xml:S3:3529:10	O
(	BREO.xml:S3:3540:1	O
13	BREO.xml:S3:3541:2	O
13	BREO.xml:S3:3544:2	O
,	BREO.xml:S3:3546:1	O
176	BREO.xml:S3:3547:3	O
in	BREO.xml:S3:3551:2	O
subjects	BREO.xml:S3:3554:8	O
treated	BREO.xml:S3:3563:7	O
with	BREO.xml:S3:3571:4	O
salmeterol	BREO.xml:S3:3576:10	O
vs	BREO.xml:S3:3587:2	O
.	BREO.xml:S3:3589:1	O

3	BREO.xml:S3:3591:1	O
13	BREO.xml:S3:3593:2	O
,	BREO.xml:S3:3595:1	O
179	BREO.xml:S3:3596:3	O
in	BREO.xml:S3:3600:2	O
subjects	BREO.xml:S3:3603:8	O
treated	BREO.xml:S3:3612:7	O
with	BREO.xml:S3:3620:4	O
placebo	BREO.xml:S3:3625:7	O
;	BREO.xml:S3:3632:1	O
relative	BREO.xml:S3:3634:8	O
risk	BREO.xml:S3:3643:4	O
:	BREO.xml:S3:3647:1	O
4.37	BREO.xml:S3:3649:4	O
[	BREO.xml:S3:3654:1	O
95%	BREO.xml:S3:3655:3	O
CI	BREO.xml:S3:3659:2	O
:	BREO.xml:S3:3661:1	O
1.25	BREO.xml:S3:3663:4	O
,	BREO.xml:S3:3667:1	O
15.34	BREO.xml:S3:3669:5	O
])	BREO.xml:S3:3674:2	O
.	BREO.xml:S3:3676:1	O

The	BREO.xml:S3:3678:3	O
increased	BREO.xml:S3:3682:9	O
risk	BREO.xml:S3:3692:4	O
of	BREO.xml:S3:3697:2	O
asthma	BREO.xml:S3:3700:6	O
-	BREO.xml:S3:3706:1	O
related	BREO.xml:S3:3707:7	O
death	BREO.xml:S3:3715:5	B-AdverseReaction
is	BREO.xml:S3:3721:2	O
considered	BREO.xml:S3:3724:10	O
a	BREO.xml:S3:3735:1	O
class	BREO.xml:S3:3737:5	O
effect	BREO.xml:S3:3743:6	O
of	BREO.xml:S3:3750:2	O
LABA	BREO.xml:S3:3753:4	B-DrugClass
,	BREO.xml:S3:3757:1	O
including	BREO.xml:S3:3759:9	O
vilanterol	BREO.xml:S3:3769:10	O
,	BREO.xml:S3:3779:1	O
one	BREO.xml:S3:3781:3	O
of	BREO.xml:S3:3785:2	O
the	BREO.xml:S3:3788:3	O
active	BREO.xml:S3:3792:6	O
ingredients	BREO.xml:S3:3799:11	O
in	BREO.xml:S3:3811:2	O
BREO	BREO.xml:S3:3814:4	O
ELLIPTA	BREO.xml:S3:3819:7	O
.	BREO.xml:S3:3826:1	O

No	BREO.xml:S3:3828:2	B-Factor
trial	BREO.xml:S3:3831:5	I-Factor
adequate	BREO.xml:S3:3837:8	I-Factor
to	BREO.xml:S3:3846:2	O
determine	BREO.xml:S3:3849:9	O
whether	BREO.xml:S3:3859:7	O
the	BREO.xml:S3:3867:3	O
rate	BREO.xml:S3:3871:4	O
of	BREO.xml:S3:3876:2	O
asthma	BREO.xml:S3:3879:6	O
-	BREO.xml:S3:3885:1	O
related	BREO.xml:S3:3886:7	O
death	BREO.xml:S3:3894:5	B-AdverseReaction
is	BREO.xml:S3:3900:2	O
increased	BREO.xml:S3:3903:9	O
in	BREO.xml:S3:3913:2	O
subjects	BREO.xml:S3:3916:8	O
treated	BREO.xml:S3:3925:7	O
with	BREO.xml:S3:3933:4	O
BREO	BREO.xml:S3:3938:4	O
ELLIPTA	BREO.xml:S3:3943:7	O
has	BREO.xml:S3:3951:3	O
been	BREO.xml:S3:3955:4	O
conducted	BREO.xml:S3:3960:9	O
.	BREO.xml:S3:3969:1	O

Data	BREO.xml:S3:3975:4	O
are	BREO.xml:S3:3980:3	O
not	BREO.xml:S3:3984:3	B-Factor
available	BREO.xml:S3:3988:9	I-Factor
to	BREO.xml:S3:3998:2	O
determine	BREO.xml:S3:4001:9	O
whether	BREO.xml:S3:4011:7	O
the	BREO.xml:S3:4019:3	O
rate	BREO.xml:S3:4023:4	O
of	BREO.xml:S3:4028:2	O
death	BREO.xml:S3:4031:5	B-AdverseReaction
in	BREO.xml:S3:4037:2	O
patients	BREO.xml:S3:4040:8	O
with	BREO.xml:S3:4049:4	O
COPD	BREO.xml:S3:4054:4	O
is	BREO.xml:S3:4059:2	O
increased	BREO.xml:S3:4062:9	O
by	BREO.xml:S3:4072:2	O
LABA	BREO.xml:S3:4075:4	O
.	BREO.xml:S3:4079:1	O

5.2	BREO.xml:S3:4088:3	O
Deterioration	BREO.xml:S3:4092:13	O
of	BREO.xml:S3:4106:2	O
Disease	BREO.xml:S3:4109:7	O
and	BREO.xml:S3:4117:3	O
Acute	BREO.xml:S3:4121:5	O
Episodes	BREO.xml:S3:4127:8	O

BREO	BREO.xml:S3:4141:4	O
ELLIPTA	BREO.xml:S3:4146:7	O
should	BREO.xml:S3:4154:6	O
not	BREO.xml:S3:4161:3	O
be	BREO.xml:S3:4165:2	O
initiated	BREO.xml:S3:4168:9	O
in	BREO.xml:S3:4178:2	O
patients	BREO.xml:S3:4181:8	O
during	BREO.xml:S3:4190:6	O
rapidly	BREO.xml:S3:4197:7	O
deteriorating	BREO.xml:S3:4205:13	O
or	BREO.xml:S3:4219:2	O
potentially	BREO.xml:S3:4222:11	O
life	BREO.xml:S3:4234:4	O
-	BREO.xml:S3:4238:1	O
threatening	BREO.xml:S3:4239:11	O
episodes	BREO.xml:S3:4251:8	O
of	BREO.xml:S3:4260:2	O
COPD	BREO.xml:S3:4263:4	O
or	BREO.xml:S3:4268:2	O
asthma	BREO.xml:S3:4271:6	O
.	BREO.xml:S3:4277:1	O

BREO	BREO.xml:S3:4279:4	O
ELLIPTA	BREO.xml:S3:4284:7	O
has	BREO.xml:S3:4292:3	O
not	BREO.xml:S3:4296:3	O
been	BREO.xml:S3:4300:4	O
studied	BREO.xml:S3:4305:7	O
in	BREO.xml:S3:4313:2	O
subjects	BREO.xml:S3:4316:8	O
with	BREO.xml:S3:4325:4	O
acutely	BREO.xml:S3:4330:7	O
deteriorating	BREO.xml:S3:4338:13	O
COPD	BREO.xml:S3:4352:4	O
or	BREO.xml:S3:4357:2	O
asthma	BREO.xml:S3:4360:6	O
.	BREO.xml:S3:4366:1	O

The	BREO.xml:S3:4368:3	O
initiation	BREO.xml:S3:4372:10	O
of	BREO.xml:S3:4383:2	O
BREO	BREO.xml:S3:4386:4	O
ELLIPTA	BREO.xml:S3:4391:7	O
in	BREO.xml:S3:4399:2	O
this	BREO.xml:S3:4402:4	O
setting	BREO.xml:S3:4407:7	O
is	BREO.xml:S3:4415:2	O
not	BREO.xml:S3:4418:3	O
appropriate	BREO.xml:S3:4422:11	O
.	BREO.xml:S3:4433:1	O

COPD	BREO.xml:S3:4439:4	O
may	BREO.xml:S3:4444:3	O
deteriorate	BREO.xml:S3:4448:11	O
acutely	BREO.xml:S3:4460:7	O
over	BREO.xml:S3:4468:4	O
a	BREO.xml:S3:4473:1	O
period	BREO.xml:S3:4475:6	O
of	BREO.xml:S3:4482:2	O
hours	BREO.xml:S3:4485:5	O
or	BREO.xml:S3:4491:2	O
chronically	BREO.xml:S3:4494:11	O
over	BREO.xml:S3:4506:4	O
several	BREO.xml:S3:4511:7	O
days	BREO.xml:S3:4519:4	O
or	BREO.xml:S3:4524:2	O
longer	BREO.xml:S3:4527:6	O
.	BREO.xml:S3:4533:1	O

If	BREO.xml:S3:4535:2	O
BREO	BREO.xml:S3:4538:4	O
ELLIPTA	BREO.xml:S3:4543:7	O
100	BREO.xml:S3:4551:3	O
25	BREO.xml:S3:4555:2	O
no	BREO.xml:S3:4558:2	O
longer	BREO.xml:S3:4561:6	O
controls	BREO.xml:S3:4568:8	O
symptoms	BREO.xml:S3:4577:8	O
of	BREO.xml:S3:4586:2	O
bronchoconstriction	BREO.xml:S3:4589:19	O
;	BREO.xml:S3:4608:1	O
the	BREO.xml:S3:4610:3	O
patient	BREO.xml:S3:4614:7	O
's	BREO.xml:S3:4621:2	O
inhaled	BREO.xml:S3:4624:7	O
,	BREO.xml:S3:4631:1	O
short	BREO.xml:S3:4633:5	O
-	BREO.xml:S3:4638:1	O
acting	BREO.xml:S3:4639:6	O
,	BREO.xml:S3:4645:1	O
beta2	BREO.xml:S3:4647:5	O
-	BREO.xml:S3:4652:1	O
agonist	BREO.xml:S3:4653:7	O
becomes	BREO.xml:S3:4661:7	O
less	BREO.xml:S3:4669:4	O
effective	BREO.xml:S3:4674:9	O
;	BREO.xml:S3:4683:1	O
or	BREO.xml:S3:4685:2	O
the	BREO.xml:S3:4688:3	O
patient	BREO.xml:S3:4692:7	O
needs	BREO.xml:S3:4700:5	O
more	BREO.xml:S3:4706:4	O
short	BREO.xml:S3:4711:5	O
-	BREO.xml:S3:4716:1	O
acting	BREO.xml:S3:4717:6	O
beta2	BREO.xml:S3:4724:5	O
-	BREO.xml:S3:4729:1	O
agonist	BREO.xml:S3:4730:7	O
than	BREO.xml:S3:4738:4	O
usual	BREO.xml:S3:4743:5	O
,	BREO.xml:S3:4748:1	O
these	BREO.xml:S3:4750:5	O
may	BREO.xml:S3:4756:3	O
be	BREO.xml:S3:4760:2	O
markers	BREO.xml:S3:4763:7	O
of	BREO.xml:S3:4771:2	O
deterioration	BREO.xml:S3:4774:13	O
of	BREO.xml:S3:4788:2	O
disease	BREO.xml:S3:4791:7	O
.	BREO.xml:S3:4798:1	O

In	BREO.xml:S3:4800:2	O
this	BREO.xml:S3:4803:4	O
setting	BREO.xml:S3:4808:7	O
a	BREO.xml:S3:4816:1	O
reevaluation	BREO.xml:S3:4818:12	O
of	BREO.xml:S3:4831:2	O
the	BREO.xml:S3:4834:3	O
patient	BREO.xml:S3:4838:7	O
and	BREO.xml:S3:4846:3	O
the	BREO.xml:S3:4850:3	O
COPD	BREO.xml:S3:4854:4	O
treatment	BREO.xml:S3:4859:9	O
regimen	BREO.xml:S3:4869:7	O
should	BREO.xml:S3:4877:6	O
be	BREO.xml:S3:4884:2	O
undertaken	BREO.xml:S3:4887:10	O
at	BREO.xml:S3:4898:2	O
once	BREO.xml:S3:4901:4	O
.	BREO.xml:S3:4905:1	O

For	BREO.xml:S3:4907:3	O
COPD	BREO.xml:S3:4911:4	O
,	BREO.xml:S3:4915:1	O
increasing	BREO.xml:S3:4917:10	O
the	BREO.xml:S3:4928:3	O
daily	BREO.xml:S3:4932:5	O
dose	BREO.xml:S3:4938:4	O
of	BREO.xml:S3:4943:2	O
BREO	BREO.xml:S3:4946:4	O
ELLIPTA	BREO.xml:S3:4951:7	O
100	BREO.xml:S3:4959:3	O
25	BREO.xml:S3:4963:2	O
is	BREO.xml:S3:4966:2	O
not	BREO.xml:S3:4969:3	O
appropriate	BREO.xml:S3:4973:11	O
in	BREO.xml:S3:4985:2	O
this	BREO.xml:S3:4988:4	O
situation	BREO.xml:S3:4993:9	O
.	BREO.xml:S3:5002:1	O

Increasing	BREO.xml:S3:5008:10	O
use	BREO.xml:S3:5019:3	O
of	BREO.xml:S3:5023:2	O
inhaled	BREO.xml:S3:5026:7	O
,	BREO.xml:S3:5033:1	O
short	BREO.xml:S3:5035:5	O
-	BREO.xml:S3:5040:1	O
acting	BREO.xml:S3:5041:6	O
beta2	BREO.xml:S3:5048:5	O
-	BREO.xml:S3:5053:1	O
agonists	BREO.xml:S3:5054:8	O
is	BREO.xml:S3:5063:2	O
a	BREO.xml:S3:5066:1	O
marker	BREO.xml:S3:5068:6	O
of	BREO.xml:S3:5075:2	O
deteriorating	BREO.xml:S3:5078:13	O
asthma	BREO.xml:S3:5092:6	O
.	BREO.xml:S3:5098:1	O

In	BREO.xml:S3:5100:2	O
this	BREO.xml:S3:5103:4	O
situation	BREO.xml:S3:5108:9	O
,	BREO.xml:S3:5117:1	O
the	BREO.xml:S3:5119:3	O
patient	BREO.xml:S3:5123:7	O
requires	BREO.xml:S3:5131:8	O
immediate	BREO.xml:S3:5140:9	O
reevaluation	BREO.xml:S3:5150:12	O
with	BREO.xml:S3:5163:4	O
reassessment	BREO.xml:S3:5168:12	O
of	BREO.xml:S3:5181:2	O
the	BREO.xml:S3:5184:3	O
treatment	BREO.xml:S3:5188:9	O
regimen	BREO.xml:S3:5198:7	O
,	BREO.xml:S3:5205:1	O
giving	BREO.xml:S3:5207:6	O
special	BREO.xml:S3:5214:7	O
consideration	BREO.xml:S3:5222:13	O
to	BREO.xml:S3:5236:2	O
the	BREO.xml:S3:5239:3	O
possible	BREO.xml:S3:5243:8	O
need	BREO.xml:S3:5252:4	O
for	BREO.xml:S3:5257:3	O
replacing	BREO.xml:S3:5261:9	O
the	BREO.xml:S3:5271:3	O
current	BREO.xml:S3:5275:7	O
strength	BREO.xml:S3:5283:8	O
of	BREO.xml:S3:5292:2	O
BREO	BREO.xml:S3:5295:4	O
ELLIPTA	BREO.xml:S3:5300:7	O
with	BREO.xml:S3:5308:4	O
a	BREO.xml:S3:5313:1	O
higher	BREO.xml:S3:5315:6	O
strength	BREO.xml:S3:5322:8	O
,	BREO.xml:S3:5330:1	O
adding	BREO.xml:S3:5332:6	O
additional	BREO.xml:S3:5339:10	O
inhaled	BREO.xml:S3:5350:7	O
corticosteroid	BREO.xml:S3:5358:14	O
,	BREO.xml:S3:5372:1	O
or	BREO.xml:S3:5374:2	O
initiating	BREO.xml:S3:5377:10	O
systemic	BREO.xml:S3:5388:8	O
corticosteroids	BREO.xml:S3:5397:15	O
.	BREO.xml:S3:5412:1	O

Patients	BREO.xml:S3:5414:8	O
should	BREO.xml:S3:5423:6	O
not	BREO.xml:S3:5430:3	O
use	BREO.xml:S3:5434:3	O
more	BREO.xml:S3:5438:4	O
than	BREO.xml:S3:5443:4	O
1	BREO.xml:S3:5448:1	O
inhalation	BREO.xml:S3:5450:10	O
once	BREO.xml:S3:5461:4	O
daily	BREO.xml:S3:5466:5	O
of	BREO.xml:S3:5472:2	O
BREO	BREO.xml:S3:5475:4	O
ELLIPTA	BREO.xml:S3:5480:7	O
.	BREO.xml:S3:5487:1	O

BREO	BREO.xml:S3:5493:4	O
ELLIPTA	BREO.xml:S3:5498:7	O
should	BREO.xml:S3:5506:6	O
not	BREO.xml:S3:5513:3	O
be	BREO.xml:S3:5517:2	O
used	BREO.xml:S3:5520:4	O
for	BREO.xml:S3:5525:3	O
the	BREO.xml:S3:5529:3	O
relief	BREO.xml:S3:5533:6	O
of	BREO.xml:S3:5540:2	O
acute	BREO.xml:S3:5543:5	O
symptoms	BREO.xml:S3:5549:8	O
,	BREO.xml:S3:5557:1	O
i	BREO.xml:S3:5559:1	O
.	BREO.xml:S3:5560:1	O
e	BREO.xml:S3:5561:1	O
.	BREO.xml:S3:5562:1	O
,	BREO.xml:S3:5563:1	O
as	BREO.xml:S3:5565:2	O
rescue	BREO.xml:S3:5568:6	O
therapy	BREO.xml:S3:5575:7	O
for	BREO.xml:S3:5583:3	O
the	BREO.xml:S3:5587:3	O
treatment	BREO.xml:S3:5591:9	O
of	BREO.xml:S3:5601:2	O
acute	BREO.xml:S3:5604:5	O
episodes	BREO.xml:S3:5610:8	O
of	BREO.xml:S3:5619:2	O
bronchospasm	BREO.xml:S3:5622:12	O
.	BREO.xml:S3:5634:1	O

BREO	BREO.xml:S3:5636:4	O
ELLIPTA	BREO.xml:S3:5641:7	O
has	BREO.xml:S3:5649:3	O
not	BREO.xml:S3:5653:3	O
been	BREO.xml:S3:5657:4	O
studied	BREO.xml:S3:5662:7	O
in	BREO.xml:S3:5670:2	O
the	BREO.xml:S3:5673:3	O
relief	BREO.xml:S3:5677:6	O
of	BREO.xml:S3:5684:2	O
acute	BREO.xml:S3:5687:5	O
symptoms	BREO.xml:S3:5693:8	O
and	BREO.xml:S3:5702:3	O
extra	BREO.xml:S3:5706:5	O
doses	BREO.xml:S3:5712:5	O
should	BREO.xml:S3:5718:6	O
not	BREO.xml:S3:5725:3	O
be	BREO.xml:S3:5729:2	O
used	BREO.xml:S3:5732:4	O
for	BREO.xml:S3:5737:3	O
that	BREO.xml:S3:5741:4	O
purpose	BREO.xml:S3:5746:7	O
.	BREO.xml:S3:5753:1	O

Acute	BREO.xml:S3:5755:5	O
symptoms	BREO.xml:S3:5761:8	O
should	BREO.xml:S3:5770:6	O
be	BREO.xml:S3:5777:2	O
treated	BREO.xml:S3:5780:7	O
with	BREO.xml:S3:5788:4	O
an	BREO.xml:S3:5793:2	O
inhaled	BREO.xml:S3:5796:7	O
,	BREO.xml:S3:5803:1	O
short	BREO.xml:S3:5805:5	O
-	BREO.xml:S3:5810:1	O
acting	BREO.xml:S3:5811:6	O
beta2	BREO.xml:S3:5818:5	O
-	BREO.xml:S3:5823:1	O
agonist	BREO.xml:S3:5824:7	O
.	BREO.xml:S3:5831:1	O

When	BREO.xml:S3:5837:4	O
beginning	BREO.xml:S3:5842:9	O
treatment	BREO.xml:S3:5852:9	O
with	BREO.xml:S3:5862:4	O
BREO	BREO.xml:S3:5867:4	O
ELLIPTA	BREO.xml:S3:5872:7	O
,	BREO.xml:S3:5879:1	O
patients	BREO.xml:S3:5881:8	O
who	BREO.xml:S3:5890:3	O
have	BREO.xml:S3:5894:4	O
been	BREO.xml:S3:5899:4	O
taking	BREO.xml:S3:5904:6	O
oral	BREO.xml:S3:5911:4	O
or	BREO.xml:S3:5916:2	O
inhaled	BREO.xml:S3:5919:7	O
,	BREO.xml:S3:5926:1	O
short	BREO.xml:S3:5928:5	O
-	BREO.xml:S3:5933:1	O
acting	BREO.xml:S3:5934:6	O
beta2	BREO.xml:S3:5941:5	O
-	BREO.xml:S3:5946:1	O
agonists	BREO.xml:S3:5947:8	O
on	BREO.xml:S3:5956:2	O
a	BREO.xml:S3:5959:1	O
regular	BREO.xml:S3:5961:7	O
basis	BREO.xml:S3:5969:5	O
(	BREO.xml:S3:5975:1	O
e	BREO.xml:S3:5976:1	O
.	BREO.xml:S3:5977:1	O
g	BREO.xml:S3:5978:1	O
.	BREO.xml:S3:5979:1	O
,	BREO.xml:S3:5980:1	O
4	BREO.xml:S3:5982:1	O
times	BREO.xml:S3:5984:5	O
a	BREO.xml:S3:5990:1	O
day	BREO.xml:S3:5992:3	O
)	BREO.xml:S3:5995:1	O
should	BREO.xml:S3:5997:6	O
be	BREO.xml:S3:6004:2	O
instructed	BREO.xml:S3:6007:10	O
to	BREO.xml:S3:6018:2	O
discontinue	BREO.xml:S3:6021:11	O
the	BREO.xml:S3:6033:3	O
regular	BREO.xml:S3:6037:7	O
use	BREO.xml:S3:6045:3	O
of	BREO.xml:S3:6049:2	O
these	BREO.xml:S3:6052:5	O
drugs	BREO.xml:S3:6058:5	O
and	BREO.xml:S3:6064:3	O
to	BREO.xml:S3:6068:2	O
use	BREO.xml:S3:6071:3	O
them	BREO.xml:S3:6075:4	O
only	BREO.xml:S3:6080:4	O
for	BREO.xml:S3:6085:3	O
symptomatic	BREO.xml:S3:6089:11	O
relief	BREO.xml:S3:6101:6	O
of	BREO.xml:S3:6108:2	O
acute	BREO.xml:S3:6111:5	O
respiratory	BREO.xml:S3:6117:11	O
symptoms	BREO.xml:S3:6129:8	O
.	BREO.xml:S3:6137:1	O

When	BREO.xml:S3:6139:4	O
prescribing	BREO.xml:S3:6144:11	O
BREO	BREO.xml:S3:6156:4	O
ELLIPTA	BREO.xml:S3:6161:7	O
,	BREO.xml:S3:6168:1	O
the	BREO.xml:S3:6170:3	O
healthcare	BREO.xml:S3:6174:10	O
provider	BREO.xml:S3:6185:8	O
should	BREO.xml:S3:6194:6	O
also	BREO.xml:S3:6201:4	O
prescribe	BREO.xml:S3:6206:9	O
an	BREO.xml:S3:6216:2	O
inhaled	BREO.xml:S3:6219:7	O
,	BREO.xml:S3:6226:1	O
short	BREO.xml:S3:6228:5	O
-	BREO.xml:S3:6233:1	O
acting	BREO.xml:S3:6234:6	O
beta2	BREO.xml:S3:6241:5	O
-	BREO.xml:S3:6246:1	O
agonist	BREO.xml:S3:6247:7	O
and	BREO.xml:S3:6255:3	O
instruct	BREO.xml:S3:6259:8	O
the	BREO.xml:S3:6268:3	O
patient	BREO.xml:S3:6272:7	O
on	BREO.xml:S3:6280:2	O
how	BREO.xml:S3:6283:3	O
it	BREO.xml:S3:6287:2	O
should	BREO.xml:S3:6290:6	O
be	BREO.xml:S3:6297:2	O
used	BREO.xml:S3:6300:4	O
.	BREO.xml:S3:6304:1	O

5.3	BREO.xml:S3:6313:3	O
Excessive	BREO.xml:S3:6317:9	O
Use	BREO.xml:S3:6327:3	O
of	BREO.xml:S3:6331:2	O
BREO	BREO.xml:S3:6334:4	O
ELLIPTA	BREO.xml:S3:6339:7	O
and	BREO.xml:S3:6347:3	O
Use	BREO.xml:S3:6351:3	O
with	BREO.xml:S3:6355:4	O
Other	BREO.xml:S3:6360:5	O
Long	BREO.xml:S3:6366:4	O
-	BREO.xml:S3:6370:1	O
Acting	BREO.xml:S3:6371:6	O
Beta2	BREO.xml:S3:6378:5	O
-	BREO.xml:S3:6383:1	O
Agonists	BREO.xml:S3:6384:8	O

BREO	BREO.xml:S3:6398:4	O
ELLIPTA	BREO.xml:S3:6403:7	O
should	BREO.xml:S3:6411:6	O
not	BREO.xml:S3:6418:3	O
be	BREO.xml:S3:6422:2	O
used	BREO.xml:S3:6425:4	O
more	BREO.xml:S3:6430:4	O
often	BREO.xml:S3:6435:5	O
than	BREO.xml:S3:6441:4	O
recommended	BREO.xml:S3:6446:11	O
,	BREO.xml:S3:6457:1	O
at	BREO.xml:S3:6459:2	O
higher	BREO.xml:S3:6462:6	O
doses	BREO.xml:S3:6469:5	O
than	BREO.xml:S3:6475:4	O
recommended	BREO.xml:S3:6480:11	O
,	BREO.xml:S3:6491:1	O
or	BREO.xml:S3:6493:2	O
in	BREO.xml:S3:6496:2	O
conjunction	BREO.xml:S3:6499:11	O
with	BREO.xml:S3:6511:4	O
other	BREO.xml:S3:6516:5	O
medicines	BREO.xml:S3:6522:9	O
containing	BREO.xml:S3:6532:10	O
LABA	BREO.xml:S3:6543:4	O
,	BREO.xml:S3:6547:1	O
as	BREO.xml:S3:6549:2	O
an	BREO.xml:S3:6552:2	O
overdose	BREO.xml:S3:6555:8	O
may	BREO.xml:S3:6564:3	O
result	BREO.xml:S3:6568:6	O
.	BREO.xml:S3:6574:1	O

Clinically	BREO.xml:S3:6576:10	O
significant	BREO.xml:S3:6587:11	O
cardiovascular	BREO.xml:S3:6599:14	O
effects	BREO.xml:S3:6614:7	O
and	BREO.xml:S3:6622:3	O
fatalities	BREO.xml:S3:6626:10	B-AdverseReaction
have	BREO.xml:S3:6637:4	O
been	BREO.xml:S3:6642:4	O
reported	BREO.xml:S3:6647:8	O
in	BREO.xml:S3:6656:2	O
association	BREO.xml:S3:6659:11	O
with	BREO.xml:S3:6671:4	O
excessive	BREO.xml:S3:6676:9	O
use	BREO.xml:S3:6686:3	O
of	BREO.xml:S3:6690:2	O
inhaled	BREO.xml:S3:6693:7	B-DrugClass
sympathomimetic	BREO.xml:S3:6701:15	I-DrugClass
drugs	BREO.xml:S3:6717:5	I-DrugClass
.	BREO.xml:S3:6722:1	O

Patients	BREO.xml:S3:6724:8	O
using	BREO.xml:S3:6733:5	O
BREO	BREO.xml:S3:6739:4	O
ELLIPTA	BREO.xml:S3:6744:7	O
should	BREO.xml:S3:6752:6	O
not	BREO.xml:S3:6759:3	O
use	BREO.xml:S3:6763:3	O
another	BREO.xml:S3:6767:7	O
medicine	BREO.xml:S3:6775:8	O
containing	BREO.xml:S3:6784:10	O
a	BREO.xml:S3:6795:1	O
LABA	BREO.xml:S3:6797:4	O
(	BREO.xml:S3:6802:1	O
e	BREO.xml:S3:6803:1	O
.	BREO.xml:S3:6804:1	O
g	BREO.xml:S3:6805:1	O
.	BREO.xml:S3:6806:1	O
,	BREO.xml:S3:6807:1	O
salmeterol	BREO.xml:S3:6809:10	O
,	BREO.xml:S3:6819:1	O
formoterol	BREO.xml:S3:6821:10	O
fumarate	BREO.xml:S3:6832:8	O
,	BREO.xml:S3:6840:1	O
arformoterol	BREO.xml:S3:6842:12	O
tartrate	BREO.xml:S3:6855:8	O
,	BREO.xml:S3:6863:1	O
indacaterol	BREO.xml:S3:6865:11	O
)	BREO.xml:S3:6876:1	O
for	BREO.xml:S3:6878:3	O
any	BREO.xml:S3:6882:3	O
reason	BREO.xml:S3:6886:6	O
.	BREO.xml:S3:6892:1	O

5.4	BREO.xml:S3:6901:3	O
Local	BREO.xml:S3:6905:5	O
Effects	BREO.xml:S3:6911:7	O
of	BREO.xml:S3:6919:2	O
Inhaled	BREO.xml:S3:6922:7	O
Corticosteroids	BREO.xml:S3:6930:15	O

In	BREO.xml:S3:6951:2	O
clinical	BREO.xml:S3:6954:8	O
trials	BREO.xml:S3:6963:6	O
,	BREO.xml:S3:6969:1	O
the	BREO.xml:S3:6971:3	O
development	BREO.xml:S3:6975:11	O
of	BREO.xml:S3:6987:2	O
localized	BREO.xml:S3:6990:9	O
infections	BREO.xml:S3:7000:10	B-AdverseReaction
of	BREO.xml:S3:7011:2	I-AdverseReaction
the	BREO.xml:S3:7014:3	I-AdverseReaction
mouth	BREO.xml:S3:7018:5	I-AdverseReaction
and	BREO.xml:S3:7024:3	O
pharynx	BREO.xml:S3:7028:7	I-AdverseReaction
with	BREO.xml:S3:7036:4	I-AdverseReaction
Candida	BREO.xml:S3:7041:7	I-AdverseReaction
albicans	BREO.xml:S3:7049:8	I-AdverseReaction
has	BREO.xml:S3:7059:3	O
occurred	BREO.xml:S3:7063:8	O
in	BREO.xml:S3:7072:2	O
subjects	BREO.xml:S3:7075:8	O
treated	BREO.xml:S3:7084:7	O
with	BREO.xml:S3:7092:4	O
BREO	BREO.xml:S3:7097:4	O
ELLIPTA	BREO.xml:S3:7102:7	O
.	BREO.xml:S3:7109:1	O

When	BREO.xml:S3:7111:4	O
such	BREO.xml:S3:7116:4	O
an	BREO.xml:S3:7121:2	O
infection	BREO.xml:S3:7124:9	O
develops	BREO.xml:S3:7134:8	O
,	BREO.xml:S3:7142:1	O
it	BREO.xml:S3:7144:2	O
should	BREO.xml:S3:7147:6	O
be	BREO.xml:S3:7154:2	O
treated	BREO.xml:S3:7157:7	O
with	BREO.xml:S3:7165:4	O
appropriate	BREO.xml:S3:7170:11	O
local	BREO.xml:S3:7182:5	O
or	BREO.xml:S3:7188:2	O
systemic	BREO.xml:S3:7191:8	O
(	BREO.xml:S3:7200:1	O
i	BREO.xml:S3:7201:1	O
.	BREO.xml:S3:7202:1	O
e	BREO.xml:S3:7203:1	O
.	BREO.xml:S3:7204:1	O
,	BREO.xml:S3:7205:1	O
oral	BREO.xml:S3:7207:4	O
)	BREO.xml:S3:7211:1	O
antifungal	BREO.xml:S3:7213:10	O
therapy	BREO.xml:S3:7224:7	O
while	BREO.xml:S3:7232:5	O
treatment	BREO.xml:S3:7238:9	O
with	BREO.xml:S3:7248:4	O
BREO	BREO.xml:S3:7253:4	O
ELLIPTA	BREO.xml:S3:7258:7	O
continues	BREO.xml:S3:7266:9	O
,	BREO.xml:S3:7275:1	O
but	BREO.xml:S3:7277:3	O
at	BREO.xml:S3:7281:2	O
times	BREO.xml:S3:7284:5	O
therapy	BREO.xml:S3:7290:7	O
with	BREO.xml:S3:7298:4	O
BREO	BREO.xml:S3:7303:4	O
ELLIPTA	BREO.xml:S3:7308:7	O
may	BREO.xml:S3:7316:3	O
need	BREO.xml:S3:7320:4	O
to	BREO.xml:S3:7325:2	O
be	BREO.xml:S3:7328:2	O
interrupted	BREO.xml:S3:7331:11	O
.	BREO.xml:S3:7342:1	O

Advise	BREO.xml:S3:7344:6	O
the	BREO.xml:S3:7351:3	O
patient	BREO.xml:S3:7355:7	O
to	BREO.xml:S3:7363:2	O
rinse	BREO.xml:S3:7366:5	O
his	BREO.xml:S3:7372:3	O
her	BREO.xml:S3:7376:3	O
mouth	BREO.xml:S3:7380:5	O
with	BREO.xml:S3:7386:4	O
water	BREO.xml:S3:7391:5	O
without	BREO.xml:S3:7397:7	O
swallowing	BREO.xml:S3:7405:10	O
following	BREO.xml:S3:7416:9	O
inhalation	BREO.xml:S3:7426:10	O
to	BREO.xml:S3:7437:2	O
help	BREO.xml:S3:7440:4	O
reduce	BREO.xml:S3:7445:6	O
the	BREO.xml:S3:7452:3	O
risk	BREO.xml:S3:7456:4	O
of	BREO.xml:S3:7461:2	O
oropharyngeal	BREO.xml:S3:7464:13	O
candidiasis	BREO.xml:S3:7478:11	O
.	BREO.xml:S3:7489:1	O

5.5	BREO.xml:S3:7498:3	O
Pneumonia	BREO.xml:S3:7502:9	O

An	BREO.xml:S3:7517:2	O
increase	BREO.xml:S3:7520:8	O
in	BREO.xml:S3:7529:2	O
the	BREO.xml:S3:7532:3	O
incidence	BREO.xml:S3:7536:9	O
of	BREO.xml:S3:7546:2	O
pneumonia	BREO.xml:S3:7549:9	B-AdverseReaction
has	BREO.xml:S3:7559:3	O
been	BREO.xml:S3:7563:4	O
observed	BREO.xml:S3:7568:8	O
in	BREO.xml:S3:7577:2	O
subjects	BREO.xml:S3:7580:8	O
with	BREO.xml:S3:7589:4	O
COPD	BREO.xml:S3:7594:4	O
receiving	BREO.xml:S3:7599:9	O
BREO	BREO.xml:S3:7609:4	O
ELLIPTA	BREO.xml:S3:7614:7	O
100	BREO.xml:S3:7622:3	O
25	BREO.xml:S3:7626:2	O
in	BREO.xml:S3:7629:2	O
clinical	BREO.xml:S3:7632:8	O
trials	BREO.xml:S3:7641:6	O
.	BREO.xml:S3:7647:1	O

There	BREO.xml:S3:7649:5	O
was	BREO.xml:S3:7655:3	O
also	BREO.xml:S3:7659:4	O
an	BREO.xml:S3:7664:2	O
increased	BREO.xml:S3:7667:9	O
incidence	BREO.xml:S3:7677:9	O
of	BREO.xml:S3:7687:2	O
pneumonias	BREO.xml:S3:7690:10	B-AdverseReaction
resulting	BREO.xml:S3:7701:9	O
in	BREO.xml:S3:7711:2	O
hospitalization	BREO.xml:S3:7714:15	O
.	BREO.xml:S3:7729:1	O

In	BREO.xml:S3:7731:2	O
some	BREO.xml:S3:7734:4	O
incidences	BREO.xml:S3:7739:10	O
these	BREO.xml:S3:7750:5	O
pneumonia	BREO.xml:S3:7756:9	B-AdverseReaction
events	BREO.xml:S3:7766:6	O
were	BREO.xml:S3:7773:4	O
fatal	BREO.xml:S3:7778:5	B-AdverseReaction
.	BREO.xml:S3:7783:1	O

Physicians	BREO.xml:S3:7785:10	O
should	BREO.xml:S3:7796:6	O
remain	BREO.xml:S3:7803:6	O
vigilant	BREO.xml:S3:7810:8	O
for	BREO.xml:S3:7819:3	O
the	BREO.xml:S3:7823:3	O
possible	BREO.xml:S3:7827:8	O
development	BREO.xml:S3:7836:11	O
of	BREO.xml:S3:7848:2	O
pneumonia	BREO.xml:S3:7851:9	O
in	BREO.xml:S3:7861:2	O
patients	BREO.xml:S3:7864:8	O
with	BREO.xml:S3:7873:4	O
COPD	BREO.xml:S3:7878:4	O
as	BREO.xml:S3:7883:2	O
the	BREO.xml:S3:7886:3	O
clinical	BREO.xml:S3:7890:8	O
features	BREO.xml:S3:7899:8	O
of	BREO.xml:S3:7908:2	O
such	BREO.xml:S3:7911:4	O
infections	BREO.xml:S3:7916:10	O
overlap	BREO.xml:S3:7927:7	O
with	BREO.xml:S3:7935:4	O
the	BREO.xml:S3:7940:3	O
symptoms	BREO.xml:S3:7944:8	O
of	BREO.xml:S3:7953:2	O
COPD	BREO.xml:S3:7956:4	O
exacerbations	BREO.xml:S3:7961:13	O
.	BREO.xml:S3:7974:1	O

In	BREO.xml:S3:7980:2	O
replicate	BREO.xml:S3:7983:9	O
12	BREO.xml:S3:7993:2	O
-	BREO.xml:S3:7995:1	O
month	BREO.xml:S3:7996:5	O
trials	BREO.xml:S3:8002:6	O
in	BREO.xml:S3:8009:2	O
3	BREO.xml:S3:8012:1	O
,	BREO.xml:S3:8013:1	O
255	BREO.xml:S3:8014:3	O
subjects	BREO.xml:S3:8018:8	O
with	BREO.xml:S3:8027:4	O
COPD	BREO.xml:S3:8032:4	O
who	BREO.xml:S3:8037:3	O
had	BREO.xml:S3:8041:3	O
experienced	BREO.xml:S3:8045:11	O
a	BREO.xml:S3:8057:1	O
COPD	BREO.xml:S3:8059:4	O
exacerbation	BREO.xml:S3:8064:12	O
in	BREO.xml:S3:8077:2	O
the	BREO.xml:S3:8080:3	O
previous	BREO.xml:S3:8084:8	O
year	BREO.xml:S3:8093:4	O
,	BREO.xml:S3:8097:1	O
there	BREO.xml:S3:8099:5	O
was	BREO.xml:S3:8105:3	O
a	BREO.xml:S3:8109:1	O
higher	BREO.xml:S3:8111:6	O
incidence	BREO.xml:S3:8118:9	O
of	BREO.xml:S3:8128:2	O
pneumonia	BREO.xml:S3:8131:9	B-AdverseReaction
reported	BREO.xml:S3:8141:8	O
in	BREO.xml:S3:8150:2	O
subjects	BREO.xml:S3:8153:8	O
receiving	BREO.xml:S3:8162:9	O
fluticasone	BREO.xml:S3:8172:11	O
furoate	BREO.xml:S3:8184:7	O
vilanterol	BREO.xml:S3:8192:10	O
50	BREO.xml:S3:8203:2	O
mcg	BREO.xml:S3:8206:3	O
25	BREO.xml:S3:8210:2	O
mcg	BREO.xml:S3:8213:3	O
:	BREO.xml:S3:8216:1	O
6%	BREO.xml:S3:8218:2	O
(	BREO.xml:S3:8221:1	O
48	BREO.xml:S3:8222:2	O
of	BREO.xml:S3:8225:2	O
820	BREO.xml:S3:8228:3	O
subjects	BREO.xml:S3:8232:8	O
)	BREO.xml:S3:8240:1	O
;	BREO.xml:S3:8241:1	O
BREO	BREO.xml:S3:8243:4	O
ELLIPTA	BREO.xml:S3:8248:7	O
100	BREO.xml:S3:8256:3	O
25	BREO.xml:S3:8260:2	O
:	BREO.xml:S3:8262:1	O
6%	BREO.xml:S3:8264:2	O
(	BREO.xml:S3:8267:1	O
51	BREO.xml:S3:8268:2	O
of	BREO.xml:S3:8271:2	O
806	BREO.xml:S3:8274:3	O
subjects	BREO.xml:S3:8278:8	O
)	BREO.xml:S3:8286:1	O
;	BREO.xml:S3:8287:1	O
or	BREO.xml:S3:8289:2	O
BREO	BREO.xml:S3:8292:4	O
ELLIPTA	BREO.xml:S3:8297:7	O
200	BREO.xml:S3:8305:3	O
25	BREO.xml:S3:8309:2	O
:	BREO.xml:S3:8311:1	O
7%	BREO.xml:S3:8313:2	O
(	BREO.xml:S3:8316:1	O
55	BREO.xml:S3:8317:2	O
of	BREO.xml:S3:8320:2	O
811	BREO.xml:S3:8323:3	O
subjects	BREO.xml:S3:8327:8	O
)	BREO.xml:S3:8335:1	O
than	BREO.xml:S3:8337:4	O
in	BREO.xml:S3:8342:2	O
subjects	BREO.xml:S3:8345:8	O
receiving	BREO.xml:S3:8354:9	O
vilanterol	BREO.xml:S3:8364:10	O
25	BREO.xml:S3:8375:2	O
mcg	BREO.xml:S3:8378:3	O
:	BREO.xml:S3:8381:1	O
3%	BREO.xml:S3:8383:2	O
(	BREO.xml:S3:8386:1	O
27	BREO.xml:S3:8387:2	O
of	BREO.xml:S3:8390:2	O
818	BREO.xml:S3:8393:3	O
subjects	BREO.xml:S3:8397:8	O
)	BREO.xml:S3:8405:1	O
.	BREO.xml:S3:8406:1	O

There	BREO.xml:S3:8408:5	O
was	BREO.xml:S3:8414:3	O
no	BREO.xml:S3:8418:2	B-Negation
fatal	BREO.xml:S3:8421:5	B-AdverseReaction
pneumonia	BREO.xml:S3:8427:9	B-AdverseReaction
in	BREO.xml:S3:8437:2	O
subjects	BREO.xml:S3:8440:8	O
receiving	BREO.xml:S3:8449:9	O
vilanterol	BREO.xml:S3:8459:10	O
or	BREO.xml:S3:8470:2	O
fluticasone	BREO.xml:S3:8473:11	O
furoate	BREO.xml:S3:8485:7	O
vilanterol	BREO.xml:S3:8493:10	O
50	BREO.xml:S3:8504:2	O
mcg	BREO.xml:S3:8507:3	O
25	BREO.xml:S3:8511:2	O
mcg	BREO.xml:S3:8514:3	O
.	BREO.xml:S3:8517:1	O

There	BREO.xml:S3:8519:5	O
was	BREO.xml:S3:8525:3	O
fatal	BREO.xml:S3:8529:5	B-AdverseReaction
pneumonia	BREO.xml:S3:8535:9	B-AdverseReaction
in	BREO.xml:S3:8545:2	O
1	BREO.xml:S3:8548:1	O
subject	BREO.xml:S3:8550:7	O
receiving	BREO.xml:S3:8558:9	O
BREO	BREO.xml:S3:8568:4	O
ELLIPTA	BREO.xml:S3:8573:7	O
100	BREO.xml:S3:8581:3	O
25	BREO.xml:S3:8585:2	O
and	BREO.xml:S3:8588:3	O
in	BREO.xml:S3:8592:2	O
7	BREO.xml:S3:8595:1	O
subjects	BREO.xml:S3:8597:8	O
receiving	BREO.xml:S3:8606:9	O
BREO	BREO.xml:S3:8616:4	O
ELLIPTA	BREO.xml:S3:8621:7	O
200	BREO.xml:S3:8629:3	O
25	BREO.xml:S3:8633:2	O
(	BREO.xml:S3:8636:1	O
less	BREO.xml:S3:8637:4	O
than	BREO.xml:S3:8642:4	O
1%	BREO.xml:S3:8647:2	O
for	BREO.xml:S3:8650:3	O
each	BREO.xml:S3:8654:4	O
treatment	BREO.xml:S3:8659:9	O
group	BREO.xml:S3:8669:5	O
)	BREO.xml:S3:8674:1	O
.	BREO.xml:S3:8675:1	O

5.6	BREO.xml:S3:8684:3	O
Immunosuppression	BREO.xml:S3:8688:17	O

Persons	BREO.xml:S3:8711:7	O
who	BREO.xml:S3:8719:3	O
are	BREO.xml:S3:8723:3	O
using	BREO.xml:S3:8727:5	O
drugs	BREO.xml:S3:8733:5	B-DrugClass
that	BREO.xml:S3:8739:4	I-DrugClass
suppress	BREO.xml:S3:8744:8	I-DrugClass
the	BREO.xml:S3:8753:3	I-DrugClass
immune	BREO.xml:S3:8757:6	I-DrugClass
system	BREO.xml:S3:8764:6	I-DrugClass
are	BREO.xml:S3:8771:3	O
more	BREO.xml:S3:8775:4	O
susceptible	BREO.xml:S3:8780:11	O
to	BREO.xml:S3:8792:2	O
infections	BREO.xml:S3:8795:10	B-AdverseReaction
than	BREO.xml:S3:8806:4	O
healthy	BREO.xml:S3:8811:7	O
individuals	BREO.xml:S3:8819:11	O
.	BREO.xml:S3:8830:1	O

Chickenpox	BREO.xml:S3:8832:10	B-AdverseReaction
and	BREO.xml:S3:8843:3	O
measles	BREO.xml:S3:8847:7	B-AdverseReaction
,	BREO.xml:S3:8854:1	O
for	BREO.xml:S3:8856:3	O
example	BREO.xml:S3:8860:7	O
,	BREO.xml:S3:8867:1	O
can	BREO.xml:S3:8869:3	O
have	BREO.xml:S3:8873:4	O
a	BREO.xml:S3:8878:1	O
more	BREO.xml:S3:8880:4	O
serious	BREO.xml:S3:8885:7	B-Severity
or	BREO.xml:S3:8893:2	O
even	BREO.xml:S3:8896:4	O
fatal	BREO.xml:S3:8901:5	B-AdverseReaction
course	BREO.xml:S3:8907:6	O
in	BREO.xml:S3:8914:2	O
susceptible	BREO.xml:S3:8917:11	O
children	BREO.xml:S3:8929:8	O
or	BREO.xml:S3:8938:2	O
adults	BREO.xml:S3:8941:6	O
using	BREO.xml:S3:8948:5	O
corticosteroids	BREO.xml:S3:8954:15	B-DrugClass
.	BREO.xml:S3:8969:1	O

In	BREO.xml:S3:8971:2	O
such	BREO.xml:S3:8974:4	O
children	BREO.xml:S3:8979:8	O
or	BREO.xml:S3:8988:2	O
adults	BREO.xml:S3:8991:6	O
who	BREO.xml:S3:8998:3	O
have	BREO.xml:S3:9002:4	O
not	BREO.xml:S3:9007:3	O
had	BREO.xml:S3:9011:3	O
these	BREO.xml:S3:9015:5	O
diseases	BREO.xml:S3:9021:8	O
or	BREO.xml:S3:9030:2	O
been	BREO.xml:S3:9033:4	O
properly	BREO.xml:S3:9038:8	O
immunized	BREO.xml:S3:9047:9	O
,	BREO.xml:S3:9056:1	O
particular	BREO.xml:S3:9058:10	O
care	BREO.xml:S3:9069:4	O
should	BREO.xml:S3:9074:6	O
be	BREO.xml:S3:9081:2	O
taken	BREO.xml:S3:9084:5	O
to	BREO.xml:S3:9090:2	O
avoid	BREO.xml:S3:9093:5	O
exposure	BREO.xml:S3:9099:8	O
.	BREO.xml:S3:9107:1	O

How	BREO.xml:S3:9109:3	O
the	BREO.xml:S3:9113:3	O
dose	BREO.xml:S3:9117:4	O
,	BREO.xml:S3:9121:1	O
route	BREO.xml:S3:9123:5	O
,	BREO.xml:S3:9128:1	O
and	BREO.xml:S3:9130:3	O
duration	BREO.xml:S3:9134:8	O
of	BREO.xml:S3:9143:2	O
corticosteroid	BREO.xml:S3:9146:14	O
administration	BREO.xml:S3:9161:14	O
affect	BREO.xml:S3:9176:6	O
the	BREO.xml:S3:9183:3	O
risk	BREO.xml:S3:9187:4	O
of	BREO.xml:S3:9192:2	O
developing	BREO.xml:S3:9195:10	O
a	BREO.xml:S3:9206:1	O
disseminated	BREO.xml:S3:9208:12	O
infection	BREO.xml:S3:9221:9	O
is	BREO.xml:S3:9231:2	O
not	BREO.xml:S3:9234:3	O
known	BREO.xml:S3:9238:5	O
.	BREO.xml:S3:9243:1	O

The	BREO.xml:S3:9245:3	O
contribution	BREO.xml:S3:9249:12	O
of	BREO.xml:S3:9262:2	O
the	BREO.xml:S3:9265:3	O
underlying	BREO.xml:S3:9269:10	O
disease	BREO.xml:S3:9280:7	O
and	BREO.xml:S3:9288:3	O
or	BREO.xml:S3:9292:2	O
prior	BREO.xml:S3:9295:5	O
corticosteroid	BREO.xml:S3:9301:14	O
treatment	BREO.xml:S3:9316:9	O
to	BREO.xml:S3:9326:2	O
the	BREO.xml:S3:9329:3	O
risk	BREO.xml:S3:9333:4	O
is	BREO.xml:S3:9338:2	O
also	BREO.xml:S3:9341:4	O
not	BREO.xml:S3:9346:3	O
known	BREO.xml:S3:9350:5	O
.	BREO.xml:S3:9355:1	O

If	BREO.xml:S3:9357:2	O
a	BREO.xml:S3:9360:1	O
patient	BREO.xml:S3:9362:7	O
is	BREO.xml:S3:9370:2	O
exposed	BREO.xml:S3:9373:7	O
to	BREO.xml:S3:9381:2	O
chickenpox	BREO.xml:S3:9384:10	O
,	BREO.xml:S3:9394:1	O
prophylaxis	BREO.xml:S3:9396:11	O
with	BREO.xml:S3:9408:4	O
varicella	BREO.xml:S3:9413:9	O
zoster	BREO.xml:S3:9423:6	O
immune	BREO.xml:S3:9430:6	O
globulin	BREO.xml:S3:9437:8	O
(	BREO.xml:S3:9446:1	O
VZIG	BREO.xml:S3:9447:4	O
)	BREO.xml:S3:9451:1	O
may	BREO.xml:S3:9453:3	O
be	BREO.xml:S3:9457:2	O
indicated	BREO.xml:S3:9460:9	O
.	BREO.xml:S3:9469:1	O

If	BREO.xml:S3:9471:2	O
a	BREO.xml:S3:9474:1	O
patient	BREO.xml:S3:9476:7	O
is	BREO.xml:S3:9484:2	O
exposed	BREO.xml:S3:9487:7	O
to	BREO.xml:S3:9495:2	O
measles	BREO.xml:S3:9498:7	O
,	BREO.xml:S3:9505:1	O
prophylaxis	BREO.xml:S3:9507:11	O
with	BREO.xml:S3:9519:4	O
pooled	BREO.xml:S3:9524:6	O
intramuscular	BREO.xml:S3:9531:13	O
immunoglobulin	BREO.xml:S3:9545:14	O
(	BREO.xml:S3:9560:1	O
IG	BREO.xml:S3:9561:2	O
)	BREO.xml:S3:9563:1	O
may	BREO.xml:S3:9565:3	O
be	BREO.xml:S3:9569:2	O
indicated	BREO.xml:S3:9572:9	O
.	BREO.xml:S3:9581:1	O

(	BREO.xml:S3:9583:1	O
See	BREO.xml:S3:9584:3	O
the	BREO.xml:S3:9588:3	O
respective	BREO.xml:S3:9592:10	O
package	BREO.xml:S3:9603:7	O
inserts	BREO.xml:S3:9611:7	O
for	BREO.xml:S3:9619:3	O
complete	BREO.xml:S3:9623:8	O
VZIG	BREO.xml:S3:9632:4	O
and	BREO.xml:S3:9637:3	O
IG	BREO.xml:S3:9641:2	O
prescribing	BREO.xml:S3:9644:11	O
information	BREO.xml:S3:9656:11	O
.	BREO.xml:S3:9667:1	O
)	BREO.xml:S3:9668:1	O

If	BREO.xml:S3:9670:2	O
chickenpox	BREO.xml:S3:9673:10	O
develops	BREO.xml:S3:9684:8	O
,	BREO.xml:S3:9692:1	O
treatment	BREO.xml:S3:9694:9	O
with	BREO.xml:S3:9704:4	O
antiviral	BREO.xml:S3:9709:9	O
agents	BREO.xml:S3:9719:6	O
may	BREO.xml:S3:9726:3	O
be	BREO.xml:S3:9730:2	O
considered	BREO.xml:S3:9733:10	O
.	BREO.xml:S3:9743:1	O

Inhaled	BREO.xml:S3:9749:7	O
corticosteroids	BREO.xml:S3:9757:15	O
should	BREO.xml:S3:9773:6	O
be	BREO.xml:S3:9780:2	O
used	BREO.xml:S3:9783:4	O
with	BREO.xml:S3:9788:4	O
caution	BREO.xml:S3:9793:7	O
,	BREO.xml:S3:9800:1	O
if	BREO.xml:S3:9802:2	O
at	BREO.xml:S3:9805:2	O
all	BREO.xml:S3:9808:3	O
,	BREO.xml:S3:9811:1	O
in	BREO.xml:S3:9813:2	O
patients	BREO.xml:S3:9816:8	O
with	BREO.xml:S3:9825:4	O
active	BREO.xml:S3:9830:6	O
or	BREO.xml:S3:9837:2	O
quiescent	BREO.xml:S3:9840:9	O
tuberculosis	BREO.xml:S3:9850:12	O
infections	BREO.xml:S3:9863:10	O
of	BREO.xml:S3:9874:2	O
the	BREO.xml:S3:9877:3	O
respiratory	BREO.xml:S3:9881:11	O
tract	BREO.xml:S3:9893:5	O
;	BREO.xml:S3:9898:1	O
systemic	BREO.xml:S3:9900:8	O
fungal	BREO.xml:S3:9909:6	O
,	BREO.xml:S3:9915:1	O
bacterial	BREO.xml:S3:9917:9	O
,	BREO.xml:S3:9926:1	O
viral	BREO.xml:S3:9928:5	O
,	BREO.xml:S3:9933:1	O
or	BREO.xml:S3:9935:2	O
parasitic	BREO.xml:S3:9938:9	O
infections	BREO.xml:S3:9948:10	O
;	BREO.xml:S3:9958:1	O
or	BREO.xml:S3:9960:2	O
ocular	BREO.xml:S3:9963:6	O
herpes	BREO.xml:S3:9970:6	O
simplex	BREO.xml:S3:9977:7	O
.	BREO.xml:S3:9984:1	O

5.7	BREO.xml:S3:9993:3	O
Transferring	BREO.xml:S3:9997:12	O
Patients	BREO.xml:S3:10010:8	O
from	BREO.xml:S3:10019:4	O
Systemic	BREO.xml:S3:10024:8	O
Corticosteroid	BREO.xml:S3:10033:14	O
Therapy	BREO.xml:S3:10048:7	O

Particular	BREO.xml:S3:10061:10	O
care	BREO.xml:S3:10072:4	O
is	BREO.xml:S3:10077:2	O
needed	BREO.xml:S3:10080:6	O
for	BREO.xml:S3:10087:3	O
patients	BREO.xml:S3:10091:8	O
who	BREO.xml:S3:10100:3	O
have	BREO.xml:S3:10104:4	O
been	BREO.xml:S3:10109:4	O
transferred	BREO.xml:S3:10114:11	O
from	BREO.xml:S3:10126:4	O
systemically	BREO.xml:S3:10131:12	O
active	BREO.xml:S3:10144:6	O
corticosteroids	BREO.xml:S3:10151:15	O
to	BREO.xml:S3:10167:2	O
inhaled	BREO.xml:S3:10170:7	O
corticosteroids	BREO.xml:S3:10178:15	O
because	BREO.xml:S3:10194:7	O
deaths	BREO.xml:S3:10202:6	O
due	BREO.xml:S3:10209:3	O
to	BREO.xml:S3:10213:2	O
adrenal	BREO.xml:S3:10216:7	O
insufficiency	BREO.xml:S3:10224:13	O
have	BREO.xml:S3:10238:4	O
occurred	BREO.xml:S3:10243:8	O
in	BREO.xml:S3:10252:2	O
patients	BREO.xml:S3:10255:8	O
with	BREO.xml:S3:10264:4	O
asthma	BREO.xml:S3:10269:6	O
during	BREO.xml:S3:10276:6	O
and	BREO.xml:S3:10283:3	O
after	BREO.xml:S3:10287:5	O
transfer	BREO.xml:S3:10293:8	O
from	BREO.xml:S3:10302:4	O
systemic	BREO.xml:S3:10307:8	O
corticosteroids	BREO.xml:S3:10316:15	O
to	BREO.xml:S3:10332:2	O
less	BREO.xml:S3:10335:4	O
systemically	BREO.xml:S3:10340:12	O
available	BREO.xml:S3:10353:9	O
inhaled	BREO.xml:S3:10363:7	O
corticosteroids	BREO.xml:S3:10371:15	O
.	BREO.xml:S3:10386:1	O

After	BREO.xml:S3:10388:5	O
withdrawal	BREO.xml:S3:10394:10	O
from	BREO.xml:S3:10405:4	O
systemic	BREO.xml:S3:10410:8	O
corticosteroids	BREO.xml:S3:10419:15	O
,	BREO.xml:S3:10434:1	O
a	BREO.xml:S3:10436:1	O
number	BREO.xml:S3:10438:6	O
of	BREO.xml:S3:10445:2	O
months	BREO.xml:S3:10448:6	O
are	BREO.xml:S3:10455:3	O
required	BREO.xml:S3:10459:8	O
for	BREO.xml:S3:10468:3	O
recovery	BREO.xml:S3:10472:8	O
of	BREO.xml:S3:10481:2	O
hypothalamic	BREO.xml:S3:10484:12	O
-	BREO.xml:S3:10496:1	O
pituitary	BREO.xml:S3:10497:9	O
-	BREO.xml:S3:10506:1	O
adrenal	BREO.xml:S3:10507:7	O
(	BREO.xml:S3:10515:1	O
HPA	BREO.xml:S3:10516:3	O
)	BREO.xml:S3:10519:1	O
function	BREO.xml:S3:10521:8	O
.	BREO.xml:S3:10529:1	O

Patients	BREO.xml:S3:10535:8	O
who	BREO.xml:S3:10544:3	O
have	BREO.xml:S3:10548:4	O
been	BREO.xml:S3:10553:4	O
previously	BREO.xml:S3:10558:10	O
maintained	BREO.xml:S3:10569:10	O
on	BREO.xml:S3:10580:2	O
20	BREO.xml:S3:10583:2	O
mg	BREO.xml:S3:10586:2	O
or	BREO.xml:S3:10589:2	O
more	BREO.xml:S3:10592:4	O
of	BREO.xml:S3:10597:2	O
prednisone	BREO.xml:S3:10600:10	O
(	BREO.xml:S3:10611:1	O
or	BREO.xml:S3:10612:2	O
its	BREO.xml:S3:10615:3	O
equivalent	BREO.xml:S3:10619:10	O
)	BREO.xml:S3:10629:1	O
may	BREO.xml:S3:10631:3	O
be	BREO.xml:S3:10635:2	O
most	BREO.xml:S3:10638:4	O
susceptible	BREO.xml:S3:10643:11	O
,	BREO.xml:S3:10654:1	O
particularly	BREO.xml:S3:10656:12	O
when	BREO.xml:S3:10669:4	O
their	BREO.xml:S3:10674:5	O
systemic	BREO.xml:S3:10680:8	O
corticosteroids	BREO.xml:S3:10689:15	O
have	BREO.xml:S3:10705:4	O
been	BREO.xml:S3:10710:4	O
almost	BREO.xml:S3:10715:6	O
completely	BREO.xml:S3:10722:10	O
withdrawn	BREO.xml:S3:10733:9	O
.	BREO.xml:S3:10742:1	O

During	BREO.xml:S3:10744:6	O
this	BREO.xml:S3:10751:4	O
period	BREO.xml:S3:10756:6	O
of	BREO.xml:S3:10763:2	O
HPA	BREO.xml:S3:10766:3	O
suppression	BREO.xml:S3:10770:11	O
,	BREO.xml:S3:10781:1	O
patients	BREO.xml:S3:10783:8	O
may	BREO.xml:S3:10792:3	O
exhibit	BREO.xml:S3:10796:7	O
signs	BREO.xml:S3:10804:5	O
and	BREO.xml:S3:10810:3	O
symptoms	BREO.xml:S3:10814:8	O
of	BREO.xml:S3:10823:2	O
adrenal	BREO.xml:S3:10826:7	O
insufficiency	BREO.xml:S3:10834:13	O
when	BREO.xml:S3:10848:4	O
exposed	BREO.xml:S3:10853:7	O
to	BREO.xml:S3:10861:2	O
trauma	BREO.xml:S3:10864:6	O
,	BREO.xml:S3:10870:1	O
surgery	BREO.xml:S3:10872:7	O
,	BREO.xml:S3:10879:1	O
or	BREO.xml:S3:10881:2	O
infection	BREO.xml:S3:10884:9	O
(	BREO.xml:S3:10894:1	O
particularly	BREO.xml:S3:10895:12	O
gastroenteritis	BREO.xml:S3:10908:15	O
)	BREO.xml:S3:10923:1	O
or	BREO.xml:S3:10925:2	O
other	BREO.xml:S3:10928:5	O
conditions	BREO.xml:S3:10934:10	O
associated	BREO.xml:S3:10945:10	O
with	BREO.xml:S3:10956:4	O
severe	BREO.xml:S3:10961:6	O
electrolyte	BREO.xml:S3:10968:11	O
loss	BREO.xml:S3:10980:4	O
.	BREO.xml:S3:10984:1	O

Although	BREO.xml:S3:10986:8	O
BREO	BREO.xml:S3:10995:4	O
ELLIPTA	BREO.xml:S3:11000:7	O
may	BREO.xml:S3:11008:3	O
control	BREO.xml:S3:11012:7	O
COPD	BREO.xml:S3:11020:4	O
or	BREO.xml:S3:11025:2	O
asthma	BREO.xml:S3:11028:6	O
symptoms	BREO.xml:S3:11035:8	O
during	BREO.xml:S3:11044:6	O
these	BREO.xml:S3:11051:5	O
episodes	BREO.xml:S3:11057:8	O
,	BREO.xml:S3:11065:1	O
in	BREO.xml:S3:11067:2	O
recommended	BREO.xml:S3:11070:11	O
doses	BREO.xml:S3:11082:5	O
it	BREO.xml:S3:11088:2	O
supplies	BREO.xml:S3:11091:8	O
less	BREO.xml:S3:11100:4	O
than	BREO.xml:S3:11105:4	O
normal	BREO.xml:S3:11110:6	O
physiological	BREO.xml:S3:11117:13	O
amounts	BREO.xml:S3:11131:7	O
of	BREO.xml:S3:11139:2	O
glucocorticoid	BREO.xml:S3:11142:14	O
systemically	BREO.xml:S3:11157:12	O
and	BREO.xml:S3:11170:3	O
does	BREO.xml:S3:11174:4	O
NOT	BREO.xml:S3:11179:3	O
provide	BREO.xml:S3:11183:7	O
the	BREO.xml:S3:11191:3	O
mineralocorticoid	BREO.xml:S3:11195:17	O
activity	BREO.xml:S3:11213:8	O
that	BREO.xml:S3:11222:4	O
is	BREO.xml:S3:11227:2	O
necessary	BREO.xml:S3:11230:9	O
for	BREO.xml:S3:11240:3	O
coping	BREO.xml:S3:11244:6	O
with	BREO.xml:S3:11251:4	O
these	BREO.xml:S3:11256:5	O
emergencies	BREO.xml:S3:11262:11	O
.	BREO.xml:S3:11273:1	O

During	BREO.xml:S3:11279:6	O
periods	BREO.xml:S3:11286:7	O
of	BREO.xml:S3:11294:2	O
stress	BREO.xml:S3:11297:6	O
,	BREO.xml:S3:11303:1	O
a	BREO.xml:S3:11305:1	O
severe	BREO.xml:S3:11307:6	O
COPD	BREO.xml:S3:11314:4	O
exacerbation	BREO.xml:S3:11319:12	O
,	BREO.xml:S3:11331:1	O
or	BREO.xml:S3:11333:2	O
a	BREO.xml:S3:11336:1	O
severe	BREO.xml:S3:11338:6	O
asthma	BREO.xml:S3:11345:6	O
attack	BREO.xml:S3:11352:6	O
,	BREO.xml:S3:11358:1	O
patients	BREO.xml:S3:11360:8	O
who	BREO.xml:S3:11369:3	O
have	BREO.xml:S3:11373:4	O
been	BREO.xml:S3:11378:4	O
withdrawn	BREO.xml:S3:11383:9	O
from	BREO.xml:S3:11393:4	O
systemic	BREO.xml:S3:11398:8	O
corticosteroids	BREO.xml:S3:11407:15	O
should	BREO.xml:S3:11423:6	O
be	BREO.xml:S3:11430:2	O
instructed	BREO.xml:S3:11433:10	O
to	BREO.xml:S3:11444:2	O
resume	BREO.xml:S3:11447:6	O
oral	BREO.xml:S3:11454:4	O
corticosteroids	BREO.xml:S3:11459:15	O
(	BREO.xml:S3:11475:1	O
in	BREO.xml:S3:11476:2	O
large	BREO.xml:S3:11479:5	O
doses	BREO.xml:S3:11485:5	O
)	BREO.xml:S3:11490:1	O
immediately	BREO.xml:S3:11492:11	O
and	BREO.xml:S3:11504:3	O
to	BREO.xml:S3:11508:2	O
contact	BREO.xml:S3:11511:7	O
their	BREO.xml:S3:11519:5	O
physicians	BREO.xml:S3:11525:10	O
for	BREO.xml:S3:11536:3	O
further	BREO.xml:S3:11540:7	O
instruction	BREO.xml:S3:11548:11	O
.	BREO.xml:S3:11559:1	O

These	BREO.xml:S3:11561:5	O
patients	BREO.xml:S3:11567:8	O
should	BREO.xml:S3:11576:6	O
also	BREO.xml:S3:11583:4	O
be	BREO.xml:S3:11588:2	O
instructed	BREO.xml:S3:11591:10	O
to	BREO.xml:S3:11602:2	O
carry	BREO.xml:S3:11605:5	O
a	BREO.xml:S3:11611:1	O
warning	BREO.xml:S3:11613:7	O
card	BREO.xml:S3:11621:4	O
indicating	BREO.xml:S3:11626:10	O
that	BREO.xml:S3:11637:4	O
they	BREO.xml:S3:11642:4	O
may	BREO.xml:S3:11647:3	O
need	BREO.xml:S3:11651:4	O
supplementary	BREO.xml:S3:11656:13	O
systemic	BREO.xml:S3:11670:8	O
corticosteroids	BREO.xml:S3:11679:15	O
during	BREO.xml:S3:11695:6	O
periods	BREO.xml:S3:11702:7	O
of	BREO.xml:S3:11710:2	O
stress	BREO.xml:S3:11713:6	O
,	BREO.xml:S3:11719:1	O
a	BREO.xml:S3:11721:1	O
severe	BREO.xml:S3:11723:6	O
COPD	BREO.xml:S3:11730:4	O
exacerbation	BREO.xml:S3:11735:12	O
,	BREO.xml:S3:11747:1	O
or	BREO.xml:S3:11749:2	O
a	BREO.xml:S3:11752:1	O
severe	BREO.xml:S3:11754:6	O
asthma	BREO.xml:S3:11761:6	O
attack	BREO.xml:S3:11768:6	O
.	BREO.xml:S3:11774:1	O

Patients	BREO.xml:S3:11780:8	O
requiring	BREO.xml:S3:11789:9	O
oral	BREO.xml:S3:11799:4	O
corticosteroids	BREO.xml:S3:11804:15	O
should	BREO.xml:S3:11820:6	O
be	BREO.xml:S3:11827:2	O
weaned	BREO.xml:S3:11830:6	O
slowly	BREO.xml:S3:11837:6	O
from	BREO.xml:S3:11844:4	O
systemic	BREO.xml:S3:11849:8	O
corticosteroid	BREO.xml:S3:11858:14	O
use	BREO.xml:S3:11873:3	O
after	BREO.xml:S3:11877:5	O
transferring	BREO.xml:S3:11883:12	O
to	BREO.xml:S3:11896:2	O
BREO	BREO.xml:S3:11899:4	O
ELLIPTA	BREO.xml:S3:11904:7	O
.	BREO.xml:S3:11911:1	O

Prednisone	BREO.xml:S3:11913:10	O
reduction	BREO.xml:S3:11924:9	O
can	BREO.xml:S3:11934:3	O
be	BREO.xml:S3:11938:2	O
accomplished	BREO.xml:S3:11941:12	O
by	BREO.xml:S3:11954:2	O
reducing	BREO.xml:S3:11957:8	O
the	BREO.xml:S3:11966:3	O
daily	BREO.xml:S3:11970:5	O
prednisone	BREO.xml:S3:11976:10	O
dose	BREO.xml:S3:11987:4	O
by	BREO.xml:S3:11992:2	O
2.5	BREO.xml:S3:11995:3	O
mg	BREO.xml:S3:11999:2	O
on	BREO.xml:S3:12002:2	O
a	BREO.xml:S3:12005:1	O
weekly	BREO.xml:S3:12007:6	O
basis	BREO.xml:S3:12014:5	O
during	BREO.xml:S3:12020:6	O
therapy	BREO.xml:S3:12027:7	O
with	BREO.xml:S3:12035:4	O
BREO	BREO.xml:S3:12040:4	O
ELLIPTA	BREO.xml:S3:12045:7	O
.	BREO.xml:S3:12052:1	O

Lung	BREO.xml:S3:12054:4	O
function	BREO.xml:S3:12059:8	O
(	BREO.xml:S3:12068:1	O
FEV1or	BREO.xml:S3:12069:6	O
peak	BREO.xml:S3:12076:4	O
expiratory	BREO.xml:S3:12081:10	O
flow	BREO.xml:S3:12092:4	O
)	BREO.xml:S3:12096:1	O
,	BREO.xml:S3:12097:1	O
beta	BREO.xml:S3:12099:4	O
-	BREO.xml:S3:12103:1	O
agonist	BREO.xml:S3:12104:7	O
use	BREO.xml:S3:12112:3	O
,	BREO.xml:S3:12115:1	O
and	BREO.xml:S3:12117:3	O
COPD	BREO.xml:S3:12121:4	O
or	BREO.xml:S3:12126:2	O
asthma	BREO.xml:S3:12129:6	O
symptoms	BREO.xml:S3:12136:8	O
should	BREO.xml:S3:12145:6	O
be	BREO.xml:S3:12152:2	O
carefully	BREO.xml:S3:12155:9	O
monitored	BREO.xml:S3:12165:9	O
during	BREO.xml:S3:12175:6	O
withdrawal	BREO.xml:S3:12182:10	O
of	BREO.xml:S3:12193:2	O
oral	BREO.xml:S3:12196:4	O
corticosteroids	BREO.xml:S3:12201:15	O
.	BREO.xml:S3:12216:1	O

In	BREO.xml:S3:12218:2	O
addition	BREO.xml:S3:12221:8	O
,	BREO.xml:S3:12229:1	O
patients	BREO.xml:S3:12231:8	O
should	BREO.xml:S3:12240:6	O
be	BREO.xml:S3:12247:2	O
observed	BREO.xml:S3:12250:8	O
for	BREO.xml:S3:12259:3	O
signs	BREO.xml:S3:12263:5	O
and	BREO.xml:S3:12269:3	O
symptoms	BREO.xml:S3:12273:8	O
of	BREO.xml:S3:12282:2	O
adrenal	BREO.xml:S3:12285:7	O
insufficiency	BREO.xml:S3:12293:13	O
,	BREO.xml:S3:12306:1	O
such	BREO.xml:S3:12308:4	O
as	BREO.xml:S3:12313:2	O
fatigue	BREO.xml:S3:12316:7	O
,	BREO.xml:S3:12323:1	O
lassitude	BREO.xml:S3:12325:9	O
,	BREO.xml:S3:12334:1	O
weakness	BREO.xml:S3:12336:8	O
,	BREO.xml:S3:12344:1	O
nausea	BREO.xml:S3:12346:6	O
and	BREO.xml:S3:12353:3	O
vomiting	BREO.xml:S3:12357:8	O
,	BREO.xml:S3:12365:1	O
and	BREO.xml:S3:12367:3	O
hypotension	BREO.xml:S3:12371:11	O
.	BREO.xml:S3:12382:1	O

Transfer	BREO.xml:S3:12388:8	O
of	BREO.xml:S3:12397:2	O
patients	BREO.xml:S3:12400:8	O
from	BREO.xml:S3:12409:4	O
systemic	BREO.xml:S3:12414:8	O
corticosteroid	BREO.xml:S3:12423:14	O
therapy	BREO.xml:S3:12438:7	O
to	BREO.xml:S3:12446:2	O
BREO	BREO.xml:S3:12449:4	O
ELLIPTA	BREO.xml:S3:12454:7	O
may	BREO.xml:S3:12462:3	O
unmask	BREO.xml:S3:12466:6	O
allergic	BREO.xml:S3:12473:8	O
conditions	BREO.xml:S3:12482:10	O
previously	BREO.xml:S3:12493:10	O
suppressed	BREO.xml:S3:12504:10	O
by	BREO.xml:S3:12515:2	O
the	BREO.xml:S3:12518:3	O
systemic	BREO.xml:S3:12522:8	O
corticosteroid	BREO.xml:S3:12531:14	O
therapy	BREO.xml:S3:12546:7	O
(	BREO.xml:S3:12554:1	O
e	BREO.xml:S3:12555:1	O
.	BREO.xml:S3:12556:1	O
g	BREO.xml:S3:12557:1	O
.	BREO.xml:S3:12558:1	O
,	BREO.xml:S3:12559:1	O
rhinitis	BREO.xml:S3:12561:8	O
,	BREO.xml:S3:12569:1	O
conjunctivitis	BREO.xml:S3:12571:14	O
,	BREO.xml:S3:12585:1	O
eczema	BREO.xml:S3:12587:6	O
,	BREO.xml:S3:12593:1	O
arthritis	BREO.xml:S3:12595:9	O
,	BREO.xml:S3:12604:1	O
eosinophilic	BREO.xml:S3:12606:12	O
conditions	BREO.xml:S3:12619:10	O
)	BREO.xml:S3:12629:1	O
.	BREO.xml:S3:12630:1	O

During	BREO.xml:S3:12636:6	O
withdrawal	BREO.xml:S3:12643:10	O
from	BREO.xml:S3:12654:4	O
oral	BREO.xml:S3:12659:4	O
corticosteroids	BREO.xml:S3:12664:15	O
,	BREO.xml:S3:12679:1	O
some	BREO.xml:S3:12681:4	O
patients	BREO.xml:S3:12686:8	O
may	BREO.xml:S3:12695:3	O
experience	BREO.xml:S3:12699:10	O
symptoms	BREO.xml:S3:12710:8	O
of	BREO.xml:S3:12719:2	O
systemically	BREO.xml:S3:12722:12	O
active	BREO.xml:S3:12735:6	O
corticosteroid	BREO.xml:S3:12742:14	O
withdrawal	BREO.xml:S3:12757:10	O
(	BREO.xml:S3:12768:1	O
e	BREO.xml:S3:12769:1	O
.	BREO.xml:S3:12770:1	O
g	BREO.xml:S3:12771:1	O
.	BREO.xml:S3:12772:1	O
,	BREO.xml:S3:12773:1	O
joint	BREO.xml:S3:12775:5	O
and	BREO.xml:S3:12781:3	O
or	BREO.xml:S3:12785:2	O
muscular	BREO.xml:S3:12788:8	O
pain	BREO.xml:S3:12797:4	O
,	BREO.xml:S3:12801:1	O
lassitude	BREO.xml:S3:12803:9	O
,	BREO.xml:S3:12812:1	O
depression	BREO.xml:S3:12814:10	O
)	BREO.xml:S3:12824:1	O
despite	BREO.xml:S3:12826:7	O
maintenance	BREO.xml:S3:12834:11	O
or	BREO.xml:S3:12846:2	O
even	BREO.xml:S3:12849:4	O
improvement	BREO.xml:S3:12854:11	O
of	BREO.xml:S3:12866:2	O
respiratory	BREO.xml:S3:12869:11	O
function	BREO.xml:S3:12881:8	O
.	BREO.xml:S3:12889:1	O

5.8	BREO.xml:S3:12898:3	O
Hypercorticism	BREO.xml:S3:12902:14	O
and	BREO.xml:S3:12917:3	O
Adrenal	BREO.xml:S3:12921:7	O
Suppression	BREO.xml:S3:12929:11	O

Inhaled	BREO.xml:S3:12946:7	O
fluticasone	BREO.xml:S3:12954:11	O
furoate	BREO.xml:S3:12966:7	O
is	BREO.xml:S3:12974:2	O
absorbed	BREO.xml:S3:12977:8	O
into	BREO.xml:S3:12986:4	O
the	BREO.xml:S3:12991:3	O
circulation	BREO.xml:S3:12995:11	O
and	BREO.xml:S3:13007:3	O
can	BREO.xml:S3:13011:3	O
be	BREO.xml:S3:13015:2	O
systemically	BREO.xml:S3:13018:12	O
active	BREO.xml:S3:13031:6	O
.	BREO.xml:S3:13037:1	O

Effects	BREO.xml:S3:13039:7	O
of	BREO.xml:S3:13047:2	O
fluticasone	BREO.xml:S3:13050:11	O
furoate	BREO.xml:S3:13062:7	O
on	BREO.xml:S3:13070:2	O
the	BREO.xml:S3:13073:3	O
HPA	BREO.xml:S3:13077:3	O
axis	BREO.xml:S3:13081:4	O
are	BREO.xml:S3:13086:3	O
not	BREO.xml:S3:13090:3	O
observed	BREO.xml:S3:13094:8	O
with	BREO.xml:S3:13103:4	O
the	BREO.xml:S3:13108:3	O
therapeutic	BREO.xml:S3:13112:11	O
doses	BREO.xml:S3:13124:5	O
of	BREO.xml:S3:13130:2	O
BREO	BREO.xml:S3:13133:4	O
ELLIPTA	BREO.xml:S3:13138:7	O
.	BREO.xml:S3:13145:1	O

However	BREO.xml:S3:13147:7	O
,	BREO.xml:S3:13154:1	O
exceeding	BREO.xml:S3:13156:9	O
the	BREO.xml:S3:13166:3	O
recommended	BREO.xml:S3:13170:11	O
dosage	BREO.xml:S3:13182:6	O
or	BREO.xml:S3:13189:2	O
coadministration	BREO.xml:S3:13192:16	O
with	BREO.xml:S3:13209:4	O
a	BREO.xml:S3:13214:1	O
strong	BREO.xml:S3:13216:6	O
cytochrome	BREO.xml:S3:13223:10	O
P450	BREO.xml:S3:13234:4	O
3	BREO.xml:S3:13239:1	O
A4	BREO.xml:S3:13240:2	O
(	BREO.xml:S3:13243:1	O
CYP3A4	BREO.xml:S3:13244:6	O
)	BREO.xml:S3:13250:1	O
inhibitor	BREO.xml:S3:13252:9	O
may	BREO.xml:S3:13262:3	B-Factor
result	BREO.xml:S3:13266:6	O
in	BREO.xml:S3:13273:2	O
HPA	BREO.xml:S3:13276:3	B-AdverseReaction
dysfunction	BREO.xml:S3:13280:11	I-AdverseReaction
[	BREO.xml:S3:13292:1	O
see	BREO.xml:S3:13293:3	O
Warnings	BREO.xml:S3:13297:8	O
and	BREO.xml:S3:13306:3	O
Precautions	BREO.xml:S3:13310:11	O
(	BREO.xml:S3:13322:1	O
5.9	BREO.xml:S3:13323:3	O
)	BREO.xml:S3:13326:1	O
,	BREO.xml:S3:13327:1	O
Drug	BREO.xml:S3:13329:4	O
Interactions	BREO.xml:S3:13334:12	O
(	BREO.xml:S3:13347:1	O
7.1	BREO.xml:S3:13348:3	O
)]	BREO.xml:S3:13351:2	O
.	BREO.xml:S3:13355:1	O

Because	BREO.xml:S3:13361:7	O
of	BREO.xml:S3:13369:2	O
the	BREO.xml:S3:13372:3	O
possibility	BREO.xml:S3:13376:11	O
of	BREO.xml:S3:13388:2	O
significant	BREO.xml:S3:13391:11	O
systemic	BREO.xml:S3:13403:8	O
absorption	BREO.xml:S3:13412:10	O
of	BREO.xml:S3:13423:2	O
inhaled	BREO.xml:S3:13426:7	O
corticosteroids	BREO.xml:S3:13434:15	O
in	BREO.xml:S3:13450:2	O
sensitive	BREO.xml:S3:13453:9	O
patients	BREO.xml:S3:13463:8	O
,	BREO.xml:S3:13471:1	O
patients	BREO.xml:S3:13473:8	O
treated	BREO.xml:S3:13482:7	O
with	BREO.xml:S3:13490:4	O
BREO	BREO.xml:S3:13495:4	O
ELLIPTA	BREO.xml:S3:13500:7	O
should	BREO.xml:S3:13508:6	O
be	BREO.xml:S3:13515:2	O
observed	BREO.xml:S3:13518:8	O
carefully	BREO.xml:S3:13527:9	O
for	BREO.xml:S3:13537:3	O
any	BREO.xml:S3:13541:3	O
evidence	BREO.xml:S3:13545:8	O
of	BREO.xml:S3:13554:2	O
systemic	BREO.xml:S3:13557:8	O
corticosteroid	BREO.xml:S3:13566:14	O
effects	BREO.xml:S3:13581:7	O
.	BREO.xml:S3:13588:1	O

Particular	BREO.xml:S3:13590:10	O
care	BREO.xml:S3:13601:4	O
should	BREO.xml:S3:13606:6	O
be	BREO.xml:S3:13613:2	O
taken	BREO.xml:S3:13616:5	O
in	BREO.xml:S3:13622:2	O
observing	BREO.xml:S3:13625:9	O
patients	BREO.xml:S3:13635:8	O
postoperatively	BREO.xml:S3:13644:15	O
or	BREO.xml:S3:13660:2	O
during	BREO.xml:S3:13663:6	O
periods	BREO.xml:S3:13670:7	O
of	BREO.xml:S3:13678:2	O
stress	BREO.xml:S3:13681:6	O
for	BREO.xml:S3:13688:3	O
evidence	BREO.xml:S3:13692:8	O
of	BREO.xml:S3:13701:2	O
inadequate	BREO.xml:S3:13704:10	O
adrenal	BREO.xml:S3:13715:7	O
response	BREO.xml:S3:13723:8	O
.	BREO.xml:S3:13731:1	O

It	BREO.xml:S3:13737:2	O
is	BREO.xml:S3:13740:2	O
possible	BREO.xml:S3:13743:8	O
that	BREO.xml:S3:13752:4	O
systemic	BREO.xml:S3:13757:8	O
corticosteroid	BREO.xml:S3:13766:14	O
effects	BREO.xml:S3:13781:7	O
such	BREO.xml:S3:13789:4	O
as	BREO.xml:S3:13794:2	O
hypercorticism	BREO.xml:S3:13797:14	B-AdverseReaction
and	BREO.xml:S3:13812:3	O
adrenal	BREO.xml:S3:13816:7	B-AdverseReaction
suppression	BREO.xml:S3:13824:11	I-AdverseReaction
(	BREO.xml:S3:13836:1	O
including	BREO.xml:S3:13837:9	O
adrenal	BREO.xml:S3:13847:7	B-AdverseReaction
crisis	BREO.xml:S3:13855:6	I-AdverseReaction
)	BREO.xml:S3:13861:1	O
may	BREO.xml:S3:13863:3	B-Factor
appear	BREO.xml:S3:13867:6	O
in	BREO.xml:S3:13874:2	O
a	BREO.xml:S3:13877:1	O
small	BREO.xml:S3:13879:5	O
number	BREO.xml:S3:13885:6	O
of	BREO.xml:S3:13892:2	O
patients	BREO.xml:S3:13895:8	O
who	BREO.xml:S3:13904:3	O
are	BREO.xml:S3:13908:3	O
sensitive	BREO.xml:S3:13912:9	O
to	BREO.xml:S3:13922:2	O
these	BREO.xml:S3:13925:5	O
effects	BREO.xml:S3:13931:7	O
.	BREO.xml:S3:13938:1	O

If	BREO.xml:S3:13940:2	O
such	BREO.xml:S3:13943:4	O
effects	BREO.xml:S3:13948:7	O
occur	BREO.xml:S3:13956:5	O
,	BREO.xml:S3:13961:1	O
BREO	BREO.xml:S3:13963:4	O
ELLIPTA	BREO.xml:S3:13968:7	O
should	BREO.xml:S3:13976:6	O
be	BREO.xml:S3:13983:2	O
reduced	BREO.xml:S3:13986:7	O
slowly	BREO.xml:S3:13994:6	O
,	BREO.xml:S3:14000:1	O
consistent	BREO.xml:S3:14002:10	O
with	BREO.xml:S3:14013:4	O
accepted	BREO.xml:S3:14018:8	O
procedures	BREO.xml:S3:14027:10	O
for	BREO.xml:S3:14038:3	O
reducing	BREO.xml:S3:14042:8	O
systemic	BREO.xml:S3:14051:8	O
corticosteroids	BREO.xml:S3:14060:15	O
,	BREO.xml:S3:14075:1	O
and	BREO.xml:S3:14077:3	O
other	BREO.xml:S3:14081:5	O
treatments	BREO.xml:S3:14087:10	O
for	BREO.xml:S3:14098:3	O
management	BREO.xml:S3:14102:10	O
of	BREO.xml:S3:14113:2	O
COPD	BREO.xml:S3:14116:4	O
or	BREO.xml:S3:14121:2	O
asthma	BREO.xml:S3:14124:6	O
symptoms	BREO.xml:S3:14131:8	O
should	BREO.xml:S3:14140:6	O
be	BREO.xml:S3:14147:2	O
considered	BREO.xml:S3:14150:10	O
.	BREO.xml:S3:14160:1	O

5.9	BREO.xml:S3:14169:3	O
Drug	BREO.xml:S3:14173:4	O
Interactions	BREO.xml:S3:14178:12	O
with	BREO.xml:S3:14191:4	O
Strong	BREO.xml:S3:14196:6	O
Cytochrome	BREO.xml:S3:14203:10	O
P450	BREO.xml:S3:14214:4	O
3	BREO.xml:S3:14219:1	O
A4	BREO.xml:S3:14220:2	O
Inhibitors	BREO.xml:S3:14223:10	O

Caution	BREO.xml:S3:14239:7	O
should	BREO.xml:S3:14247:6	O
be	BREO.xml:S3:14254:2	O
exercised	BREO.xml:S3:14257:9	O
when	BREO.xml:S3:14267:4	O
considering	BREO.xml:S3:14272:11	O
the	BREO.xml:S3:14284:3	O
coadministration	BREO.xml:S3:14288:16	O
of	BREO.xml:S3:14305:2	O
BREO	BREO.xml:S3:14308:4	O
ELLIPTA	BREO.xml:S3:14313:7	O
with	BREO.xml:S3:14321:4	O
long	BREO.xml:S3:14326:4	O
-	BREO.xml:S3:14330:1	O
term	BREO.xml:S3:14331:4	O
ketoconazole	BREO.xml:S3:14336:12	O
and	BREO.xml:S3:14349:3	O
other	BREO.xml:S3:14353:5	O
known	BREO.xml:S3:14359:5	O
strong	BREO.xml:S3:14365:6	O
CYP3A4	BREO.xml:S3:14372:6	O
inhibitors	BREO.xml:S3:14379:10	O
(	BREO.xml:S3:14390:1	O
e	BREO.xml:S3:14391:1	O
.	BREO.xml:S3:14392:1	O
g	BREO.xml:S3:14393:1	O
.	BREO.xml:S3:14394:1	O
,	BREO.xml:S3:14395:1	O
ritonavir	BREO.xml:S3:14397:9	O
,	BREO.xml:S3:14406:1	O
clarithromycin	BREO.xml:S3:14408:14	O
,	BREO.xml:S3:14422:1	O
conivaptan	BREO.xml:S3:14424:10	O
,	BREO.xml:S3:14434:1	O
indinavir	BREO.xml:S3:14436:9	O
,	BREO.xml:S3:14445:1	O
itraconazole	BREO.xml:S3:14447:12	O
,	BREO.xml:S3:14459:1	O
lopinavir	BREO.xml:S3:14461:9	O
,	BREO.xml:S3:14470:1	O
nefazodone	BREO.xml:S3:14472:10	O
,	BREO.xml:S3:14482:1	O
nelfinavir	BREO.xml:S3:14484:10	O
,	BREO.xml:S3:14494:1	O
saquinavir	BREO.xml:S3:14496:10	O
,	BREO.xml:S3:14506:1	O
telithromycin	BREO.xml:S3:14508:13	O
,	BREO.xml:S3:14521:1	O
troleandomycin	BREO.xml:S3:14523:14	O
,	BREO.xml:S3:14537:1	O
voriconazole	BREO.xml:S3:14539:12	O
)	BREO.xml:S3:14551:1	O
because	BREO.xml:S3:14553:7	O
increased	BREO.xml:S3:14561:9	O
systemic	BREO.xml:S3:14571:8	O
corticosteroid	BREO.xml:S3:14580:14	O
and	BREO.xml:S3:14595:3	O
increased	BREO.xml:S3:14599:9	O
cardiovascular	BREO.xml:S3:14609:14	O
adverse	BREO.xml:S3:14624:7	O
effects	BREO.xml:S3:14632:7	O
may	BREO.xml:S3:14640:3	O
occur	BREO.xml:S3:14644:5	O
[	BREO.xml:S3:14650:1	O
see	BREO.xml:S3:14651:3	O
Drug	BREO.xml:S3:14655:4	O
Interactions	BREO.xml:S3:14660:12	O
(	BREO.xml:S3:14673:1	O
7.1	BREO.xml:S3:14674:3	O
)	BREO.xml:S3:14677:1	O
,	BREO.xml:S3:14678:1	O
Clinical	BREO.xml:S3:14680:8	O
Pharmacology	BREO.xml:S3:14689:12	O
(	BREO.xml:S3:14702:1	O
12.3	BREO.xml:S3:14703:4	O
)]	BREO.xml:S3:14707:2	O
.	BREO.xml:S3:14709:1	O

5.10	BREO.xml:S3:14720:4	O
Paradoxical	BREO.xml:S3:14725:11	O
Bronchospasm	BREO.xml:S3:14737:12	O

As	BREO.xml:S3:14755:2	O
with	BREO.xml:S3:14758:4	O
other	BREO.xml:S3:14763:5	O
inhaled	BREO.xml:S3:14769:7	O
medicines	BREO.xml:S3:14777:9	O
,	BREO.xml:S3:14786:1	O
BREO	BREO.xml:S3:14788:4	O
ELLIPTA	BREO.xml:S3:14793:7	O
can	BREO.xml:S3:14801:3	B-Factor
produce	BREO.xml:S3:14805:7	O
paradoxical	BREO.xml:S3:14813:11	B-AdverseReaction
bronchospasm	BREO.xml:S3:14825:12	I-AdverseReaction
,	BREO.xml:S3:14837:1	O
which	BREO.xml:S3:14839:5	O
may	BREO.xml:S3:14845:3	B-Factor
be	BREO.xml:S3:14849:2	O
life	BREO.xml:S3:14852:4	B-Severity
threatening	BREO.xml:S3:14857:11	I-Severity
.	BREO.xml:S3:14868:1	O

If	BREO.xml:S3:14870:2	O
paradoxical	BREO.xml:S3:14873:11	O
bronchospasm	BREO.xml:S3:14885:12	O
occurs	BREO.xml:S3:14898:6	O
following	BREO.xml:S3:14905:9	O
dosing	BREO.xml:S3:14915:6	O
with	BREO.xml:S3:14922:4	O
BREO	BREO.xml:S3:14927:4	O
ELLIPTA	BREO.xml:S3:14932:7	O
,	BREO.xml:S3:14939:1	O
it	BREO.xml:S3:14941:2	O
should	BREO.xml:S3:14944:6	O
be	BREO.xml:S3:14951:2	O
treated	BREO.xml:S3:14954:7	O
immediately	BREO.xml:S3:14962:11	O
with	BREO.xml:S3:14974:4	O
an	BREO.xml:S3:14979:2	O
inhaled	BREO.xml:S3:14982:7	O
,	BREO.xml:S3:14989:1	O
short	BREO.xml:S3:14991:5	O
-	BREO.xml:S3:14996:1	O
acting	BREO.xml:S3:14997:6	O
bronchodilator	BREO.xml:S3:15004:14	O
;	BREO.xml:S3:15018:1	O
BREO	BREO.xml:S3:15020:4	O
ELLIPTA	BREO.xml:S3:15025:7	O
should	BREO.xml:S3:15033:6	O
be	BREO.xml:S3:15040:2	O
discontinued	BREO.xml:S3:15043:12	O
immediately	BREO.xml:S3:15056:11	O
;	BREO.xml:S3:15067:1	O
and	BREO.xml:S3:15069:3	O
alternative	BREO.xml:S3:15073:11	O
therapy	BREO.xml:S3:15085:7	O
should	BREO.xml:S3:15093:6	O
be	BREO.xml:S3:15100:2	O
instituted	BREO.xml:S3:15103:10	O
.	BREO.xml:S3:15113:1	O

5.11	BREO.xml:S3:15122:4	O
Hypersensitivity	BREO.xml:S3:15127:16	O
Reactions	BREO.xml:S3:15144:9	O
,	BREO.xml:S3:15153:1	O
Including	BREO.xml:S3:15155:9	O
Anaphylaxis	BREO.xml:S3:15165:11	O

Hypersensitivity	BREO.xml:S3:15182:16	B-AdverseReaction
reactions	BREO.xml:S3:15199:9	I-AdverseReaction
such	BREO.xml:S3:15209:4	O
as	BREO.xml:S3:15214:2	O
anaphylaxis	BREO.xml:S3:15217:11	B-AdverseReaction
,	BREO.xml:S3:15228:1	O
angioedema	BREO.xml:S3:15230:10	B-AdverseReaction
,	BREO.xml:S3:15240:1	O
rash	BREO.xml:S3:15242:4	B-AdverseReaction
,	BREO.xml:S3:15246:1	O
and	BREO.xml:S3:15248:3	O
urticaria	BREO.xml:S3:15252:9	B-AdverseReaction
may	BREO.xml:S3:15262:3	B-Factor
occur	BREO.xml:S3:15266:5	O
after	BREO.xml:S3:15272:5	O
administration	BREO.xml:S3:15278:14	O
of	BREO.xml:S3:15293:2	O
BREO	BREO.xml:S3:15296:4	O
ELLIPTA	BREO.xml:S3:15301:7	O
.	BREO.xml:S3:15308:1	O

Discontinue	BREO.xml:S3:15310:11	O
BREO	BREO.xml:S3:15322:4	O
ELLIPTA	BREO.xml:S3:15327:7	O
if	BREO.xml:S3:15335:2	O
such	BREO.xml:S3:15338:4	O
reactions	BREO.xml:S3:15343:9	O
occur	BREO.xml:S3:15353:5	O
.	BREO.xml:S3:15358:1	O

There	BREO.xml:S3:15360:5	O
have	BREO.xml:S3:15366:4	O
been	BREO.xml:S3:15371:4	O
reports	BREO.xml:S3:15376:7	O
of	BREO.xml:S3:15384:2	O
anaphylactic	BREO.xml:S3:15387:12	B-AdverseReaction
reactions	BREO.xml:S3:15400:9	I-AdverseReaction
in	BREO.xml:S3:15410:2	O
patients	BREO.xml:S3:15413:8	O
with	BREO.xml:S3:15422:4	O
severe	BREO.xml:S3:15427:6	O
milk	BREO.xml:S3:15434:4	O
protein	BREO.xml:S3:15439:7	O
allergy	BREO.xml:S3:15447:7	O
after	BREO.xml:S3:15455:5	O
inhalation	BREO.xml:S3:15461:10	O
of	BREO.xml:S3:15472:2	O
other	BREO.xml:S3:15475:5	O
powder	BREO.xml:S3:15481:6	B-DrugClass
medications	BREO.xml:S3:15488:11	I-DrugClass
containing	BREO.xml:S3:15500:10	I-DrugClass
lactose	BREO.xml:S3:15511:7	I-DrugClass
;	BREO.xml:S3:15518:1	O
therefore	BREO.xml:S3:15520:9	O
,	BREO.xml:S3:15529:1	O
patients	BREO.xml:S3:15531:8	O
with	BREO.xml:S3:15540:4	O
severe	BREO.xml:S3:15545:6	O
milk	BREO.xml:S3:15552:4	O
protein	BREO.xml:S3:15557:7	O
allergy	BREO.xml:S3:15565:7	O
should	BREO.xml:S3:15573:6	O
not	BREO.xml:S3:15580:3	O
use	BREO.xml:S3:15584:3	O
BREO	BREO.xml:S3:15588:4	O
ELLIPTA	BREO.xml:S3:15593:7	O
[	BREO.xml:S3:15601:1	O
see	BREO.xml:S3:15602:3	O
Contraindications	BREO.xml:S3:15606:17	O
(	BREO.xml:S3:15624:1	O
4	BREO.xml:S3:15625:1	O
)]	BREO.xml:S3:15626:2	O
.	BREO.xml:S3:15630:1	O

5.12	BREO.xml:S3:15639:4	O
Cardiovascular	BREO.xml:S3:15644:14	O
Effects	BREO.xml:S3:15659:7	O

Vilanterol	BREO.xml:S3:15672:10	O
,	BREO.xml:S3:15682:1	O
like	BREO.xml:S3:15684:4	O
other	BREO.xml:S3:15689:5	O
beta2	BREO.xml:S3:15695:5	O
-	BREO.xml:S3:15700:1	O
agonists	BREO.xml:S3:15701:8	O
,	BREO.xml:S3:15709:1	O
can	BREO.xml:S3:15711:3	B-Factor
produce	BREO.xml:S3:15715:7	O
a	BREO.xml:S3:15723:1	O
clinically	BREO.xml:S3:15725:10	O
significant	BREO.xml:S3:15736:11	O
cardiovascular	BREO.xml:S3:15748:14	O
effect	BREO.xml:S3:15763:6	O
in	BREO.xml:S3:15770:2	O
some	BREO.xml:S3:15773:4	O
patients	BREO.xml:S3:15778:8	O
as	BREO.xml:S3:15787:2	O
measured	BREO.xml:S3:15790:8	O
by	BREO.xml:S3:15799:2	O
increases	BREO.xml:S3:15802:9	B-AdverseReaction
in	BREO.xml:S3:15812:2	I-AdverseReaction
pulse	BREO.xml:S3:15815:5	I-AdverseReaction
rate	BREO.xml:S3:15821:4	I-AdverseReaction
,	BREO.xml:S3:15825:1	O
systolic	BREO.xml:S3:15827:8	I-AdverseReaction
or	BREO.xml:S3:15836:2	O
diastolic	BREO.xml:S3:15839:9	I-AdverseReaction
blood	BREO.xml:S3:15849:5	I-AdverseReaction
pressure	BREO.xml:S3:15855:8	I-AdverseReaction
,	BREO.xml:S3:15863:1	O
and	BREO.xml:S3:15865:3	O
also	BREO.xml:S3:15869:4	O
cardiac	BREO.xml:S3:15874:7	B-AdverseReaction
arrhythmias	BREO.xml:S3:15882:11	I-AdverseReaction
,	BREO.xml:S3:15893:1	O
such	BREO.xml:S3:15895:4	O
as	BREO.xml:S3:15900:2	O
supraventricular	BREO.xml:S3:15903:16	B-AdverseReaction
tachycardia	BREO.xml:S3:15920:11	I-AdverseReaction
and	BREO.xml:S3:15932:3	O
extrasystoles	BREO.xml:S3:15936:13	B-AdverseReaction
.	BREO.xml:S3:15949:1	O

If	BREO.xml:S3:15951:2	O
such	BREO.xml:S3:15954:4	O
effects	BREO.xml:S3:15959:7	O
occur	BREO.xml:S3:15967:5	O
,	BREO.xml:S3:15972:1	O
BREO	BREO.xml:S3:15974:4	O
ELLIPTA	BREO.xml:S3:15979:7	O
may	BREO.xml:S3:15987:3	O
need	BREO.xml:S3:15991:4	O
to	BREO.xml:S3:15996:2	O
be	BREO.xml:S3:15999:2	O
discontinued	BREO.xml:S3:16002:12	O
.	BREO.xml:S3:16014:1	O

In	BREO.xml:S3:16016:2	O
addition	BREO.xml:S3:16019:8	O
,	BREO.xml:S3:16027:1	O
beta	BREO.xml:S3:16029:4	B-DrugClass
-	BREO.xml:S3:16033:1	I-DrugClass
agonists	BREO.xml:S3:16034:8	I-DrugClass
have	BREO.xml:S3:16043:4	O
been	BREO.xml:S3:16048:4	O
reported	BREO.xml:S3:16053:8	O
to	BREO.xml:S3:16062:2	O
produce	BREO.xml:S3:16065:7	O
electrocardiographic	BREO.xml:S3:16073:20	B-AdverseReaction
changes	BREO.xml:S3:16094:7	I-AdverseReaction
,	BREO.xml:S3:16101:1	O
such	BREO.xml:S3:16103:4	O
as	BREO.xml:S3:16108:2	O
flattening	BREO.xml:S3:16111:10	B-AdverseReaction
of	BREO.xml:S3:16122:2	I-AdverseReaction
the	BREO.xml:S3:16125:3	I-AdverseReaction
T	BREO.xml:S3:16129:1	I-AdverseReaction
wave	BREO.xml:S3:16131:4	I-AdverseReaction
,	BREO.xml:S3:16135:1	O
prolongation	BREO.xml:S3:16137:12	B-AdverseReaction
of	BREO.xml:S3:16150:2	I-AdverseReaction
the	BREO.xml:S3:16153:3	I-AdverseReaction
QTc	BREO.xml:S3:16157:3	I-AdverseReaction
interval	BREO.xml:S3:16161:8	I-AdverseReaction
,	BREO.xml:S3:16169:1	O
and	BREO.xml:S3:16171:3	O
ST	BREO.xml:S3:16175:2	B-AdverseReaction
segment	BREO.xml:S3:16178:7	I-AdverseReaction
depression	BREO.xml:S3:16186:10	I-AdverseReaction
,	BREO.xml:S3:16196:1	O
although	BREO.xml:S3:16198:8	O
the	BREO.xml:S3:16207:3	O
clinical	BREO.xml:S3:16211:8	O
significance	BREO.xml:S3:16220:12	O
of	BREO.xml:S3:16233:2	O
these	BREO.xml:S3:16236:5	O
findings	BREO.xml:S3:16242:8	O
is	BREO.xml:S3:16251:2	O
unknown	BREO.xml:S3:16254:7	O
.	BREO.xml:S3:16261:1	O

Fatalities	BREO.xml:S3:16263:10	B-AdverseReaction
have	BREO.xml:S3:16274:4	O
been	BREO.xml:S3:16279:4	O
reported	BREO.xml:S3:16284:8	O
in	BREO.xml:S3:16293:2	O
association	BREO.xml:S3:16296:11	O
with	BREO.xml:S3:16308:4	O
excessive	BREO.xml:S3:16313:9	O
use	BREO.xml:S3:16323:3	O
of	BREO.xml:S3:16327:2	O
inhaled	BREO.xml:S3:16330:7	O
sympathomimetic	BREO.xml:S3:16338:15	O
drugs	BREO.xml:S3:16354:5	O
.	BREO.xml:S3:16359:1	O

In	BREO.xml:S3:16365:2	O
healthy	BREO.xml:S3:16368:7	O
subjects	BREO.xml:S3:16376:8	O
,	BREO.xml:S3:16384:1	O
large	BREO.xml:S3:16386:5	O
doses	BREO.xml:S3:16392:5	O
of	BREO.xml:S3:16398:2	O
inhaled	BREO.xml:S3:16401:7	O
fluticasone	BREO.xml:S3:16409:11	O
furoate	BREO.xml:S3:16421:7	O
vilanterol	BREO.xml:S3:16429:10	O
(	BREO.xml:S3:16440:1	O
4	BREO.xml:S3:16441:1	O
times	BREO.xml:S3:16443:5	O
the	BREO.xml:S3:16449:3	O
recommended	BREO.xml:S3:16453:11	O
dose	BREO.xml:S3:16465:4	O
of	BREO.xml:S3:16470:2	O
vilanterol	BREO.xml:S3:16473:10	O
,	BREO.xml:S3:16483:1	O
representing	BREO.xml:S3:16485:12	O
a	BREO.xml:S3:16498:1	O
12	BREO.xml:S3:16500:2	O
-	BREO.xml:S3:16502:1	O
or	BREO.xml:S3:16504:2	O
10	BREO.xml:S3:16507:2	O
-	BREO.xml:S3:16509:1	O
fold	BREO.xml:S3:16510:4	O
higher	BREO.xml:S3:16515:6	O
systemic	BREO.xml:S3:16522:8	O
exposure	BREO.xml:S3:16531:8	O
than	BREO.xml:S3:16540:4	O
seen	BREO.xml:S3:16545:4	O
in	BREO.xml:S3:16550:2	O
subjects	BREO.xml:S3:16553:8	O
with	BREO.xml:S3:16562:4	O
COPD	BREO.xml:S3:16567:4	O
or	BREO.xml:S3:16572:2	O
asthma	BREO.xml:S3:16575:6	O
,	BREO.xml:S3:16581:1	O
respectively	BREO.xml:S3:16583:12	O
)	BREO.xml:S3:16595:1	O
have	BREO.xml:S3:16597:4	O
been	BREO.xml:S3:16602:4	O
associated	BREO.xml:S3:16607:10	O
with	BREO.xml:S3:16618:4	O
clinically	BREO.xml:S3:16623:10	B-Severity
significant	BREO.xml:S3:16634:11	I-Severity
prolongation	BREO.xml:S3:16646:12	B-AdverseReaction
of	BREO.xml:S3:16659:2	I-AdverseReaction
the	BREO.xml:S3:16662:3	I-AdverseReaction
QTc	BREO.xml:S3:16666:3	I-AdverseReaction
interval	BREO.xml:S3:16670:8	I-AdverseReaction
,	BREO.xml:S3:16678:1	O
which	BREO.xml:S3:16680:5	O
has	BREO.xml:S3:16686:3	O
the	BREO.xml:S3:16690:3	O
potential	BREO.xml:S3:16694:9	B-Factor
for	BREO.xml:S3:16704:3	O
producing	BREO.xml:S3:16708:9	O
ventricular	BREO.xml:S3:16718:11	B-AdverseReaction
arrhythmias	BREO.xml:S3:16730:11	I-AdverseReaction
.	BREO.xml:S3:16741:1	O

Therefore	BREO.xml:S3:16743:9	O
,	BREO.xml:S3:16752:1	O
BREO	BREO.xml:S3:16754:4	O
ELLIPTA	BREO.xml:S3:16759:7	O
,	BREO.xml:S3:16766:1	O
like	BREO.xml:S3:16768:4	O
other	BREO.xml:S3:16773:5	O
sympathomimetic	BREO.xml:S3:16779:15	O
amines	BREO.xml:S3:16795:6	O
,	BREO.xml:S3:16801:1	O
should	BREO.xml:S3:16803:6	O
be	BREO.xml:S3:16810:2	O
used	BREO.xml:S3:16813:4	O
with	BREO.xml:S3:16818:4	O
caution	BREO.xml:S3:16823:7	O
in	BREO.xml:S3:16831:2	O
patients	BREO.xml:S3:16834:8	O
with	BREO.xml:S3:16843:4	O
cardiovascular	BREO.xml:S3:16848:14	O
disorders	BREO.xml:S3:16863:9	O
,	BREO.xml:S3:16872:1	O
especially	BREO.xml:S3:16874:10	O
coronary	BREO.xml:S3:16885:8	O
insufficiency	BREO.xml:S3:16894:13	O
,	BREO.xml:S3:16907:1	O
cardiac	BREO.xml:S3:16909:7	O
arrhythmias	BREO.xml:S3:16917:11	O
,	BREO.xml:S3:16928:1	O
and	BREO.xml:S3:16930:3	O
hypertension	BREO.xml:S3:16934:12	O
.	BREO.xml:S3:16946:1	O

5.13	BREO.xml:S3:16955:4	O
Reduction	BREO.xml:S3:16960:9	O
in	BREO.xml:S3:16970:2	O
Bone	BREO.xml:S3:16973:4	O
Mineral	BREO.xml:S3:16978:7	O
Density	BREO.xml:S3:16986:7	O

Decreases	BREO.xml:S3:16999:9	B-AdverseReaction
in	BREO.xml:S3:17009:2	I-AdverseReaction
bone	BREO.xml:S3:17012:4	I-AdverseReaction
mineral	BREO.xml:S3:17017:7	I-AdverseReaction
density	BREO.xml:S3:17025:7	I-AdverseReaction
(	BREO.xml:S3:17033:1	O
BMD	BREO.xml:S3:17034:3	I-AdverseReaction
)	BREO.xml:S3:17037:1	O
have	BREO.xml:S3:17039:4	O
been	BREO.xml:S3:17044:4	O
observed	BREO.xml:S3:17049:8	O
with	BREO.xml:S3:17058:4	O
long	BREO.xml:S3:17063:4	O
-	BREO.xml:S3:17067:1	O
term	BREO.xml:S3:17068:4	O
administration	BREO.xml:S3:17073:14	O
of	BREO.xml:S3:17088:2	O
products	BREO.xml:S3:17091:8	O
containing	BREO.xml:S3:17100:10	O
inhaled	BREO.xml:S3:17111:7	O
corticosteroids	BREO.xml:S3:17119:15	B-DrugClass
.	BREO.xml:S3:17134:1	O

The	BREO.xml:S3:17136:3	O
clinical	BREO.xml:S3:17140:8	O
significance	BREO.xml:S3:17149:12	O
of	BREO.xml:S3:17162:2	O
small	BREO.xml:S3:17165:5	O
changes	BREO.xml:S3:17171:7	O
in	BREO.xml:S3:17179:2	O
BMD	BREO.xml:S3:17182:3	O
with	BREO.xml:S3:17186:4	O
regard	BREO.xml:S3:17191:6	O
to	BREO.xml:S3:17198:2	O
long	BREO.xml:S3:17201:4	O
-	BREO.xml:S3:17205:1	O
term	BREO.xml:S3:17206:4	O
consequences	BREO.xml:S3:17211:12	O
such	BREO.xml:S3:17224:4	O
as	BREO.xml:S3:17229:2	O
fracture	BREO.xml:S3:17232:8	O
is	BREO.xml:S3:17241:2	O
unknown	BREO.xml:S3:17244:7	O
.	BREO.xml:S3:17251:1	O

Patients	BREO.xml:S3:17253:8	O
with	BREO.xml:S3:17262:4	O
major	BREO.xml:S3:17267:5	O
risk	BREO.xml:S3:17273:4	O
factors	BREO.xml:S3:17278:7	O
for	BREO.xml:S3:17286:3	O
decreased	BREO.xml:S3:17290:9	O
bone	BREO.xml:S3:17300:4	O
mineral	BREO.xml:S3:17305:7	O
content	BREO.xml:S3:17313:7	O
,	BREO.xml:S3:17320:1	O
such	BREO.xml:S3:17322:4	O
as	BREO.xml:S3:17327:2	O
prolonged	BREO.xml:S3:17330:9	O
immobilization	BREO.xml:S3:17340:14	O
,	BREO.xml:S3:17354:1	O
family	BREO.xml:S3:17356:6	O
history	BREO.xml:S3:17363:7	O
of	BREO.xml:S3:17371:2	O
osteoporosis	BREO.xml:S3:17374:12	O
,	BREO.xml:S3:17386:1	O
postmenopausal	BREO.xml:S3:17388:14	O
status	BREO.xml:S3:17403:6	O
,	BREO.xml:S3:17409:1	O
tobacco	BREO.xml:S3:17411:7	O
use	BREO.xml:S3:17419:3	O
,	BREO.xml:S3:17422:1	O
advanced	BREO.xml:S3:17424:8	O
age	BREO.xml:S3:17433:3	O
,	BREO.xml:S3:17436:1	O
poor	BREO.xml:S3:17438:4	O
nutrition	BREO.xml:S3:17443:9	O
,	BREO.xml:S3:17452:1	O
or	BREO.xml:S3:17454:2	O
chronic	BREO.xml:S3:17457:7	O
use	BREO.xml:S3:17465:3	O
of	BREO.xml:S3:17469:2	O
drugs	BREO.xml:S3:17472:5	O
that	BREO.xml:S3:17478:4	O
can	BREO.xml:S3:17483:3	O
reduce	BREO.xml:S3:17487:6	O
bone	BREO.xml:S3:17494:4	O
mass	BREO.xml:S3:17499:4	O
(	BREO.xml:S3:17504:1	O
e	BREO.xml:S3:17505:1	O
.	BREO.xml:S3:17506:1	O
g	BREO.xml:S3:17507:1	O
.	BREO.xml:S3:17508:1	O
,	BREO.xml:S3:17509:1	O
anticonvulsants	BREO.xml:S3:17511:15	O
,	BREO.xml:S3:17526:1	O
oral	BREO.xml:S3:17528:4	O
corticosteroids	BREO.xml:S3:17533:15	O
)	BREO.xml:S3:17548:1	O
should	BREO.xml:S3:17550:6	O
be	BREO.xml:S3:17557:2	O
monitored	BREO.xml:S3:17560:9	O
and	BREO.xml:S3:17570:3	O
treated	BREO.xml:S3:17574:7	O
with	BREO.xml:S3:17582:4	O
established	BREO.xml:S3:17587:11	O
standards	BREO.xml:S3:17599:9	O
of	BREO.xml:S3:17609:2	O
care	BREO.xml:S3:17612:4	O
.	BREO.xml:S3:17616:1	O

Since	BREO.xml:S3:17618:5	O
patients	BREO.xml:S3:17624:8	O
with	BREO.xml:S3:17633:4	O
COPD	BREO.xml:S3:17638:4	O
often	BREO.xml:S3:17643:5	O
have	BREO.xml:S3:17649:4	O
multiple	BREO.xml:S3:17654:8	O
risk	BREO.xml:S3:17663:4	O
factors	BREO.xml:S3:17668:7	O
for	BREO.xml:S3:17676:3	O
reduced	BREO.xml:S3:17680:7	O
BMD	BREO.xml:S3:17688:3	O
,	BREO.xml:S3:17691:1	O
assessment	BREO.xml:S3:17693:10	O
of	BREO.xml:S3:17704:2	O
BMD	BREO.xml:S3:17707:3	O
is	BREO.xml:S3:17711:2	O
recommended	BREO.xml:S3:17714:11	O
prior	BREO.xml:S3:17726:5	O
to	BREO.xml:S3:17732:2	O
initiating	BREO.xml:S3:17735:10	O
BREO	BREO.xml:S3:17746:4	O
ELLIPTA	BREO.xml:S3:17751:7	O
and	BREO.xml:S3:17759:3	O
periodically	BREO.xml:S3:17763:12	O
thereafter	BREO.xml:S3:17776:10	O
.	BREO.xml:S3:17786:1	O

If	BREO.xml:S3:17788:2	O
significant	BREO.xml:S3:17791:11	O
reductions	BREO.xml:S3:17803:10	O
in	BREO.xml:S3:17814:2	O
BMD	BREO.xml:S3:17817:3	O
are	BREO.xml:S3:17821:3	O
seen	BREO.xml:S3:17825:4	O
and	BREO.xml:S3:17830:3	O
BREO	BREO.xml:S3:17834:4	O
ELLIPTA	BREO.xml:S3:17839:7	O
is	BREO.xml:S3:17847:2	O
still	BREO.xml:S3:17850:5	O
considered	BREO.xml:S3:17856:10	O
medically	BREO.xml:S3:17867:9	O
important	BREO.xml:S3:17877:9	O
for	BREO.xml:S3:17887:3	O
that	BREO.xml:S3:17891:4	O
patient	BREO.xml:S3:17896:7	O
's	BREO.xml:S3:17903:2	O
COPD	BREO.xml:S3:17906:4	O
therapy	BREO.xml:S3:17911:7	O
,	BREO.xml:S3:17918:1	O
use	BREO.xml:S3:17920:3	O
of	BREO.xml:S3:17924:2	O
medicine	BREO.xml:S3:17927:8	O
to	BREO.xml:S3:17936:2	O
treat	BREO.xml:S3:17939:5	O
or	BREO.xml:S3:17945:2	O
prevent	BREO.xml:S3:17948:7	O
osteoporosis	BREO.xml:S3:17956:12	O
should	BREO.xml:S3:17969:6	O
be	BREO.xml:S3:17976:2	O
strongly	BREO.xml:S3:17979:8	O
considered	BREO.xml:S3:17988:10	O
.	BREO.xml:S3:17998:1	O

5.14	BREO.xml:S3:18007:4	O
Glaucoma	BREO.xml:S3:18012:8	O
and	BREO.xml:S3:18021:3	O
Cataracts	BREO.xml:S3:18025:9	O

Glaucoma	BREO.xml:S3:18040:8	B-AdverseReaction
,	BREO.xml:S3:18048:1	O
increased	BREO.xml:S3:18050:9	B-AdverseReaction
intraocular	BREO.xml:S3:18060:11	I-AdverseReaction
pressure	BREO.xml:S3:18072:8	I-AdverseReaction
,	BREO.xml:S3:18080:1	O
and	BREO.xml:S3:18082:3	O
cataracts	BREO.xml:S3:18086:9	B-AdverseReaction
have	BREO.xml:S3:18096:4	O
been	BREO.xml:S3:18101:4	O
reported	BREO.xml:S3:18106:8	O
in	BREO.xml:S3:18115:2	O
patients	BREO.xml:S3:18118:8	O
with	BREO.xml:S3:18127:4	O
COPD	BREO.xml:S3:18132:4	O
or	BREO.xml:S3:18137:2	O
asthma	BREO.xml:S3:18140:6	O
following	BREO.xml:S3:18147:9	O
the	BREO.xml:S3:18157:3	O
long	BREO.xml:S3:18161:4	O
-	BREO.xml:S3:18165:1	O
term	BREO.xml:S3:18166:4	O
administration	BREO.xml:S3:18171:14	O
of	BREO.xml:S3:18186:2	O
inhaled	BREO.xml:S3:18189:7	O
corticosteroids	BREO.xml:S3:18197:15	B-DrugClass
.	BREO.xml:S3:18212:1	O

Therefore	BREO.xml:S3:18214:9	O
,	BREO.xml:S3:18223:1	O
close	BREO.xml:S3:18225:5	O
monitoring	BREO.xml:S3:18231:10	O
is	BREO.xml:S3:18242:2	O
warranted	BREO.xml:S3:18245:9	O
in	BREO.xml:S3:18255:2	O
patients	BREO.xml:S3:18258:8	O
with	BREO.xml:S3:18267:4	O
a	BREO.xml:S3:18272:1	O
change	BREO.xml:S3:18274:6	O
in	BREO.xml:S3:18281:2	O
vision	BREO.xml:S3:18284:6	O
or	BREO.xml:S3:18291:2	O
with	BREO.xml:S3:18294:4	O
a	BREO.xml:S3:18299:1	O
history	BREO.xml:S3:18301:7	O
of	BREO.xml:S3:18309:2	O
increased	BREO.xml:S3:18312:9	O
intraocular	BREO.xml:S3:18322:11	O
pressure	BREO.xml:S3:18334:8	O
,	BREO.xml:S3:18342:1	O
glaucoma	BREO.xml:S3:18344:8	O
,	BREO.xml:S3:18352:1	O
and	BREO.xml:S3:18354:3	O
or	BREO.xml:S3:18358:2	O
cataracts	BREO.xml:S3:18361:9	O
.	BREO.xml:S3:18370:1	O

5.15	BREO.xml:S3:18379:4	O
Coexisting	BREO.xml:S3:18384:10	O
Conditions	BREO.xml:S3:18395:10	O

BREO	BREO.xml:S3:18411:4	O
ELLIPTA	BREO.xml:S3:18416:7	O
,	BREO.xml:S3:18423:1	O
like	BREO.xml:S3:18425:4	O
all	BREO.xml:S3:18430:3	O
medicines	BREO.xml:S3:18434:9	O
containing	BREO.xml:S3:18444:10	O
sympathomimetic	BREO.xml:S3:18455:15	O
amines	BREO.xml:S3:18471:6	O
,	BREO.xml:S3:18477:1	O
should	BREO.xml:S3:18479:6	O
be	BREO.xml:S3:18486:2	O
used	BREO.xml:S3:18489:4	O
with	BREO.xml:S3:18494:4	O
caution	BREO.xml:S3:18499:7	O
in	BREO.xml:S3:18507:2	O
patients	BREO.xml:S3:18510:8	O
with	BREO.xml:S3:18519:4	O
convulsive	BREO.xml:S3:18524:10	O
disorders	BREO.xml:S3:18535:9	O
or	BREO.xml:S3:18545:2	O
thyrotoxicosis	BREO.xml:S3:18548:14	O
and	BREO.xml:S3:18563:3	O
in	BREO.xml:S3:18567:2	O
those	BREO.xml:S3:18570:5	O
who	BREO.xml:S3:18576:3	O
are	BREO.xml:S3:18580:3	O
unusually	BREO.xml:S3:18584:9	O
responsive	BREO.xml:S3:18594:10	O
to	BREO.xml:S3:18605:2	O
sympathomimetic	BREO.xml:S3:18608:15	O
amines	BREO.xml:S3:18624:6	O
.	BREO.xml:S3:18630:1	O

Doses	BREO.xml:S3:18632:5	O
of	BREO.xml:S3:18638:2	O
the	BREO.xml:S3:18641:3	O
related	BREO.xml:S3:18645:7	O
beta2	BREO.xml:S3:18653:5	B-DrugClass
-	BREO.xml:S3:18658:1	I-DrugClass
adrenoceptor	BREO.xml:S3:18659:12	I-DrugClass
agonist	BREO.xml:S3:18672:7	I-DrugClass
albuterol	BREO.xml:S3:18680:9	O
,	BREO.xml:S3:18689:1	O
when	BREO.xml:S3:18691:4	O
administered	BREO.xml:S3:18696:12	O
intravenously	BREO.xml:S3:18709:13	O
,	BREO.xml:S3:18722:1	O
have	BREO.xml:S3:18724:4	O
been	BREO.xml:S3:18729:4	O
reported	BREO.xml:S3:18734:8	O
to	BREO.xml:S3:18743:2	O
aggravate	BREO.xml:S3:18746:9	B-AdverseReaction
preexisting	BREO.xml:S3:18756:11	I-AdverseReaction
diabetes	BREO.xml:S3:18768:8	I-AdverseReaction
mellitus	BREO.xml:S3:18777:8	I-AdverseReaction
and	BREO.xml:S3:18786:3	O
ketoacidosis	BREO.xml:S3:18790:12	I-AdverseReaction
.	BREO.xml:S3:18802:1	O

5.16	BREO.xml:S3:18811:4	O
Hypokalemia	BREO.xml:S3:18816:11	O
and	BREO.xml:S3:18828:3	O
Hyperglycemia	BREO.xml:S3:18832:13	O

Beta	BREO.xml:S3:18851:4	O
-	BREO.xml:S3:18855:1	O
adrenergic	BREO.xml:S3:18856:10	O
agonist	BREO.xml:S3:18867:7	O
medicines	BREO.xml:S3:18875:9	O
may	BREO.xml:S3:18885:3	B-Factor
produce	BREO.xml:S3:18889:7	O
significant	BREO.xml:S3:18897:11	B-Severity
hypokalemia	BREO.xml:S3:18909:11	B-AdverseReaction
in	BREO.xml:S3:18921:2	O
some	BREO.xml:S3:18924:4	O
patients	BREO.xml:S3:18929:8	O
,	BREO.xml:S3:18937:1	O
possibly	BREO.xml:S3:18939:8	O
through	BREO.xml:S3:18948:7	O
intracellular	BREO.xml:S3:18956:13	O
shunting	BREO.xml:S3:18970:8	O
,	BREO.xml:S3:18978:1	O
which	BREO.xml:S3:18980:5	O
has	BREO.xml:S3:18986:3	O
the	BREO.xml:S3:18990:3	O
potential	BREO.xml:S3:18994:9	O
to	BREO.xml:S3:19004:2	O
produce	BREO.xml:S3:19007:7	O
adverse	BREO.xml:S3:19015:7	O
cardiovascular	BREO.xml:S3:19023:14	O
effects	BREO.xml:S3:19038:7	O
.	BREO.xml:S3:19045:1	O

The	BREO.xml:S3:19047:3	O
decrease	BREO.xml:S3:19051:8	B-AdverseReaction
in	BREO.xml:S3:19060:2	I-AdverseReaction
serum	BREO.xml:S3:19063:5	I-AdverseReaction
potassium	BREO.xml:S3:19069:9	I-AdverseReaction
is	BREO.xml:S3:19079:2	O
usually	BREO.xml:S3:19082:7	O
transient	BREO.xml:S3:19090:9	O
,	BREO.xml:S3:19099:1	O
not	BREO.xml:S3:19101:3	O
requiring	BREO.xml:S3:19105:9	O
supplementation	BREO.xml:S3:19115:15	O
.	BREO.xml:S3:19130:1	O

Beta	BREO.xml:S3:19132:4	B-DrugClass
-	BREO.xml:S3:19136:1	I-DrugClass
agonist	BREO.xml:S3:19137:7	I-DrugClass
medications	BREO.xml:S3:19145:11	I-DrugClass
may	BREO.xml:S3:19157:3	O
produce	BREO.xml:S3:19161:7	O
transient	BREO.xml:S3:19169:9	B-Severity
hyperglycemia	BREO.xml:S3:19179:13	B-AdverseReaction
in	BREO.xml:S3:19193:2	O
some	BREO.xml:S3:19196:4	O
patients	BREO.xml:S3:19201:8	O
.	BREO.xml:S3:19209:1	O

In	BREO.xml:S3:19211:2	O
clinical	BREO.xml:S3:19214:8	O
trials	BREO.xml:S3:19223:6	O
evaluating	BREO.xml:S3:19230:10	O
BREO	BREO.xml:S3:19241:4	O
ELLIPTA	BREO.xml:S3:19246:7	O
in	BREO.xml:S3:19254:2	O
subjects	BREO.xml:S3:19257:8	O
with	BREO.xml:S3:19266:4	O
COPD	BREO.xml:S3:19271:4	O
or	BREO.xml:S3:19276:2	O
asthma	BREO.xml:S3:19279:6	O
,	BREO.xml:S3:19285:1	O
there	BREO.xml:S3:19287:5	O
was	BREO.xml:S3:19293:3	O
no	BREO.xml:S3:19297:2	O
evidence	BREO.xml:S3:19300:8	O
of	BREO.xml:S3:19309:2	O
a	BREO.xml:S3:19312:1	O
treatment	BREO.xml:S3:19314:9	O
effect	BREO.xml:S3:19324:6	O
on	BREO.xml:S3:19331:2	O
serum	BREO.xml:S3:19334:5	O
glucose	BREO.xml:S3:19340:7	O
or	BREO.xml:S3:19348:2	O
potassium	BREO.xml:S3:19351:9	O
.	BREO.xml:S3:19360:1	O

5.17	BREO.xml:S3:19369:4	O
Effect	BREO.xml:S3:19374:6	O
on	BREO.xml:S3:19381:2	O
Growth	BREO.xml:S3:19384:6	O

Orally	BREO.xml:S3:19396:6	B-DrugClass
inhaled	BREO.xml:S3:19403:7	I-DrugClass
corticosteroids	BREO.xml:S3:19411:15	I-DrugClass
may	BREO.xml:S3:19427:3	O
cause	BREO.xml:S3:19431:5	O
a	BREO.xml:S3:19437:1	O
reduction	BREO.xml:S3:19439:9	B-AdverseReaction
in	BREO.xml:S3:19449:2	I-AdverseReaction
growth	BREO.xml:S3:19452:6	I-AdverseReaction
velocity	BREO.xml:S3:19459:8	I-AdverseReaction
when	BREO.xml:S3:19468:4	O
administered	BREO.xml:S3:19473:12	O
to	BREO.xml:S3:19486:2	O
children	BREO.xml:S3:19489:8	O
and	BREO.xml:S3:19498:3	O
adolescents	BREO.xml:S3:19502:11	O
.	BREO.xml:S3:19513:1	O

[	BREO.xml:S3:19515:1	O
See	BREO.xml:S3:19516:3	O
Use	BREO.xml:S3:19520:3	O
in	BREO.xml:S3:19524:2	O
Specific	BREO.xml:S3:19527:8	O
Populations	BREO.xml:S3:19536:11	O
(	BREO.xml:S3:19548:1	O
8.4	BREO.xml:S3:19549:3	O
)	BREO.xml:S3:19552:1	O
.	BREO.xml:S3:19553:1	O
]	BREO.xml:S3:19554:1	O
